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      Proteins are very crucial for cellular and metabolic functions. They play crucial roles 
like cell division, cell migration, cell-cell communication, signal transduction, cell death 
etc., and malfunction of proteins leads to major human diseases like AIDS, Cancer, 
Alzheimer’s, diabetes etc. Enzymes account for more than 20% of the drug targets and 
from an analysis of the FDA orange book, it has been estimated that atleast 370 marketed 
drugs work by inhibiting an enzyme. There are around 18-29% of the eukaryotic 
genomes which encode enzymes. However, little is still understood about the 
physiological role, substrate specificity and downstream targets of enzymes, which 
necessitates their study in a high-throughput manner. “Catalomics” is the emerging sub-
field of Chemical Biology in which one aims at studying enzymes at the organism wide 
scale by employing high-throughput chemistry and technology. High-throughput 
platform offers an efficient and rapid analysis of proteome on a global scale. The major 
part of my Ph.D research concentrates on the development or fine-tuning of high-
throughput amenable chemical platform to study enzymes especially Protein Tyrosine 
Phosphatases (PTPs), the last part of my research work is focused on Activity-based 
profiling and Bioimaging. 
     One of the main challenges in the field of Catalomics is the development of high-
throughput (HT) amenable chemical reactions that allow rapid synthesis of diverse 
chemical libraries for the interrogation of different classes of enzymes.  High-throughput 
(HT) amenable reactions are mainly characterized by near-perfect, modular and robust 
and biocompatible nature. Among the HT amenable chemistry tools, we have explored on 
Click chemistry, Solid-phase chemistry and Microwave (MW) assisted reactions 
 xvi
synthesis for enzyme inhibitor libraries and fragments. We have successfully adopted the 
click chemistry platform to construct a 66-member isoxazole based bidentate inhibitor 
library targeting against various PTPs. Subsequent in situ screening revealed a potential 
inhibitor against PTP1B (IC50 = 4.7 µM) which is comparable to that of a most potent cell 
active PTP1B inhibitor known.  Following the results, next we successfully designed and 
developed a traceless solid-phase methodology to construct different azide fragments, the 
azides were of high-quality and 100s of azides can be easily made within a week. These 
azide library was used constructed a library of 3250-member isoxazole-based bidentate 
inhibitor library targeting various PTPs in a high-throughput fashion. 
     Next, we successfully adopted out traceless solid-phase methodology to rapidly 
assemble PTP inhibitors using amide bond-formation reaction. The highlight of our 
method is that again no purification was required after the synthesis and cleavage from 
the solid-support. The inhibitors were of high-purity and were suitable for in situ 
screening. By screening these inhibitors against PTP1B, we have uncovered a candidate 
molecule which possesses an inhibition of Ki = 7.0 µM against PTP1B.  
     We have devised another simple and practical microwave-assisted strategy for the 
conversion of readily available alcohol building blocks into azides. In the first route tosyl 
resin was used for the first time to synthesize azides in a catch and release approach. In 
the second approach, alcohol building blocks were readily converted into azides via MW-
assisted azidation of tosylates/mesylates/chlorides. After a simple purification procedure, 
the azides synthesized from the above methods were suitable for directly click chemistry 
applications.  
 xvii
     The next part of the thesis work was focused on the synthesis of 16 different Activity- 
based probes; these probes were used to generate unique substrate fingerprint profiles of 
proteases in gel-based proteomic experiments. We have also synthesized a tri-functional 
PTP probes. In the last part of the thesis work, I have presented the design and synthesis 
of a set of cell-permeable small molecule probes which were utilized to modify (label) 
selectively the N-terminal cysteine proteins (in vivo) in bacterial cells by the well-known 
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1.1 Catalomics  
 
     After the successful completion of the major human genome project1, more attention 
has turned towards proteomic research rather than genomic research. Proteins are very 
crucial for cellular and metabolic functions. They play crucial roles like cell division, cell 
migration, cell-cell communication, signal transduction, cell death etc and malfunction 
proteins leads to major human diseases like AIDS, cancer, Alzheimer’s, diabetes etc. It 
has been estimated that enzyme account for more than 20% of the drug targets and from 
an analysis of the FDA orange book, it has been estimated that at least 370 marketed 
drugs work by inhibiting an enzyme2. There are around 18-29% of the eukaryotic 
genomes which encode enzymes. However, little is still understood about the 
physiological role, substrate specificity and downstream targets of enzymes, which 
necessitates their study in a high-throughput manner. “Catalomics” is the emerging sub-
field of Chemical Biology in which one aims at studying enzymes at the organism wide 
scale by employing high-throughput chemistry and technology3. High-throughput 
platform offers an efficient and rapid analysis of proteome on a global scale. My Ph.D 
research mainly concentrates on the development or fine-tuning of high-throughput 
amenable chemical platform to study enzymes especially Protein Tyrosine Phosphatases 
(PTPs). 
 2
1.2 Protein Tyrosine Phosphatases (PTPs) 
     PTPs are a class of signaling enzymes which catalyze the dephosphorylation of the 
phosphotyrosine residues in their protein substrate4 (Fig. 1.1). Protein phosphorylation 
and dephosphorylation reactions are employed by living organisms for the regulation of 
innumerable cellular processes.  (e.g., Signal transduction, a process in which cell 
converts one form of signal into another). Phosphorylation states are governed by Protein 
Kinases whilst dephosphorylation states are governed by Protein Phosphatases. 
Malfunction of PTPs leads to various human diseases like Cancer, diabetes, obesity etc5 
and thus PTP is an important drug target. More than 100 identified PTPs are encoded in 





























Fig. 1.1 Biological role of Protein Tyrosine Phosphatases (PTPs) 
 
The PTP super family can be classified into 3 main sub-families according to the 
amino acid sequence of PTP catalytic domain5 (Fig. 1.2). 
 3
    
Fig. 1.2 Classification of PTP super family 
 
(a) Classical Phosphatases: 
          Classical phosphatases hydrolyse the pTyr residues in the protein substrates and 
they are further classified as intracellular and receptor like phosphatases. e.g. PTP1B  
(b) Dual specificity phosphatases: 
     They dephosphorylate the pTyr as well as pSer/pThr residues in their protein 
substrates. Their active site motif is given by the sequence (H/V)C(X)5R(S/T). 
e.g. VHR, Cdc subfamily, PTEN (It can dephosphorylate phosphoinositides as well) 
(c) Low Molecular Weight Phosphatases (LMW):  
     They are the family of 18 kDa proteins which are involved in the dephosphorylation 
of the growth factor receptors. e.g., LMW-DSP4 
 
1.2.1 Catalytic mechanism of PTPs 
     All the PTPs share the common catalytic mechanism. The active site sequence is 
C(X)5R(S/T) which is also called the PTP signature motif6. Cysteine (C) and Arginine 
(R) are invariant and necessarily essential for catalysis. The Arg (221) in the active site of 
the PTP stabilizes the negatively charged phosphate group of the substrate.  Upon 




substrate binding the enzyme undergoes a conformation change which further brings the 
substrate close, followed by the attack of the Cys(215) on the phosphate group, a water 
molecule acts as a nucleophile in the breaking of the S-P bond  resulting in the 
















































Fig. 1.3 Catalytic mechanism of PTPs 
 
1.2.2 Inhibitor development for PTPs 
     Various drug companies as well as academic groups have been working on the 
development of various PTP inhibitors based on the pTyr mimetic. The most common 
ones are listed (Fig. 1.4). However, due to the negative charge(s) on the molecule most of 
the inhibitors suffer from poor bioavailability and poor cell permeability. Also, there lies 
a major challenge in the development of an inhibitor specific towards a particular PTPs, 
which is discussed in the following chapter. Recent generation of PTP inhibitors5 like the 
oxamic acid based as well as the isoxazole based inhibitors are proven to be cell 
permeable and bioavailable. We have adopted and developed some high-throughput 
amenable chemistry tools to develop better inhibitors against PTPs, which is discussed in 
































Fig. 1.4 Various Pharmacophores targeting PTPs. 
 
1.3 High-throughput amenable chemistry to study PTPs 
     One of the main challenges in the field of Catalomics is the development of high-
throughput (HT) amenable chemical reactions that allow rapid synthesis of diverse 
chemical libraries for the interrogation of different classes of enzymes.  High-throughput 
amenable reactions are mainly characterized by near-perfect, modular and robust and 
biocompatible nature. Among the HT amenable chemistry tools (Fig. 1.5), we have 
explored on Click chemistry, Solid-phase chemistry and Microwave (MW) assisted 
reactions for synthesis for the enzyme inhibitor libraries and fragments. 
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Fig. 1.5 High-throughput Chemistry tools 
 
1.3.1 Click Chemistry  
     Sharpless et al have defined Click Chemistry as a set of powerful, virtually 100% 
reliable, selective reactions for the rapid synthesis of new compounds via heteroatom 
links (C-X-C)7. Among the various click reactions the reaction between a terminal alkyne 
and an azide in the presence of Cu(I) catalyst generate exclusively the 1,4-disubstituted 
1,2,3-triazoles discovered independently by Sharpless8 and Meldal9 in the most 
celebrated one and more generally referred to as Click chemistry (Fig. 1.6).  The reaction 
is characterized by its high chemoselectivity, modularity, near-perfect yield and 
biocompatibility in the aqueous conditions are typically employed in the reaction, which 
renders the products ‘ready-to-use’ without further purifications. As a result, click 
chemistry has become an attractive tool in many research fields ranging from materials 
sciences, biology to medicinal chemistry/chemical biology. It is for the same reasons that 
click chemistry has emerged as an integral part of the drug discovery pipeline by 






















Fig. 1.6 Cu(I) catalyzed azide-alkyne ligation 
 
Other salient features of Click Reaction10 
1. Highly exothermic reaction (∆H = -45 to -55 Kcal/mol) 
2. High kinetic barrier – due to the high energy content of the azide and alkyne (25 
kcal/mol)  
3. In the Presence of Cu(I) the reaction is not significantly affected by the steric and 
electronic properties of the groups attached to the azide and alkyne reactive 
centers. 
4. The reaction is unaffected by water and other functional group, the rate of Cu(I) 
catalyzed is 107 times faster than the uncatalyzed one 
5. Triazole ring is very stable. Inert to oxidation, hydrolysis, and reduction 
conditions even at high temperature. 
6. Strong Dipole moment, aromatic, good H-bonding acceptor. 
 
1.3.1.1 Click-based fragment assembly and in situ screening 
     Fragment-based assembly is a recently developed drug discovery approach which 
enables high-throughput identification of small molecule inhibitors using a minimal 
number of compounds as building blocks11. The approach is powerful especially against 
protein targets which possess multiple binding pockets in their active sites (e.g., 
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Proteases, Phosphatases, and Kinases etc). Currently, there are mainly three methods 
used to assist the assembly of compounds: (1) the NMR-based SAR strategy12; (2) the 
tethering method developed by Wells et al 13 and (3) the in situ screening method 
developed by Wong and co-workers14 which was largely based on the “click chemistry” 
pioneered by Sharpless et al. (Fig. 1.7). Among them, the click chemistry approach is 
highly versatile in that it requires neither specialized equipment nor mutations in the 
target proteins. 
Properties of in situ screening 
1. Reactions are usually carried out at microscale level 
2. Water compatible or non-toxic solvent should be used for the reaction 
3. No protection group required 
4. Products are not isolated or purified, Ready-to-use products. 
5. Only high yielding reactions are suitable. 
 
 
Fig. 1.7 Fragment-based assembly and in situ screening. 
 
Till to date various groups including ours have utilized this powerful tool for the 
successful discovery of inhibitors against PTP1B15,16, Matrix metalloproteases (MMPs)17,  
HIV protease18, SARS 3CL protease19, sulfotransferase20, α-1,3-fucosyltransferase21, 
acetylcholinesterase22 and caspases23 (Fig. 1.8). 

























IC50 = 4.7 µM (PTP1B)
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IC50 = 0.15 µM (α-1,3-FucT VI)
IC50 = 6.5 µM (MMP-7)





































IC50 = 4.67 µM (Caspase-3)K i = 0.4 nm (AChE)  
Fig. 1.8 ‘Click’ inhibitors targeting various enzyme classes. 
 
1.3.1.2 Amide-bond formation and in situ screening 
     The reaction between an acid and an amine to generate amide using suitable 
activating/coupling reagent is also a near-perfect reaction and can be amenable to high-
throughput synthesis and in situ screening14 (Fig. 1.9a). The most common coupling 
reagents used is EDC, HATU, HBTU, Bybop etc. The amide-forming reaction between 
an amine and an acid is one of the most efficient reactions known, and has recently been 
applied successfully in the rapid discovery of inhibitors against a number of enzymes, 
such as cysteine proteases24,  HIV proteases25, HIV-1 dimerization26 inhibitor, β-aryl 
sulfotransferase27, α-fucosidases28 and SARS-3CL proteae29 (Fig. 1.9b). This chemistry 
has some key characteristics of a high-throughput amenable reaction, in that quantitative 
product formation can be achieved using powerful acylating/coupling reagents. As such, 
in situ biological screening may be carried out directly without product purification. But 
the method is severely limited by the presence of coupling reagents and, more often than 
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not, byproduct and excessive starting materials in the reaction, a subsequently during in 







































































Ki = 1.16µM (Caspase-1)
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Fig. 1.9 (a) Amide-bond formation reaction (b) Inhibitors assembled by amide-bond 
formation reaction 
 
1.3.2 Solid-phase synthesis 
     The next high-throughput tool that we have explored in Catalomics study is the solid-
phase library synthesis (Fig. 1.10). Most of the combinatorial libraries are generated by 
solid-phase method. In 1963 Merrifield published the first landmark paper on solid-phase 
synthesis of a tetrapeptide30 and Ellman was the first to report the solid-phase 
combinatorial synthesis of non-peptide based small molecules, benzodiazepines31. Solid 
phase synthesis have several advantages over solution phase synthesis, which are listed 
below 
 11
1. Can be automated easily and amenable to high-throughput synthesis 
2. Isolation of the compound is very simple, usually by simple filtration 
3. High product purity 
4. Easier to generate a large library of compound in a shorter time 
5. In some cases the reaction can be forced to completion by using excess of reagent 
6. In some cases (especially peptide synthesis), solubility problems are minimized 
However, the main limitations of solid-phase synthesis are difficulty in monitoring the 




(Block A attached to the
solid support)
(Block B)







Fig. 1.10 General principle of solid-phase synthesis 
Two general methods include in combinatorial synthesis is the split and mix synthesis 
and parallel synthesis. 
1.3.2.1 Split and mix synthesis 
     The split and mix method consists of three processes: (a) splitting, (b) coupling (or 
other reaction) and (c) mixing32 (Fig. 1.11). First, the resin beads are split into multiple 
reaction vessels and carried out the reaction with different individual compounds. The 
polymer beads are randomly mixed after the reaction. Thus splitting and mixing are done 
alternatively. The advantage of this method is easier and faster when compared to the 
parallel synthesis method and the compounds in the library grow exponentially with the 
number of steps. 
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Fig. 1.11 Schematic representation of split and mix synthesis 
 
1.3.2.2 Parallel synthesis method 
     It is a very simple approach in which the desired compounds are synthesized in 
individual reaction vessels and therefore all products are pure, separated and well 
defined33 (Fig. 1.12). However the main bottle neck of this method is the library size is 
usually very small. The synthesis can be either manual or automated. 
 
Fig. 1.12 Schematic representation of parallel synthesis 
Mix Mix 
Reaction SplitReactionSplit 
Split Reaction Split Reaction 
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1.3.2.3 Traceless resins 
     We have developed a traceless solid phase methodology for the high-throughput 
synthesis of PTP inhibitors (Fig. 1.13). Traceless synthesis can be defined as a synthetic 
route which yields compounds composed of only from atoms inherent to the particular 
target molecule34.  Synthesis using solid-phase traceless resins leaves no residues on the 
final compound after the cleavage from the solid support. We have explored the solid 
phase amide bond formation reaction and urea formation reaction using aldehyde 
traceless resin (PL-FMP)35 and for the first time we have synthesized a library of azides 
using the traceless tosyl resin. The former traceless method can be adapted to the 
synthesis of various drug like fragments and other important organic intermediates like 



















1.3.3 Microwave-Assisted Synthesis  
      The next high-throughput chemistry tool that we have explored for rapid generation 
of compound libraries is the microwave assisted organic synthesis (MAOS). Traditional 
method of heating reactions using oil bath, mantles etc is  inefficient because it depends 
on the thermal conductivity of the various materials that must be penetrated and the 
reaction of the reaction vessels is higher than the reaction medium whilst microwave 
heating is internal and depends on the dipole moment of the molecules36. Microwave 
assisted organic reactions have been proven to an invaluable tool for high-throughput 
chemists because of the following advantages 
1. Dramatic reduction in reaction time, the reaction time can be reduced from days 
to minutes 
2. The overall process is energy efficient than the oil-bath method  
3. Precise monitoring and control of temperature and pressure possible 
4. Can be automated 
5. The choice of the solvent is not governed by the boiling point 
6. Most of the reactions are cleaner and provide higher yields. 
7. Higher reaction temperature can by obtained (sealed tubes should be used). 
8. Facilitate the discovery of novel reaction pathways 
Recently Kappe et al have generated a library of Biginelli products using automated 
sequential microwave assisted chemistry37. A total of 48 different dihydropyrimidine 
(DHPM) analogues were synthesized by automated addition of building blocks and 
subsequent sequential microwave irradiation of each process vial. The desired products 


























































R1O MW, 200 oC, 10 min
(a) (b)
 
Fig. 1.14 (a) DHPM cores synthesized by high-speed automated MW technology (b) 
Microwave assisted solid phase synthesis of bicyclic dihydropyrimidones. 
 
In another recent report, Kappe et al have synthesized a library of bicyclic 
dihydropyrimidones by traceless solid-phase approach using MW-assisted cyclization 
and cleavage38 (Fig. 1.14b). They were able to achieve 99 % conversion within 15 min at 
170 °C, as confirmed by on-bead FTIR analysis. 
 
1.4 Activity-based Protein profiling/fingerprinting 
     In order to accelerate the functional analysis of a cell’s complete protein repertoire, 
high-throughput techniques capable of genome-wide studies of proteins are essential. 
Recently, the activity-based profiling of proteins has proven to be a powerful tool in 
proteomic studies, whereby subclasses of enzymatic proteins could be selectively 
identified39. This strategy takes advantage of mechanism-based probes that react with 
different classes of enzymes, leading to the formation of covalent probe–protein 
complexes which are readily distinguished non-reactive proteins in a crude proteome 
mixture from other non-reactive proteins in a crude proteome mixture. Fig. 1.15 shows a 
general approach to activity-based enzyme profiling using a fluorescently activity-based 
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probe. The probe selectively labels a particular class of active enzyme present in a 
complex proteome with many other different proteins. The labeled enzyme can be 
separated by SDS-PAGE and visualized by fluorescent imaging, which could be further 
characterized by mass spectrometry. 
 
 
Fig. 1.15 Representation of Activity-based labeling strategy 
 
     Highly specific probes offer invaluable insights into the topology of the enzyme active 
site and catalytic mechanism of particular enzyme sub-class; whilst broad-based probes 
can label most proteins having the same activity and have more application in profiling 
enzymes on a global scale.  
 
1.4.1 Components of activity-based probes 
An activity-based probe is generally made of three units (Fig. 1.16) 
1. Reactive unit (e.g. Fluoromethyl ketone40, vinyl sulfone41, epoxides42, 
fluorophosphonate43,  α-bromophenyl phospnotate44) 
2. Linker (e.g. peptide fragment, polyethene linker or alkyl linker) 
















































X= Cl, Br or OAc
Vinyl sulfone Epoxide Sulfonate ester










































Fig. 1.16 Components of Activity-based probes 
 
     The reactive unit can be a suicide/mechanism-based inhibitor of one particular class of 
enzyme which serves as a warhead to covalently modify the enzyme. The reactive units 
are generally electrophilic chemical groups. The linker forms a bridge between the 
reactive unit and the reporter unit, the length of the linker is very important to keep the 
reporter unit away for the active site. The reporter unit can be a fluorescent or radio or 
biotin tag, the tag should be compatible with standard SDS-PAGE techniques. Biotin 
facilitates detection by simple western blot approaches. Biotin label can also be used to 





1.4.2 Click chemistry-based design concepts 
     The versatility and ease in synthesis of activity-based probes in both protein imaging 
and/or isolation can be achieved by the use of “clickable” handles to incorporate reporter 
groups postlabeling (Fig. 1.17a). In these cases, the probe and the tag are synthesized 
with a complementary pair of orthogonally reactive chemical entities. Staudinger ligation, 
which covalently links a phosphane and azido groups or the Cu(I) catalyzed 1,3-dipolar 
cycloaddition between an alkyne and an azide are examples of such click chemistry 
approaches. A desirable feature of this method is that it minimizes the size of the ABP 
the incorporation of large fluorophores or tags at the outset can inhibit the delivery of the 
probe into the cell, such a two-step labeling approach could thus could provide the 
desirable utility for studying biologically relevant systems in their native state.  
Cravatt and co-workers applied the principles of ABPP to develop a general method for 
accelerated target discovery in small-molecule cell-based screens45. They designed a 
natural products-inspired library with two features to assist target identification: (a) an 
electrophilic spiroepoxide to covalently modify cellular target and (b) an alkyne for the 
visualization of the target protein via click chemistry. The spiroepoxide library was 
screened for anti-proliferation activity against the invasive human breast cancer cell line 
MDA-MB-231. One compound from the probe library, MJE3, was identified to have the 
best inhibition on proliferation (Fig. 1.17b). On analysis of the in situ reactivity profile, a 
single protein was found to be uniquely labeled by MJE3 and this protein was identified 
as  glycolytic enzyme phosphoglycerate mutase B. 
In another recent report, Cravatt and co-workers devised ABPs targeting cytochrome 
P450 super family, which are of great pharmaceutical interests46. The probe was designed 
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to have a 2-ethylnapthalene unit (know inhibitor of cytochrome P450) tagged with an 
alkyne handle. The probe was catalytically oxidized to a reactive ketene, which then 
reacted with a nuclueophilic residue in the enzyme. Subsequently it was clicked with a 
rhodamine/biotin reporter units tagged with azide. The strategy was successful in 
profiling the drug-P450 interactions both in vitro and in vivo (Fig. 1.17c).  




















































Fig 1.17: (a) ‘Click’ based two-step labeling approach (b) MJE3, natural product inspired 
activity-based probe (c) Labeling of cytochrome P450 (d) Labeling of metalloproteases. 
 
     Our group utilized click chemistry for the modular synthesis of ABPs targeting Matrix 
metallo-proteases (MMPs) which are laborious to synthesize individually47. This enabled 
the rapid assembly of a panel of hydroxamate-based trifunctional probes that each 
contained a benzophenone unit (photocross-linker) and a rhodamine tag (fluorophore). 
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The P1' position of the ABPs was diversified with twelve natural and unnatural amino 
acids, which rendered characteristic fingerprints when profiled against a panel of several 
different metalloenzymes (Fig. 1.17d). 
 
1.4.3 Imaging of Enzyme activity 
     Cravatt and co-workers have developed cell-permeable quenched activity-based 
probes (qABP) that can be used for direct imaging of papain-family cysteine protease 
activity in living human cells48. The probes consist of a peptide fragment attached to a 
reactive unit (acyloxymethyl ketone), fluorophore (rhodamine) and a quencher 
(BODIPY). The probe becomes fluorescent upon activity-dependent covalent 
modification of protease target.  This probe is used to monitor real-time protease activity 

















Fig. 1.18 Activity-dependent labeling of cysteine protease by qABP 
 
     Our lab has developed a handful of activity-based probes which is discussed in 
chapter 5. Other high-throughput activity-based profiling techniques/platform like 
microarray49, ‘expression display’50 for the genome wide identification of enzyme 





     Activity-based probes has proven to be a vital tool in identifying the protein classes,  
the next challenging task lies in elucidating how such proteins performs their functional 
roles in their native cellular milieu. Visualizing proteins in living cells is essential for a 
better understanding of their structure and functions. With the advent of fluorescent 
proteins and other molecular labels, cell biologists and protein chemists have witnessed a 
better understanding of intracellular proteins and subcellular events. Together with 
advances in fluorescence and confocal laser scanning microscopies51, 3-dimensional 
imagings of cellular events and protein dynamics have become possible in real time52. 
Traditionally, proteins were labeled in vitro with fluorescent and other molecular 
probes53, then transferred into live cells and monitored, in real time, using advanced 
imaging techniques. Recent advances in genetic engineering have made it possible to 
directly generate fluorescent proteins in living cells or even in live animals by fusion of 
fluorescent proteins such as GFP (green fluorescent protein) to the protein of interest54. 
However, the main drawbacks of GFP-like proteins include their large sizes, obligate 
oligomerization, and sometimes slow or incomplete maturation. I have discussed few 
imaging techniques using small molecules in the below paragraphs. A good labeling 
strategy should ideally satisfy the following criteria: (1) possesses a high signal-to-noise 
ratio (i.e. high specificity for target protein); (2) upholds the integrity of the labeled 
protein; (3) does not interfere with the biochemical functions or cellular localization of 
the labeled protein and (4) has minimal perturbation to the normal cellular processes. 
One of the earliest methods for site-specific labeling of recombinant proteins with small 
organic molecules within live cells was developed by Tsien et al.55. This method exploits 
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the well-known specificity of organoarsenicals with pairs of thiols. A short peptide 
sequence CCXXCC (in which X is a non-cysteine amino acid) was genetically fused to 
the protein of interest, which was subsequently recognized and labeled by a cell 
permeable fluorescein derivative called FlAsH (Fig. 1.19a). FlAsH contains two As(III) 
substituents conjugated to ethanedithiol (EDT). The free FlAsH label is virtually non-
fluorescent, but acquiring a 50,000-fold increase in fluorescence upon binding to the 
CCXXCC motif.  
     Covalent Labeling Using hAGT Fusions strategy was developed by Keppler et al. 
whereby specific covalent labeling with a small molecule was achieved through the 
human DNA repair protein O6-alkylguanine-DNA alkyltransferase (hAGT)56 (Fig. 
1.19c). The native biological role of hAGT is to irreversibly transfer the alkyl group from 
O6-alkylguanine-DNA to one of its reactive cysteine residues, to aid in the repair of the 
alkylated DNA57. hAGT also reacts with the cell-permeable nucleobase O6-
benzylguanine (BG) and BG derivatives substituted at the 4-position of the benzyl ring. 
By exploiting this chemistry, a hAGT fusion protein expressed in live cells was labeled 
with BG derivatives, BGBT and BGAF, which contain biotin and fluorescein, 
respectively.  
     Vogel et al  reported a generic method for the site-selective and reversible labeling of 
membrane proteins containing a polyhistidine sequence in live cells with small molecular 
probes58 (Fig. 1.19b). The labeling strategy was based on the well-known interaction 
between polyhistidine sequences and the Ni2+-NTA moiety59, in which a small organic 
fluorophores conjugated to nitrilotriacetate (NTA) moiety were used. The structure, as 
well as the plasma membrane distribution, of the ionotropic 5-hydroxytryptamine 
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serotonin receptor (5HT3R) was studied using this approach. Our own contribution to the 
field of bioimaging involves a novel strategy for site-specific covalent labeling of 
proteins in vivo60 by taking advantage of the chemoselective reaction of native chemical 
ligation61, which is explained in detail in the last chapter of the thesis. 























































Fig. 1.19 (a) Site-specific labeling of tetracysteine motif by FlAsH (b) NTA probe 
coordinating to Ni (II) ion. (c) Labeling of hAGT fusion protein with BG derivative 
    
 










Chapter 2  
 
High-Throughput Assembly of Protein Tyrosine Phosphatases 




     Click chemistry coupled with in situ screening is the simplest and versatile of all the 
fragment-based drug discovery approaches. This chapter summarises the development of 
a 66-member bidentate inhibitors of PTPs, by employing click chemistry for the first 
time, in the fragment based assembly of PTP1B. Screening of the library against a panel 
of different PTPs and non-PTPs revealed a specific inhibitor of PTP1B (IC50 = 4.7 µM). 
The second part of this chapter narrates the successful traceless solid-phase synthesis of 
325-member azide library suitable for direct click chemistry applications. The utility of 
the library is demonstrated with its subsequent high-throughput “click” assembly of 
3250-member library of bidentate inhibitors targeting various PTPs.  
2.2 Introduction 
2.2.1 Fragment-based drug discovery of PTP inhibitors 
     Fragment-based drug discovery approach is currently predominant in pharmaceutical 
industries62. The approach aims at identifying weekly active ligands (KD ~ 100-1000 µM) 
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and translates them into low nanomolar inhibitors against targets of low or borderline 
druggability targets using a variety of design strategies. Currently the most common 
strategy to assemble the compounds includes: (1) SAR by NMR/X-ray/MS strategy, (2) 
Tethering approach by Sunesis, (3) in situ screening method and recently Ellman’s SAS 
method. In SAR by NMR method, small organic molecules that bind to proximal subsites 
of a protein are identified, optimized and linked together to produce compounds with 
high binding affinity. Scientists at Abbott laboratories have identified salicylic acid based 
site 2 binding ligand (Kd = 1.2 mM) and isoxazole carboxylic acid (Kd = 800 µM) as 
catalytic site binder of PTP1B through an NMR based screening of over 10,000 
compounds (Fig. 2.1a).  
     Scientists at Sunesis came up with a platform called “Tethering” which allows for the 
identification of small-molecule fragments that bind to specific regions of a protein 
target. These fragments can then be extended, combined with other molecule or 
combined with one another to provide high-affinity drug leads. Standard covalent 
tethering uses a cysteine residue to capture disulfide-containing fragments that binds to a 
site near to the active site on the protein and mass spectroscopy is generally used to 
identify the fragments (Fig. 2.1b). They extended this technology to “breakaway 
tethering”, which overcomes the difficulty of introducing a cysteine residue in the highly 
conserved active site of PTP1B and used to discovery novel ligands that binds to the 
active-site of PTP1B63. 
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Fig. 2.1 Different fragment-based approaches to discovery PTP inhibitors (a) SAR by 
NMR method (b) ‘Tethering’ approach (c) Substrate activity screening method 
 
 
     Recently, Ellman’s group devised a new fragment-based approach called substrate 
activity screening (SAS) to identify selective and low-molecular-weight PtpB inhibitors 
with submicromolar inhibitory activity (Fig. 2.1c). Their approach consists of 3 steps: (1) 
140-member library of diverse O-aryl phosphates were screened to identify phosphate 
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substrates using a simple spectrophotometric-based assay; (2) optimization of the O-aryl 
phosphate substrates by analogue synthesis and evaluation; and (3) replacement of the 
phosphate group with known isosteres. By this new approach they were able to fish-out 
the most potent PtpB inhibitor reported to date (Ki = 0.22 µM) with low molecular weight 
and good selectivity against a panel of other PTPs64. 
 
 
2.2.2 Click Chemistry as a High-throughput tool 
     Click chemistry has emerged as an integral part of the drug discovery pipeline by 
providing a high-throughput amenable chemical reaction platform for compound 
synthesis65, 66. Unlike other fragment-based approaches, click chemistry-based strategies 
require neither sophisticated instruments nor mutations in the target proteins, and at the 
same time enable the exploration of N2 possibilities with N + N chemical entities. This is 
particularly useful for small-molecule lead discovery against enzymes (and other 
proteins) that possess an extended active site (as in the case of most proteases) or 

















































IC50 = 4.7 µM
(against PTP1B)
 
Fig 2.2 Click chemistry and in situ screening of inhibitor discovery 
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2.2.3 Bidentate inhibitors against Protein Tyrosine Phosphatases 1B (PTP1B) 
     PTPs are the key signaling enzymes with plays a vital role in myriad of cellular 
processes4. There are ~40 PTPs in the human body and among the various PTPs, PTP1B 
is the prototype and recently identified to be a key player in diabetes and obesity and 
PTP1B is recognized as a druggable proteome68. Active research has been going on to 
discover potent and specific small molecule inhibitors against PTP1B. However the main 
challenge lies in developing a specific inhibitor against PTP1B, because all the PTP’s 
(including PTP1B) active sites are highly conserved and have high sequence homology. 
PTPs like LAR, CD45, SHP-2, cdc45 and T-cell PTP (TCPTP) share 51, 48, 52, 44 and 
80% homology in the catalytic domains to PTP1B which results in a challenging task to 
inhibit PTP1B selectively. 
   Recently, Zhang et al discovered the presence of a secondary aryl-phosphate binding 
site near the active site of PTP1B, thus shedding lights on the development of bidentate 
inhibitors which might impart both potency and specificity against the enzyme69 (Fig. 
2.3).  Based on this model, researchers at Abbott laboratories recently discovered cell-
permeable, micromolar bidentate inhibitors containing a core N-phenyloxamic acid 
mimic which, upon testing in PTP1B-expressing COS-7 cells, showed much greater 
cellular activities (in terms of inhibition and selectivity) and pharmacokinetic properties 
than other inhibitors possessing potent inhibitory activity in vitro but suffering from low 
cell permeability and selectivity in vivo.70,71  The key to their success is the use of NMR-
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Fig. 2.3 Bidentate inhibitors against PTP1B 
 
 
                            
2.2.4 PTP1B bidentate inhibitor design 
 
     We designed a total of 5 alkyne functionalized isoxazole-based warhead which can 
binds to the PTP1B active sites and we designed and synthesized 14 different azide 
functionalized aromatic blocks which can binds with the peripheral sites. We explored 
the in situ “Click Chemistry” to assemble these fragments. In short, our inhibitor design 
encompasses the following (Fig 2.4a). 
(1) Each member is made of a modular, bidentate structure containing both a core and a 
peripheral group for potential binding to the enzyme (Fig. 2.4b);  
(2) Whenever possible, each of the two (core and peripheral) groups should possess 
optimized pharmacological properties. 
(3) An alkyl linker (with optimized chain length) which links the active site binder with 







































2.3 Results and Discussion 
2.3.1 Chemical Synthesis of the inhibitor library 
 
Synthesis of the Alkyne fragments: 
 
     Compound 2-A was synthesized from the commercially available 4-
hydroxyacetophenone, 2-15, which upon refluxing with propargyl tosylate in the 
presence of K2CO3 and dibenzo-18-crown-6, afforded 2-16 with excellent yield (93%).  
Followed by condensation between 2-16 and dimethyloxalate in the presence of NaOMe, 
followed by cyclization of the resulting product in the presence of hyroxylamine, gave 
the isoxazole carboxylic methylester, 2-17, in modest yield (35 % for 2 steps). Similarly 
starting from  5’-chloro- or 5’-fluoro-2’-hydroxyacetophenone, compounds 2-B and 2-C 
were synthesized(i.e. 2-18 or 2-21).  For the synthesis of compound 2-D, commercially 
available 4-nitroacetophenone 2-24 was condensed with dimethyloxalate followed by 
cyclization to afford 2-25 (36% overall yield).  Subsequent reduction of the nitro group in 
2-25 with 10% Pd-C in the presence of H2 gave 2-26 (91%), which upon coupling with 
mono-Boc protected succinic acid, 2-36, generated 2-27.  Next, deprotection of the Boc 
group by 50 % TFA in dichloromethane followed by coupling with propargylamine 
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afforded 2-28. The methyl ester in 2-28 was subsequently hydrolyzed with NaOH to 
afford compound 2-D in 88% yield. In the case of 2-E, condensation of 2-19 with 
dimethyloxalate followed by direct treatment of the resulting product with hydrazine 
hydrate in the presence of p-TsOH generated the pyrazole carboxylic methylester, 2-29, 






























































































34% for 2 steps
34 % for 2 steps
NaOH
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2-19: X = Cl
2-22: X = F
2-B: X= Cl (89%)
2-C: X = F (91%)
2-20: X = Cl
2-23: X = F
2-292-E
93%
2-24 2-25 2-26 2-D
2- 28: R =
















Synthesis of the azide fragments: 
 
     The 14 different aromatic azides were synthesized using a two/three-step procedure 
(Scheme 2.2).  2-bromoacetyl chloride and 3-bromopropionyl chloride were purchased 
commercially, whilst 5-bromovaleryl chloride was synthesized from 5-bromovaleric acid, 
using thionyl chloride.  Subsequently, 9 different aromatic amines, representing different 
polarity (benzyl, phenyl, napthyl, heterocycles) and subsituents (halogens, esters, ethers, 
alcohols), were acylated with one of the above three bromoalkylacyl chlorides, followed 
by an SN2 substitution reaction with sodium azide in DMF to generate the corresponding 
azides.  Compound 2-14 was synthesized from the corresponding amino acid (i.e. lysine).   
 
 




Assembly of the Library 
     The Cu (I)-catalyzed ligation of alkyne blocks and azide blocks was next carried out.  
It was found that a mixed solvent system containing t-BuOH, water and DMSO (1:1:0.1) 
enabled both the alkynes and the azides to be completely dissolved, and at the same time 
the 1,3-dipolar coupling be carried out with extremely high efficiency. More importantly, 
the products could be taken directly without further purifications. 5 different alkynes 
were clicked with 13 different azides [(5 x 12) + (1 x 1)] to afford a 66 member library 
(Scheme 2.3). LC-MS analysis of all 66 coupling reactions indicated the complete 
consumption of the alkynes and quantitative formation of the triazole products in most 
cases.   
















Scheme 2.3 Click assembly of PTP inhibitors 
 
2.3.2 Results and conclusion of the screening experiments 
 
The 66-member library was next screened directly against 6 different phosphatases, 
including 4 PTPs (i.e., PTB1B, TCPTP, YOP and LAR), a dual-specific phosphatase (i.e. 
Lambda PPase) and serine/threonine phosphatases (i.e. PP1). Fluorescence-based 
phosphatase assay was used throughout73. A majority of the library members showed 
some degree of inhibition against three of the four PTPs, namely PTB1B, TCPTP and 
YOP.  This is expected when one considers that the library was purposefully designed to 
contain a core group which structurally resembles the original Abbott’s inhibitor. On the 
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other hand, none of the library members showed any inhibition against LAR, λPPase and 
PP1 until at very high concentrations (> 450 µM of inhibitor).  For LAR, a protein 
tyrosine phosphatase, this is somewhat surprising.  On the other hand, this may also 
underscore the feasibility of our strategy for potential discovery of inhibitors against 
specific PTPs with high potency and specificity.  Compounds 2-A13, 2-C10, 2-B1, 2-
B11, 2-B4, 2-A5 were identified to be the relatively potent ones against PTB1B, TCPTP, 
YOP, LAR, λPPase, and PP1, respectively.  These six compounds were further 
investigated by the measurement of their IC50 values.  The IC50 values of the six 
compounds against all six enzymes were shown in previous section. The IC50 values were 
obtained using dose-dependent reactions by varying the concentrations of the inhibitor, 
under the same enzyme concentration.    Representative results are shown in Fig. 2.5 and 





Fig. 2.5 IC50 graphs for selected inhibitors against PTP1B and TCP TP 
 
Among the six hits (2-A13, 2-C10, 2-B1, 2-B11, 2-B4 & 2-A5) identified, one of 
which, e.g. 2-A13, a potential potent and specific PTP1B inhibitor, and further 
characterized. The structures of the 6 inhibitors are shown in Fig. 2.6.  As shown in 
Table 2.1, compound 2-A13 indeed inhibited PTP1B with an IC50 of 4.7 µM, which is 
comparable to that of the original Abbott’s inhibitor.  More importantly, it is 
approximately 5 and 25 times more selective towards PTP1B than the other two PTPs, 
TCPTP and YOP, respectively, and is > 100 times more potent than against LAR, λPPase 
and PP1.  Another noticeable hit is 2-C10, which showed good inhibition towards 


























TP YOP LAR λPPase PP1 
2-A13 4.7 23.3 120.1 >450 >500 >750 
2-C10 58.1 17.5 24.1 >450 >500 >750 
2-B1 17.2 25.5 23.9 >450 >500 >750 
2-B11 29.6 21.7 82.2 >450 >500 >750 
2-B4 19.8 49.4 176.8 >450 >500 >750 
2-A5 34.5 64.5 74.6 >450 >500 >750 
 
Table 2.1 IC50 (in µM) of 6 selected inhibitors. 
 
 
2.4 High-throughput synthesis of 3250-member PTP inhibitor library 
 
 
2.4.1 Traceless solid-phase synthesis of 325 azide fragments  
 
        Click chemistry-based screening method is highly advantageous in identifying 
enzyme inhibitors but it remains to be truly high-throughput amenable due to the lack of 
a robust and efficient chemical strategy that give access to large, diverse libraries of azide 
functionalized enzyme binders using readily available building blocks (like alcohols or 
amines). Standard methods of preparing azides74 involves the solution phase synthesis 
and purification of the individual compounds by column purification, therefore it is time-
consuming and low-throughput. We report a truly high-throughput amenable, solid-phase 
strategy for the synthesis of high-quality azides which, without purification, could be 
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used for “click assembly” and direct in situ screening of enzyme inhibitors. Our strategy 
made use of the commercially available PL-FMP resin (aldehyde resin) on which an 
immobilized 4-formyl-3-methoxyphenoxy moiety efficiently captured a variety of 
primary amines via reductive amination and converted them to the corresponding 
secondary amines which were subsequently acylated. Following TFA cleavage, the 
desired products were obtained in uniformly high quality (Fig. 2.7). There are numerous 
advantages in this method: (1) it is a traceless solid-phase strategy, allowing the use of as-
is starting materials (i.e. same as solution-phase methods) as building blocks and is easily 
amenable to high-throughput synthesis (i.e. IRORI™ split-and-pool sorting technology) 
of a large number of azides. (2) It is highly robust, capable of making a variety of azides 
from different functionalized building blocks (i.e. amines, acids, sulfonyl chloride, and 
chloroformate) with suitable linkers; (3) it gives rise to products with extremely high 
purity, thus allowing them to be used directly for “click” assembly followed by in situ 
enzyme screening.  
 
 













 in coded microreactors 
Reaction with various 
Amine building blocks/azide 
linker 
Reaction with azide 
Linker linker/Building 
blocks 
1. Decoding the microreactors 
2. Cleavage followed by  
   Evaporation of cleavage 
    cocktail in  96-well plates 
 (The only purification step) 
3. Redissolve in DMSO   
325 – Azides suitable for 
Direct ‘Click’ Chemistry applications 
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2.4.2 Chemical synthesis of the azide fragments 
 
To demonstrate our strategy, a 325-member azide library was synthesized as shown in 
Scheme 2.4. Depending on the choice of building blocks and linkers, route A or B was 
taken. In route A, 40 different commercially available aromatic amine building blocks 
were treated with the PL-FMP aldehyde resin, 2-37, in the presence of Na(OAc)3BH/2 % 
glacial acetic acid, to give the corresponding secondary amines, 2-38. The reductive 
amination reaction proceeded smoothly with a variety of aromatic amines bearing 
different substitutents such as -F, -Cl, -OR, -SCH3, -CO2R and -R. Benzyl, napthyl and 
anthracenyl amines too underwent reductive amination smoothly. Subsequently, 
treatment with azidoalkynoyl chlorides, furnished the N-acylated products, 2-3a to 2-3e. 
Other coupling conditions attempted (e.g. DIC/EDC/HATU/PyBOP) failed to give the 
desired products in sufficient purity. In route B, we first carried out reductive amination 
with azide-functionalized amine linkers to give 2-4a to 2-4e. Subsequently, the resulting 
resins were treated with different commercial available building blocks, including acid 
chloriders, aryl acids, sulfonyl chlorides and chloroformates, giving 2-6a to 2-6e; 2-39, 2-
7a to 2-7e,  and 2-8a to 2-8e respectively. We found that coupling using acid chlorides, 
sulfonyl chlorides and chloroformates was excellent as expected. With aryl acid building 
blocks, however, the PyBOP/HOAt coupling was the method of choice, providing 
complete coupling to give 2-39. Other coupling conditions were tried but failed to give 
satisfactory results. We also found building blocks bearing different functionalities such 
as –F, -Cl, -Br, -R, -OH, -OCH3, -CF3, -CN, -OH, -NO2 and -vinyl were tolerated. 
Finally, cleavage of the resins with optimized TFA cocktails gave the desired products, 
which, upon concentration in vacuo, analysis and characterizations by LC-MS/NMR, 
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showed uniformly high purity (> 95% in most cases). In total, 198 amide-bearing azides 
(i.e. 2-A1-2C to 2-D4-6C, 2-E1-2C to 2-G10-2C, 2-H1-2C to 2-H1-6C), 115 different 
sulfonamide-containing azides (i.e. 2-I1-2C to 2-J11-6C), and 3 carbamate-derivatized 
azides (i.e. 2-L1-2C to 2-L1-6C) were successfully prepared. Stock solutions of these 
azides were prepared in uniform concentration with DMSO in 96-deep well plates and 
used directly, without any purification, for subsequent in situ click assembly followed by 
enzymatic screening.  
Na(OAc)3BH

























n = 1, 2, 3, 4 and 5
2-A1-2C to 2-D4-6C 2-E1-2C to 2-G10-2C
2-7a; n = 1
2-7b; n = 2
2-7c; n = 3
2-7d; n = 4















2-4a; n = 1
2-4b; n = 2
2-4c; n = 3
2-4d; n = 4













































2-8a; n = 1
2-8d; n = 4
2-8e; n = 5
2-6a; n = 1
2-6c; n = 3
2-6d; n = 4
2-6e; n = 5
2-3a; n = 1
2-3c; n = 3
2-3d; n = 4


















































2.4.3 Chemical synthesis of the 3250-member click library 
 
 Five different alkynes (set II) functionalized with PTP warheads were synthesized as 




40: X = OMe, Y = H








42: X = OMe, Y = H











44: X = OMe, Y = H
45: X = H, Y = Me
(1) NaOMe
Dimethyl oxalate
Ref lux, 12 h
(2) NH2OH.HCl







2-F: X = OMe, Y = H






Ref lux, 6 h
(1) NaOMe
Dimethyl oxalate
Ref lux, 12 h
(2) NH2OH.HCl



















46: X = H, Y = Br, Z = Br
47: X = F, Y = H, Z = H
48: X = H, Y = H, Z = H
49: X = H, Y = Br, Z = Br
50: X = F, Y = H, Z = H
51: X = H, Y = H, Z = H
52: X = H, Y = Br, Z = Br
53 : X = F, Y = H, Z = H
54 : X = H, Y = H, Z = H
2-H: X = H, Y = Br, Z = Br
2-I: X = F, Y = H, Z = H
2-J: X = H, Y = H, Z = H
Y Z Y Z
Y Z Y Z
67 - 90 %
34 - 44 %
92- 96 %
























































Scheme 2.5 (a) Synthesis of alkynes set-II (b) Structure of the 10different alkynes used 
Having successfully synthesized a variety of 325 azides and 10 different alkynes in total, 
next we assembled them in a high-throughput fashion by employing the Cu(I) catalyzed 
alkyne-azide ‘click’ ligation (Fig. 2.8). 
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Fig. 2.8 Schematic representation of 3250-member ‘click’ assembly 
 
 At first we optimized the ligation by attempting different reaction conditions and 
solvents (Table 2.2). In our hands CuSO4/Sodium ascorbate system in either t-BuOH or 
1,2-dichloroethane(DCE)  or dichloromethane (DCM) as co-solvent in water worked 
well. However, since chlorinated solvents were not compatible with 384-well plates due 






Catalyst Additive Solvent Yield Purity 
1* CuSO4.5H2O Sodium ascorbate t-BuOH ~100 >95 
2 CuSO4.5H2O Sodium ascorbate DMSO >95 >95 
3 CuSO4.5H2O Sodium ascorbate DCM§ ~100 ~100 
4 CuSO4.5H2O Sodium ascorbate 1,2-DCE§ ~100 ~100 
5 CuI Acetonitrile, Pyridine t-BuOH >90 80 
6 CuI Acetonitrile, pyridine DMSO >95 90 
 
*Best reaction condition in 384-well plate  
§Easily evaporated from the 384-well reaction plate, need regular top-up of the solvent. 
 




The alkyne solution in DMSO were dispensed to each well of the 384-well plate using a 
bulk-dispenser and the azides were dispensed directly from the 96-well plate to the 384-
well plate with the aid of a robotic liquid handler, followed by the transfer of the catalyst 
mix (CuSO4 and Sodium ascorbate solution in water) using the bulk dispenser. The plates 
were sealed using a silicon cap mat and shaken for 2 days after which the solvents were 
evaporated using a vacuum centrifuge and redissolved in DMSO and made into 50 mM 
stock plates and were analyzed and characterized by LC-MS. The limiting alkyne war-
head was completely used-up and the desired triazole products were formed in 
quantitative yield and were taken directly for in situ screening.   
 
2.5 Conclusion 
In conclusion, we have successfully developed bidentate inhibitors of PTPs, by 
employing click chemistry for the first time, in the fragment based assembly of PTP1B 
inhibitors. A 66-member “click” library using five different alkyne-functionalized 
isoxazole-based active-site binders and 13 different azide-functionalized aromatic 
peripheral binders were synthesized in mixed water and t-BuOH solvent system using 
CuSO4/Sodium ascorbate as the catalyst. Subsequent screening of the library again four 
PTPs (PTP1B, TCPTP, YOP and LAR), a dual specific phosphatase (PPase) and a 
serine/thronine phosphatase (PP1) revealed six potent inhibitors of the PTPs with one 
compound identified as a specific inhibitor of PTP1B (IC50 = 4.7 µM). None of the 
library members showed considerable inhibition against non-PTPs.  
    The second part of this chapter narrates the successful solid-phase synthesis of 325-
member azide library for the first time via IRORI split-pool synthesis and subsequent 
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“click assembly.” The method is highly robust and is highlighted by its simplicity and 
product purity. The utility of the library is demonstrated with its subsequent “click” 
synthesis with 10 different alkyne-functionalized isoxazole-based PTP active-site binders 
which gave access to 3250-member library of bidentate inhibitors targeting various PTPs. 
The entire operation was performed on 96/384 well plates and its truly high-throughput.  
With this new method, the whole process of inhibitor discovery, starting from the 
synthesis of building blocks to the identification of enzyme inhibitors, could now be 
completed in a very short time. We therefore envisage that this approach will provide a 














Chapter 3  
 




     This chapter summarises the development of a traceless solid-phase strategy to 
assemble PTP inhibitors using amide-bond formation reaction. The strategy is robust, 
giving high-quality products which are spectroscopically pure enough to be used for 
biological screening without any further purification. A 70-member combinatorial library 
of isoxazole-based bidentate inhibitors of PTPs were synthesized, which upon direct in 




3.2.1 High-throughput amenable chemical reactions in inhibitor discovery 
      
     High-throughput study of enzymes is very crucial in the post-genomic era75, 76. One of 
the main challenges in the filed of high-throughput Enzymology is the development of 
high-throughput (HT) amenable chemical reactions that allow rapid synthesis of diverse 
chemical libraries for the interrogation of different classes of enzymes. One such reaction 
is the Cu (I)-catalyzed, 1,3-dipolar cycloaddition between an azide and an alkyne 
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fragment, Another class of reaction possessing similar qualities is the amide bond-
forming reaction between an amine and a carboxylic acid using suitable 
activating/coupling reagents (like EDC, DCC, PyBOP, HATU, HBTU etc)77. The salient 
features of this reaction include its high yield, inoffensive by-products, compatible with 
microtiter plates, product stability etc. Numerous research groups have recently used this 
reaction for solution-phase, rapid assembly of small molecule inhibitors against a variety 
of enzymes including HIV proteases, β-aryl sulfotransferase, α-fucosidases and SARS-
3CL protease78. The reaction is highly efficient, often generating the desired products in 
nearly quantitative yields, thus allowing in situ biological screening to be carried out 
directly in some cases, even in the presence of excessive starting materials, reagents or 
by-products (Fig. 29a). Apart from 1,2,3-triazole formation and amide bond-formation 
reactions, other high-throughput amenable chemical reactions like (1) Pictet-Spengler 
reaction; (2) N- and O-alkylation reactions; and (3) epoxide opening reaction have been 
adapted by various research groups in the discovery of enzyme inhibitors. 
 
3.2.2 Limitations of Wong’s in situ screening approach 
Wong et al pioneered the microtiter-plate based reaction coupled with in situ screening 
in the discovery of enzyme inhibitors (Fig. 3.1a). Usually the reactions are done in 
microtiter-plate in microgram scale and directly taken for in situ screening without any 
further purifications or isolation of the product. The effectiveness of this method, 
however, had recently been challenged, as it was discovered that unexpected by-products 
may give rise to false results. In one typical example, Wong’s group has attempted the 
synthesis of Lopinavir®-like compounds via amide bond-formation reaction between 
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various acids and amines in microtiter plates using HBTU as a coupling reagent. 
However, no desired products were formed and instead the intermediate benzotriazole 
ester was found to be responsible for the inhibitory activity towards SARS 3CL 
proteases79 (Fig. 3.1b). To avoid such potential complications, we aim to develop solid-













































Fig. 3.1 (a) Wong’s solution-phase and in situ screening approach (b) Stable 




3.2.3 Introduction to solid-phase combinatorial library  
  
     Combinatorial chemistry has emerged as a standard platform to generate large 
libraries of compounds for the drug discovery applications. Parallel and split solid-phase 
syntheses are highly useful in generating discrete and diverse sets of molecules 
respectively. In one specific example, Merck developed a new solid-phase strategy for 
the synthesis a library of 902 compounds of Indinavir® analogues (Fig 3.2)80. On 
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evaluation of these compounds, 2,6-dimethyl-4-hydroxy phenol was found to be a good 

















































IC50 = 0.2 nm against HRV 3CP
 
























 Fig. 3.3 Yao’s solid-phase and in situ screening approach 
 
   In our strategy, we used the commercially available 4-Formyl-3-methoxyphenoxy 
(FMP) resin to capture various amine fragments via reductive amination, followed by 
attaching the isoxazole warhead. On cleaving the products form the resin, ‘only’ products 
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were obtained (Fig 3.3). Key advantages of our method include (i) it is a traceless 
approach allowing the use of exact same sets of starting material as in solution-phase 
synthesis; (ii) it’s solid-phase, enabling a large library to be constructed efficiently; (iii) 
it’s robust, giving high-quality products which in most cases are spectroscopically pure 
enough to be used directly for biological screening; (iv) ’only’ products are taken for 



























Fig 3.4 Graphical representation of our solid-phase strategy 
 
3.2.4 PTP Inhibitor Design 
In the current work, we have successfully developed our 2nd-generation, cell-
permeable PTP1B inhibitors by using a solid-phase amide-forming reaction to rapidly 
link the core (acid functionalized isoxazole unit) and the peripheral groups (aromatic 
amine blocks) together, again here the inhibitors are bidentate one (Fig. 3.5a). Unlike 
traditional solution-phase approaches, our method delivers pure bidentate inhibitors at the 
end of synthesis and therefore is suitable for direct in situ screening. By screening these 
inhibitors against PTP1B, we have uncovered a candidate molecule which possesses 















































Fig. 3.5 (a) Inhibitor design- solid-phase amide bond formation reaction (b) Most potent 




3.3 Results and Discussion 
 
 
3.3.1 Chemical Synthesis of the inhibitor library      
                                     
 
Synthesis of the acid functionalized war-heads 
 
     The synthesis of the acid-containing warheads, 3-A and 3-B, started from the 
commercially available 4-hydroxyacetophenone 3-1, which on O-benzylation  gave 3-2 
(83% yield). Subsequently, condensation between 3-2 and dimethyloxalate in the 
presence of NaOMe, followed by cyclization with hydroxylamine gave the isoxazole 
carboxylic methyl ester, 3-3, in modest yield (42% in two steps). Conversion of 3-3 to 3-
5 was carried out first by base hydrolysis, followed by t-Bu ester formation (85% in two 
steps). Next, the benzyl ether 3-5 was deprotected in the presence of hydrogen (in Pd/C) 
giving 3-6, followed by O-alkylation with two different linkers to afford 3-7a and 3-7b 
(93% and 63% yield, respectively). Subsequent deprotection of the benzyl esters gave the 
two acid-containing warheads, 3-A and 3-B, respectively.  
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Synthesis of the traceless inhibitor library 
 
   To start the assembly on solid phase, two sets of thirty-five aromatic amines were 
treated with FMP resin in the presence of Na(OAc)3BH/2% glacial acetic acid in DCE to 
give the corresponding secondary aromatic amines 3-10. Reductive amination proceeded 
smoothly with a variety of aromatic amines bearing different subsituents including -OH, -
OR, -SR, -F, -Cl, -OCF3, -CO2R and –R. Benzyl, napthyl and anthracenyl amines too 
underwent reductive amination smoothly. Subsequent amide bond-forming reaction 
between the resin-bound secondary aromatic amines and the acid warheads (3-A and 3-B) 
was found to be highly challenging and required extensive optimizations. A variety of 
coupling reagents including HATU, PyBop, HBTU, EDC and DIC were attempted, but 
none gave the desired products in satisfactory yield and purity. Fortunately, by in situ 
conversion of 3-A and 3-B into their corresponding acid chlorides, 3-8a and 3-8b, with 
one equivalent of oxalyl chloride (with DIEA in DCM), we were able to successfully 
couple them, giving the resin-bound inhibitors 3-11 with excellent purity (> 95% in most 
cases). Finally, cleavage of the products from the resin using an optimized TFA cleavage 
cocktail (TFA:DCM:Water = 10:9:1) gave a total of 70 bidentate PTP inhibitors, 3-A1 to 
3-A35 and 3-B1 to 3-B35 (Scheme 3.1). Most crude products were characterized by LC-










NaOMe, ref lux,12 h
(2) NH2OH.HCl
p-TsOH (Cat.)



















































3-A: R = OH; n=4, quantitative yield
3-B: R = OH; n=6, quantitative yield
(n=4,6)
MeOH, 4 h, rt
(83 %)




3-8a: R = Cl; n=4


































(3-A1 to 3-A35: n = 4 )














3-11a: n = 4
3-11b: n = 6  
 
 
Scheme 3.1 Traceless solid-phase synthesis of PTP1B inhibitors 
 
 
3.3.2 Results and conclusion of the screening experiments 
 
 
Ki measurements of selected inhibitors: 
 
 
The inhibitory activity of the bidentate inhibitors was determined using a standard 
fluorescence microplate assay as explained in the previous chapter. First, an inhibitor 
fingerprint of the 70-member library against PTP1B was obtained, from which six potent 































































Fig. 3.5 Six candidate hits identified against PTP1B. 
 
A kinetic evaluation was performed for three of the strongest inhibitors identified – 3-
A21, 3-A26 and 3-A34 against PTP1B. Dose-dependent reactions were carried out by 
varying both the concentration of substrate and inhibitor while keeping the enzyme 
concentration constant. Briefly, a two-fold dilution series from approximately 200 µM to 
3.125 µM (final concentration) was prepared for each inhibitor. The enzymatic   mix was 
incubated for 30 min before initiating the reaction with varying amount of substrate (2 
µM - 8 µM). The enzymatic reactions were immediately monitored at λex = 355 nm and 
λem = 460 nm for a period of 5 min. The kinetic data obtained were analyzed using the 
Dixon Plot (1/initial velocity plotted against inhibitor concentration); affording three 
different linear graphs (corresponding to the different substrate concentration) that 




Fig. 3.6 Dixon plots for determination of Ki values of three representative inhibitors 
against PTP1B 
 
Discussion of the screening results 
     The best inhibitor against PTP1B was found to be 3-A26, with IC50 and Ki values of 
10.3 µM and 7.0 µM, respectively (Table 3.1). Significantly, it also showed a 10-fold 
selectivity over TCPTP. It is interesting to note that 3-A26, as well as the other good 
inhibitors of PTP1B, as shown in Fig. 3.5, contains a bulky aromatic group. This 
coincides reasonably with previously known cell-permeable inhibitors of PTP1B 
developed using other strategies, i.e. fragment-based or “click” chemistry approaches15, 69, 
70 thus further validating our solid-phase amide-forming methodology as a feasible 
strategy for future discovery of other enzyme inhibitors.                                               
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  IC50 (Ki) in µM  
 
Enzyme  3-A21 3-A26 3-A34 3-A35 3-B7  3-B25  






35.9  60.5 28.7  
TCPTP  174.5 105.4 124.4 103.5 205.1  489.1  
 
Table 3.1 Inhibition of the six selected inhibitors 
 
3.4 Conclusion 
     In conclusion, we have successfully developed a solid-phase approach to assemble 
bidentate inhibitors of PTPs, by using amide-bond formation reaction. This strategy is 
highlighted by its robustness, product purity and allows diversification of a common core 
in a simple way. In our strategy, 35 different commercially available amines were 
captured via reductive amination on an aldehyde resin followed by coupling with two 
different acid-functionalized isoxazole warheads. Subsequent cleavage from solid-
support provided a 70-member library which was taken directly for biological screening.  
Subsequent screening of the library against two PTPs (PTP1B and TCPTP) revealed three 
potent inhibitors with one compound (Ki = 7.0 µM) identified, whose inhibitoion against 
PTP1B was comparable to that of other known PTP1B inhibitors. Unlike the existing 
microtiter plate based approach, our method provides pure products which are free from 
the by-products, excessive starting materials and coupling reagents and avoids any false 
results during in situ screening. Also, our method uses the same sets of starting materials 
as in solution based microtiter plate synthesis. This solid-phase approach was developed 
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by us for the first time in the drug discovery area and applied to the successful discovery 
of PTP1B inhibitors. This method, which is superior to the existing methods, should find 
useful applications in high-throughput inhibitor discovery against various enzymes apart 




















Chapter 4  
 




     Libraries of small molecule fragments like azides, thiols, ureas, aryloxy/alkyloxy 
amines etc., are very crucial building blocks for the high-throughput fragment-based drug 
discovery. Only few synthetic methods/platforms are available to synthesize libraries of 
those molecules. We have devised simple and practical microwave-assisted strategies for 
the conversion of readily available alcohol building blocks into azides. In the first route, 
tosyl resin was used for the first time to synthesize azides in a catch and release approach. 
In the second route, alcohol building blocks were readily converted into azides via 
microwave (MW)-assisted azidation of tosylates/mesylates/chlorides. After a simple 
purification procedure, the azides synthesized from the above methods were suitable for 
directly click chemistry applications.  
 
4.2 Introduction 
     Fragment-based drug discovery allows the modification or diversification of a core 
group (possessing moderate binding affinity towards a target protein/enzyme) using 
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simple fragments which possesses weak binding affinity to give a more potent bidentate 
type of inhibitors62. The small fragments could be either commercially and readily 
available building blocks like thiols, amines, aldehydes, acids, boronic acids etc or in 
some cases it could be molecules like azides (for click reaction), ureas (for Biginelli 
reaction), isocyanides (for Ugi multicomponent reaction), alkyl or aryloxyamines (for 
oxime formation reaction) which are difficult to access in large number for combinatorial 
library synthesis. Till-to-date no high-throughput methods are available for the versatile 
library synthesis of azides and ureas from simple and readily available starting materials. 
 
4.2.1 Synthesis of azides – a literature review 
Solid-phase azide synthesis 
     A combinatorial synthesis of 32 different aryl azides was accomplished by the TMSN3 
mediated cleavage of the polymer-bound aryl triazenes (Fig. 4.1a). The triazene can be 
modified in a number of ways, one such method is the Cu(I) mediated 
UllmannNicolaou coupling82. These azides are convertible to a broad range of 
heterocycles. In another example, Suckling et al, synthesized heteroaryl azides from 
polymer supported heteroaryl sulfones in the presence of azide ions, by a nuclueophilic 












































Fig 4.1 (a) Solid-phase synthesis of aryl azides from aryl triazenes (b) Solid-phase 
synthesis of heteroaryl azide from heteroaryl sulfone 
 
Solution-phase and MW-assisted azide synthesis 
     In recent days microwave-assisted organic synthesis has a great impact on 
medicinal/combinatorial chemistry mainly because of its unique advantages like            
(1) Reduced reaction time (2) easy automation (3) energy efficiency84. Click reaction 
between an alkyne and azide in the presence of Cu (I) catalyst occupies a niche among 
the in situ inhibitor discovery, however as explained in the previous chapters the lack of 
efficient methods to synthesis  libraries of azides in a high-throughput manner limits the 
application of click chemistry in the construction of inhibitor libraries.  Apart from click 
application azides find a wide array of uses as versatile intermediates in organic 
synthesis74, orthogonal amine protection85 and Staudinger ligation86. Recently, improved 
methods for azide synthesis have shown some compatibility with click chemistry. For 
example Fokin et al reported the in situ generation of azides from aryl and alkyl halides 
followed by direct click chemistry87, 88, however this method may not be suitable for in 
situ screening with enzymes since NaN3 is a highly toxic chemical. Other methods 
include the direct conversion of amines to azides by employing the diazo-transfer 
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reaction using TfN389, 90 or imidazole-1-sulfonyl azide hydrochloride91, the use of 
TPP/DDQ/n-Bu4NN3 reagents92 to convert alcohols directly to azides and the microwave 












(a) Fokin's in situ generation of azides followed by 'click reaction' from iodides
































(f) Nasser's synthesis of azides from alcohols/thiols
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4.2.2 Drawbacks of the existing methods to synthesis azides 
     The above methods of generation of azides either use more expensive/unstable starting 
material/reagents (e.g. Tf2O), or harsh conditions or needs column purification before or 
after click chemistry, which makes them unfit for rapid library generation. We have 
developed a MW-assisted traceless resin capture-release approach to generate azides and 
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also a practical and efficient MW-assisted approach to generate azides from readily 
available alcohol building blocks via tosylate/mesylate/chloride. We have also 
demonstrated the direct use of these azides in click reaction.  
 
 
4.2.3 Design of our azide library 
 
     As shown in Fig. 4.3a, our first strategy made use of the commercially available PS-
TsCl resin on which immobilized tosyl chloride moiety efficiently captured a variety of 
primary alcohols via simple nucleophilic substitution. The resulting resin-bound tosylates 
were subjected to a MW-assisted nucleophilic attack using sodium azide that released the 
alkyl azide from the resin. The alky azides were purified by simple extraction to remove 
the sodium azide and were directly used for click reaction. The advantage of this method 
includes (1) the method is traceless solid-phase strategy, allowing the use of as-is starting 
materials (i.e. same as solution-phase methods) as building blocks. (2) Variety of primary 
alcohols (except for some benzyl alcohols) can be converted to azides. (3) The MW-
assisted azidation can give access to large library of azides in a short period of time. Our 
second strategy (Fig. 4.3b) is quite straight-forward, here primary and secondary alcohols 
were converted to tosylates/mesylates/chlorides using tosyl chloride or mesyl chloride 
and were purified by simple extraction and were subjected to rapid MW-assisted 
azidation in the presence of NaN3 afforded the alkyl azides (primary and secondary) in 
very high purity after a simple extraction. The azides were directly used for the click 
reaction without any other purification (like column purification). The advantage of this 
method include (1) A variety of readily available 1o and 2o alcohols can be employed (2) 
MW- assisted azidation helps in the rapid synthesis of a library of compounds (3) a 
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Fig. 4.3 MW-assisted synthesize of azides followed by direct click chemistry. (a) Solid-




4.3 Results and Discussion 
 
 
4.3.1 Chemical Synthesis of the azide library 
 
4.3.1.1 Traceless solid-phase synthesis for PS-TsCl resin 
 
     To demonstrate our traceless solid-phase strategy 10 different azides were synthesized 
from the various primary alcohols (Scheme 4.1). PS-TsCl Resin was treated with 6 
equivalents of alcohol in the presence of 1:0.5 dichloromethane/pyridine to afford the 
tosylated resins (4-1a to 4-10a). The tosylated products were subjected to MW- assisted 
azidation (80 oC for 30 min) in the presence of NaN3 to release the alkyl azides which 
were purified by simple extraction to afford the product (4-1 to 4-10). However all the 
benzyl alcohol underwent poor conversion (0 to 20% yield) probably due to the steric 
hindrance between the aromatic moiety and the polymer backbone. Satisfactory yields 
(55-92%) and purity was obtained in the case of long chain alcohols (Scheme 4.1a). To 
demonstrate our second approach (Scheme 4.1b), 10 commercially available alcohol 
building blocks were treated with p-toluenesulfonyl chloride in the presence of KOH to 
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afford the tosylates (4-1b to 4-10b) in good yield and purity after a simple extraction. The 
tosylates on MW assisted azidation (80 oC for 10 min) using sodium azide, followed by 
purification by simple extraction gave the azides (4-1 to 4-4 and  4-11 to 4-16) in good 
yield (83 to 99%) and purity. 
 
4.3.1.2 Solution-phase MW-assisted azidation                                     
     10 different 1o and 2o alcohol building blocks were treated with mesyl chloride in the 
presence of DIEA. When benzyl alcohols are subjected to mesylation, surprisingly benzyl 
chlorides (4-1c to 4-6c) were formed exclusively instead of benzyl mesylates, this would 
be because of the fact that benzyl mesylates are too reactive that they underwent a 
nucleophilic substitution with the chloride ion of the DIEA.HCl salt. Rest of the alcohols 
formed the mesylates (4-7c to 4-10c) in high yield. The mesylates and the chlorides were 
accessible in less than an hour. Again purification of the mesylates/chlorides was done by 
simple extraction. It should be noted that no column purification were done to purify the 
tosylates, mesylates and the chlorides. The MW-assisted azidation (80 oC for 5-10 min) 
of chlorides/mesylates (4-1c to 4-10c) using sodium azide followed by simple extraction 
gave the azides (4-1, 4-2, 4-5 to 4-7, 4-17 to 20) in very good yield (81-99%) and purity. 
Three common azides synthesized through the different approaches were compared in 
Table 8. Short chain alcohol 4-a under went conversion to azide 4-1 (via tosylate) in 
moderate yield when synthesized through method A. While good yields were obtained 
when the azide 4-1 was synthesized via method B and C. Long chain alcohols like 4-b  
were converted to azide 4-2 in excellent yield and purity when synthesized via all the 
above three methods. Conversion of secondary alcohol 4-g to secondary azide 4-7 was 
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unsuccessful in method A. but method B gave the secondary azide 4-7 in moderate yield 
and purity, while method C  afforded the secondary azide 4-7 in excellent yield and 
purity (Scheme 4.1c). The structure of the azides synthesized by all the mentioned 
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(4-1c to 4-6c: n = 0; X = Cl
4-7c to 4-10c: n > 0; X = Cl)n = 0 - 5
 
 
Scheme 4.1 (a) Solid-phase synthesis of azides from P-TSCl resin (b) Synthesis of azides 
via tosylates (c) Synthesis of azides via mesylates/chlorides. 
 
 
4.3.1.3 Utilization of the azides in click assembly of PTP inhibitors  
     The feasibility of the above synthesized azides to be directly used for click chemistry 
application was proved by assembling PTP active site binding isoxazole functionalized  
alkynes (2-F and 2-A) with the selected azides made from the above explained methods 
to get PTP1B bidentate inhibitors (Scheme 4.2). In all the three cases, the azides were 
completely consumed yielding the triazole products which are spectroscopically pure 





Table 4.1 List of all azides and yields synthesized by three different approaches. 
 
Method  1 Method 2a Method 2b # 




















































































































































































































































































































     ‘Click’ chemistry have conquered different areas of science, mainly medicinal 
chemistry, and relies on libraries of azide fragments for drug discovery applications. Till-
to-date only very few methods are available for the rapid synthesis of azides, which calls 
for the development of new high-throughput methods to generate libraries of azides using 
simple building blocks. We have devised two simple methods to generate libraries of 
azide fragments using both solution-phase and solid-phase synthesis using readily 
available alcohol building blocks. In the first approach, alcohols were readily converted 
into azides by microwave-assisted azidation of mesylates/tosylates/chlorides and in the 
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second approach, for the first time, we have demonstrated the use of tosyl resin in the 
MW-assisted synthesis of azides by a simple catch-release approach. A total of 20 
different azides were synthesized using the above approaches and their utility for direct 
click chemistry applications was demonstrated by the synthesis of PTP1B inhibitors. We 
believe that our new approaches would be a new high-throughput synthetic tool in the 








































     The first section of this chapter reports the design, synthesis of a library of 16 activity-
based probes (ABPs) targeting different classes of proteases. These probes are designed 
for the first time to generate a reactive quinolimine methide upon hydrolysis of a peptide 
motif, which in turn covalently modify the enzyme. Further, these probes were used to 
generate unique substrate fingerprint profiles of proteases in gel-based proteomic 
experiments. The second section of this chapter narrates the synthesis of an activity-based 
tri-functional PTP probe based on p-hydroxy-mandelic acid unit and containing a biotin 
tag in addition to a fluorophore unit. This probe may find potential applications in 





5.2.1 Activity-based fingerprinting 
 
     In the post-genomic era, characterization of enzyme activity pattern is more 
meaningful than enzyme identification.  This is because the so-called substrate fingerprint 
of an enzyme reveals the type of chemical entities accepted by the enzyme as its potential 
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substrates, and thereby helps in a better understanding of its catalytic mechanism and 
properties.  Similarly, the unique pattern generated for an unknown enzyme using a set of 
known substrates may be used to delineate its identity95. With the aid of standard 
analytical tools, traditional fingerprinting experiments use a whole spectrum of substrates 
and/or their analogs on a target enzyme and create quantitative and reproducible profiles 
directly related to the enzyme’s activity.  Different classes of enzymes have been studied 
in this fashion, including cytochrome P450, protein kinases, and hydrolytic enzymes96, 97, 
98. In recent years, much effort has been expended in developing microarray-based 
bioassays99. When adopted for fingerprinting experiments, they could potentially provide 
a powerful platform by allowing the simultaneous analysis of thousands of enzymatic 
reactions on a single chip with very small sample volumes, while retaining a good degree 
of detection sensitivity100. 
     Proteases, being one of the largest groups of enzymes which are important therapeutic 
targets of major human diseases, have been the focus of new enzyme assay developments 
in recent years101.  Activity-based profiling (ABP), originally developed by Cravatt et al 
and adopted by other groups, allows studies of proteases present in a crude proteome on 
the basis of their enzymatic activities, rather than their relative abundance102  ABP works 
by using either mechanism- or affinity-based chemical probes that enable their covalent 
attachment to different classes of enzymes, thus providing a versatile tool for large-scale 
protease identification, characterizations and even fingerprinting experiments103. Fig. 5.1 
shows the structures of some of the activity-based probes targeting various classes of 
proteases developed in Yao’s and Cravatt’s lab.  Quinolimine derivatives activity-probes 
were used to study proteases in general104. Fluorophosphonate (FP) derivatives were used 
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as activity-based probes for detection of a broad spectrum of serine hydrolases105. 
Cysteine protease inhibitors, which include vinyl sulfone (VS)- and acrylamide-
containing peptide conjugates were found to selectively target cysteine proteases106. 
Similar strategies were extended to the microarray format to allow potential high-
throughput detection and identification of enzymes in a protein array49, 99. 


















































5.2.2 Design of the activity-based protease probe 
 
     We recently investigated a new class of ABP probes which target all major classes of 
proteases by their properties as enzyme substrates, rather than inhibitors.  For this reason, 
we expect that these probes may be more suitable for protease substrate fingerprinting 
experiments than existing ones. This chapter illustrates our efforts in the first time the 
chemical synthesis of a full set of these probes, their utility for activity-based 




































Fig. 5.2 Structure of the activity-based protease probe 
 
     Each of the probes contains a common p-aminomandelic acid moiety and a unique 
recognition head consisting of an N-acetylated amino acid that mimics the P1 position in 
a protease substrate. The amide bond between the two groups imitates the scissile bond in 
the protease substrate. A fluorescent reporter group, Cy3, was attached to the other end of 
p-aminomandelic acid. Upon proteolytic cleavage of the scissile bond, the probe releases 
the amino acid head group to generate a highly reactive quinolimine methide, which 
subsequently reacts covalently with the protease (that cleaves it) and renders it detectable 
(Fig. 5.3). One potential limitation of our enzyme-fingerprinting approach is that, since 
only P-site residues can be incorporated into the probe design, the approach might only 








5.3 Results and discussion 
 
 









































































Light, 4 h, 85%
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2. TFA, DCM, 1 h
AA = side-chain of an amino acid (Ala, Ile, Phe, Asp, Lys, Thr, Tyr,
Glu, Asn, Gln, Trp, Val, His, Ser, Leu, Cys). PG = protecting group.  
 
 
Scheme 5.1 Synthesis of the activity-based protease probes 
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To make the sixteen probes, commercially available p-nitrophenylacetic acid, 5-17, 
was treated with thionyl chloride in methanol to afford the methyl ester 5-18 in 93% 
yield.  Subsequently, the benzylic proton in  5-18 was brominated by NBS (85% yield), 
generating  5-19, followed by conversion to the corresponding benzyl alcohol  5-21 in 
two steps.  Reduction of the nitro group in 5-21 with 10% Pd-C in the presence of H2 
gave the intermediate  5-22 with excellent yield (93%).  A number of acylating reagents 
were tested in order to optimize the subsequent coupling reaction between the aromatic 
amine on  5-22 and a properly protected amino acid (both N- α -Boc and N- α -Fmoc 
amino acids were used), and it was found that HATU consistently gave the best yield (80-
88% on average).  Using the optimized method, a total of sixteen different amino acids 
were used to generate the same number of 5-23 in which each compound differs by its 
amino acid side chain.  Upon deprotection of the N-α-Fmoc or N- α -Boc group, the 
resulting amino acids were acylated with acetic anhydride in DIEA to afford  5-24.  The 
hydrolytic cleavage of the methyl ester in  5-24 was achieved by using LiOH solution in 
nearly quantitative yield to furnish  5-25.  The final sixteen probes were subsequently 
obtained in three steps by conversion of the benzylic OH group in 5-25 to the 
corresponding fluoride with (diethylamino)sulfur trifluoride (DAST) at 0 oC, and 
attachment of a reporter Cy3 dye via a hydrophilic linker.  The average yield of these 
three steps combined for all sixteen probes were approximately 50%.  To ensure all final 
probes are free of impurities, they were subjected to preparative reverse-phase HPLC, 
followed by characterizations with 1H-NMR and ESI-MS analysis as outlined in Table 9.  
In all, probes  5-1 to  5-16, in which each contains a different N- α -acylated natural 
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amino acid as shown in Scheme 5.1 (Ala, Ile, Phe, Asp, Lys, Thr, Tyr, Glu, Asn, Gln, 
Trp, Val, His, Ser, Leu, Cys), were successfully synthesized.  
 
 
5.3.2 Fingerprinting Experiments 
 
 
We next demonstrated this new class of substrate-based small molecule probes could 
be used to generate unique activity-based fingerprint profiles of different classes of 
proteases.  Previously, only mechanism-based small molecule probes made of known 
protease inhibitors had been used in an ABP fingerprinting experiment. They were thus 
limited to studies of only certain classes of proteases. We expect that our current ABP 
probes, designed based on substrates rather than inhibitors of a protease, may be more 
suitable to generate fingerprints of the enzyme that better reflects its substrate specificity.  
These probes may also be used to fingerprint different classes of proteases 
simultaneously.  We therefore labeled a total of thirteen different enzymes covering all 
four major sub-classes of proteases, each with our sixteen probes, 5-1 to  5-16.  The 
enzymes include serine proteases (i.e. α- & β-chymotrypsin, trypsin, thrombin, proteinase 
K and achromopeptidase), metalloproteases (i.e. actinase E and thermolysin), cysteine 
proteases (i.e. bromelain, papain and chymopapain), and aspartic proteases (i.e. renin and 
pepsin).  With trypsin as a representative, a unique activity-based fingerprinting profile of 
the enzyme against all probes was thus generated.  Based on the relative intensity of the 
labeled enzymes by each probe, a dendrogram, as shown in Fig. 5.4, were constructed 
using the programs Tree View™ and Cluster™ developed by Eisen and coworkers107. 
The thirteen proteases were hierarchically clustered based on the similarity of their 
fingerprint profiles, and shown by the tree structure on the left of the dendrogram.  The 
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degree of similarity of protease was indicated as a function of height of the lines 
connecting profiles.  In most cases, the labeling pattern of the enzyme by the probes 
correlates well with its previously known substrate preferences: α- and β-chymotrypsin, 
known to prefer hydrophobic/aromatic P1 residues were labeled strongly by F, Y and W, 
as well as Q. The two enzymes were also expectedly clustered together by the software 
Cluster™, reaffirming their similarity.  Bromelain, chymopapain, papain and proteianse 
K, by virtue of their known broad substrate specificities, were strongly labeled by a 
number of the probes and clustered together, once again indicating their similarity in 
substrate preference.  Thermolysin, a metalloprotease known to tolerate a variety of p-site 
residues and instead prefer P’-site residues, was not clustered with any other proteases 
and surprisingly was labeled strongly by E.  This underscores the potential drawback of 
our probes for fingerprinting certain classes of proteases.  Trypsin, thrombin, 
achromopeptidase and actinase E all showed strong labeling by K, and were clustered 
together. This is in good agreement with these enzymes’ known substrate preferences as 
well.  Somewhat surprisingly, clustered in the same group were two other enzymes, 
pepsin and renin, which are known to have broad substrate specificities and require 
recognition elements on both P and P’ sites.  This again may indicate the limitation of our 
current class of probes.  We previously showed that similarly designed probes, in which 
the enzyme recognition heads were made of peptides rather than single amino acids, 
confer much greater substrate specificity.  In future, conceivably the same approach could 




























Fig. 5.4 (a) Affinity-Based labeling of Trypsin with probes 16 probes in the descending 




5.4 Activity-based Probes for Protein Tyrosine Phosphatases (PTPs) 
 
     Unlike proteases there are only very few reports on the activity-based probes for 
PTPs. 4-fluromethylaryl phosphate108, 109 and α-Bromobenzylphosphonate44 based ones 
are the two known AB-probes for PTPs (Fig. 5.5a).  4-fluromethylaryl phosphate based 
probes work by generating a highly reactive quinone methide intermediate on hydrolysis 
of the phosphate group by the 1,6-elimination of the fluoride. The quinone intermediate 
can potentially trap the phosphatases by the alkylation of the nucleophilic side chains 
near by the PTPs active site (Fig. 5.5b). The drawback of 4-fluromethylaryl phosphate 
probe is that it can form adduct with other phosphatases like Ser, Thr phosphatase 
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of the unmasked quinone methide intermediate, which could potentially alkylate other 
proteins in the vicinity that carry nucleophilic residues on their surface. 
α- Bromobenzylphosphonate based probes work by generating an S-P bond between the 
active site cysteine of PTP and the P atom on the probe.  Cysteine initiates a direct 
nucleophilic on the phosphonate group to give a transient phosphorane like intermediate 
(Fig. 5.5c), which undergoes a ring-closing reaction to form an epoxides like species with 
the expulsion of the bromide. Subsequent ring opening produces the 
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Fig. 5.5 (a) Structure of ABP PTP probes; Mechanism of the PTP labeling (b) 






5.4.1 Design of the PTP probes 
 
     The structure of the activity-based tri-functional probe consists of four units: a Cy3-
containing fluorescence unit (for visualization purpose), biotin (for quantification 
purposes), a linker and a reactive unit (to capture PTPs). The fluorescence unit serves as a 
sensitive means to detect proteins upon labeling with the probe. The reactive unit is made 
of a 4-fluromethylaryl phosphate (mechanism-based group) that would covalently react 
with an enzyme in an activity-dependent fashion as shown in Fig. 5.5b. 
                
 
 
Fig. 5.2 Structure of the PTP tri-functional probe  
 
5.4.2 Chemical Synthesis of the PTP probes 
 
     The tri-funtional probe 5-16 was prepared by adopting the below protocol (Scheme 
5.2). Phenol on treatment with glyoxal under basic conditions gave the p-
hydroxymandelic acid 5-19 which was phosphorylated using (EtO)2P(O)Cl to give 5-20. 
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The acid 5-20 was coupled to an amine linker to give compound 5-21, which was 
converted to Benzylic fluoride 5-22 by using DAST as a fluorinating reagent. Compound 
5-22 on Boc deprotection furnished the TFA salt of the amine 5-23, which was coupled to 
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Scheme 5.2 Synthetic scheme for PTP tri-functional activity-based probe 
 
Deprotection of the Boc protection on compound 5-24 offered compound 5-25 as a TFA 
salt, which was coupled with NHS ester of Biotin to give compound 5-26. Compound 5-
26 on treatment with 20 % piperidine in DMF furnished compound 5-27 which was 
coupled with the NHS ester of Cy3 to furnish compound 5-28. The deprotection of the 






     In conclusion, we have successfully synthesized and tested a panel of activity-based 
small-molecule probes that target different classes of proteases on the basis of their 
enzymatic activities and substrate specificities. These probes contain a peptide 
recognition motif that is linked via an amide bond to the p-aminomandelic acid moiety; 
enzymatic hydrolysis of the scissile peptide bond induces a facile rearrangement of the 
probe to generate the reactive quinolimine methide intermediates that in turn alkylates 
neighbouring residues within the enzyme active site resulting in the formation of covalent 
enzyme-probe adduct. These differ from previously developed ABP probes in that they 
were developed based on protease substrates rather than inhibitors; this makes them more 
suitable for generating activity-based fingerprinting profiles of proteases. In addition, 
they could be used on all different classes of proteases, a key advantage that is 
unattainable with other existing ABP probes. We have demonstrated that these probes are 
useful for generating unique substrate fingerprint profiles of proteases in gel-based 
proteomic experiments. Preliminary results indicate that they might be equally amenable 
for microarray-based enzyme-profiling experiments. We are currently investigating these 
probes’ expanded utilities in proteomics research and attempting to address their potential 
limitations. The second part of the unit narrates the synthesis and of a tri-functional 
activity-based probe targeting PTPs, Briefly the structure of the probe consists of 4 units: 
a Cy3-containing fluorescence unit (for identification in gel-based experiments), a linker 
a reactive unit (based on p-hydroxymandelic acid) and a biotin tag (quantification). We 
believe that these probes may find more potential applications in high-throughput protein 













     We have demonstrated the successful use of activity-based probes for the selective 
identification of protein classes in the previous chapter. Imaging of enzyme activities 
inside the live cells is very crucial for the understanding of their cellular mechanism and 
functional roles. This chapter demonstrates the design and synthesis of a total of seven 
small molecule probes designed for site-specific labeling of N-terminal cysteine-
containing proteins expressed in live cells. Their utility for site-specific, covalent 
modifications of proteins was successfully demonstrated with purified proteins in vitro, 
and with live bacterial cells in vivo by taking advantage of the native chemical ligation. 
 
6.2 Introduction 
6.2.1 Native Chemical Ligation 
     Our own contribution to the field of bioimaging involves a novel strategy for site-
specific covalent labeling of proteins in vivo 60, 110 by taking advantage of the 
chemoselective reaction of native chemical ligation61. The native chemical reaction is one 
of the very few non-enzymatic reactions that join two unprotected protein/peptide/small 
molecule fragments containing appropriately installed chemical functionalities, to 
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generate a ligated peptide/protein product with a native peptide bond at the reaction site.  
This highly chemoselective reaction occurs in an aqueous solution at physiological pH 
and involves a peptide fragment with an N-terminal cysteine residue and a second peptide 
fragment containing a C-terminal thioester group. The essence of the native chemical 
ligation reaction lies in the transthioesterification step between the thioester in one 
peptide and the sulfhydryl group from the N-terminal cysteine residue in the other to 
generate a ligated thioester intermediate, which undergoes spontaneous S→N acyl 
rearrangement to give rise to the final ligated product containing a native peptide bond at 
the ligation junction (Fig. 6.1). The transthioesterification reaction (i.e., the first step) is 
catalyzed by a suitable thiol additive (i.e., 2-mercaptoethanesulfonic acid), and is 
reversible under physiological conditions. The subsequent intramolecular nucleophilic 
attack by the a-amino group of the N-terminal cysteine to form the final amide bond is 
irreversible, and highly favorable due to the intramolecular five-membered ring 
formation and the subsequent generation of the thermodynamically stable amide bond. 
Consequently, all of the freely equilibrating thioester intermediates (e.g., from the first 
step) will eventually be depleted by the irreversible reaction in the second step, giving 
rise to only a single stable, ligated product. A key feature of this reaction is that it is 
highly chemoselective; the reaction occurs exclusively at the N-terminal cysteine of the 
peptide, even in the presence of other unprotected side-chain residues including internal 
cysteine residues.  In our strategy, a protein of interest bearing an N-terminal cysteine is 
expressed inside a live cell by intein-mediated protein splicing 111 were selectively 
labeled by thioester containing small molecular probes. Our strategy provides an elegant 
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and simple way of site specifically labeling proteins in live cells, with little modification 





















Fig 6.1 Native chemical ligation 
 
 
6.2.2 Small-molecule design 
 
 
     In our strategy, a protein of interest having an N-terminal cysteine is expressed inside 
a live cell, by either intein-mediated protein splicing, or ubiquitin fusion112. Incubation of 
the cell with a thioester-containing, cell permeable molecule probe allows the probe to 
efficiently penetrate through the cell membrane into the cell, where the chemoselective 
native chemical reaction occurs predominantly between the thioester and the N-terminal 
cysteine of the protein, giving rise to the resulting labeled protein110, 113. Few endogenous 
N-terminal cysteine-containing proteins are known in various bacterial and mammalian 
genome databases, making our labeling strategy feasible in future for different live-cell 
imaging experiments114. Other endogenous molecules, such as cysteine and cystamine, 
are present in the cell and will also react with the probe However, their reaction products 
are also small molecules in nature, and can be easily removed, together with any 

























Fig. 6.2 Chemoselective reaction between a thioester-containing probe and an N-terminal 
Cys protein in a living cell. 
 
 
6.3 Results and Discussion 
 
 
6.3.1 Chemical Synthesis of the small molecule probes 
 
A total of 7 different probes were (Scheme 14), of which probes 6-1 to 6-4 are 
fluorophore-containing thioesters. 6-5 and 6-6 are biotin- and benzophenone-containing 
probes, respectively. 6-7 is a “caged” molecule of 6-2, in which the fluorescence is 
designed to be “turned on” selectively upon photolysis. All probes were designed to be 
cell-permeable, in that acetates of different fluorophores were incorporated in 6-1, 6-2 
and 6-4 to increase their cell permeability. The fluorophore in 6-3, tetramethylrhodamine 
(TMR), as well as the biotin and benzophenone moieties in 6-5 and 6-6, respectively, 
were previously shown to be cellpermeable115. Addition of the hydrophobic, benzyl-
based thioester in all probes should further increase their cell permeability. Probes 6-1 to 
6-4, containing different fluorophores (e.g. coumarin (CM), fluorescein (FL), TMR and 
carboxynaphthofluorescein (CF), respectively) that emit in different colors, were 
designed for potential multicolor cell labeling and imaging. Proteins labeled with probes 
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6-5 and 6-6 may be used to study protein–protein interactions by in vivo experiments 
utilizing biotin–avidin binding and protein crosslinking, respectively. Probe 6-7 may be 
used for protein labeling in a live cell where temporal and/or confined fluorescence 
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Scheme 6.1 Synthesis of the cell-permeable probes for live cell labeling 
 
  
6.3.2 Imaging experiments 
 
     In vitro labeling of proteins expressing an N-terminal cysteine was then carried out 
with the probes. A model protein, EGFP (enhanced green fluorescent protein), engineered 
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to contain an N-terminal cysteine, was incubated with probes 6-2, 6-3, 6-4 and 6-5 
individually, and the extent of protein labeling was monitored over 24 hours by SDS-
PAGE and Western blotting. 8 mM of each probe, with or without 1 mM of DTT, was 
added to the pure protein in 1 X PBS buffer. The reaction was quenched at specified time 
intervals with 10 mM of cysteine. Following protein separation on a 12% SDS-PAGE 
gel, the labeled protein was visualized and quantitated, either by a fluorescence gel 
scanner (in the cases of probes 6-2, 6-3 and 6-4) or Western blotting using anti-biotin 
HRP conjugate and Amersham’s ECL kit (in the case of probe 6-5). Results are 
summarized in Fig. 60 and Fig. 61. In all cases, the labeling was shown to reach near 
completion (> 75% labeling) within the first 3 hours of the reaction. In addition, more 
than 50% labeling occurred within the first 30 min of the reaction, making this strategy 
suitable for potential real-time bioimaging experiments in live cells. The site-specific 
nature of the labeling reaction was confirmed by repeating the experiment under identical 
conditions with control proteins which either do not have cysteine residues at all, or have 
only internal cysteines. 
In all cases, labeling occurred ONLY with proteins possessing an N-terminal cysteine 
thereby unambiguously supporting our design principle, in which exclusive labeling 
should only occur at the N-terminal cysteine of the target protein. We next applied the 
strategy to the labeling of N-terminal cysteine proteins expressed inside live bacterial 
cells. E. coli cells overexpressing an N-terminal cysteine GST (glutathione-S-transferase) 
protein were treated with probe 6-3, and the site-specific labeling of the probe inside the 
cells was assessed by fluorescence microscopy and SDS-PAGE (Fig. 2c and 2d, 
respectively): exclusive labeling occurred only with E.coli cells overexpressing N-
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terminal cysteine GST. Minimal background labeling was unambiguously confirmed by 
SDSPAGE protein analysis of the labeled cells, indicating that the labeling occurred 
predominantly with the N-terminal cysteine GST. 
 
Fig 6.4 Site-specific labeling of N-terminal cysteine proteins with the small molecule 
probes. (a) SDS-PAGE of EGFP labeling with probe 4 for 1 min, 10 min, 30 min, 1 h, 3 
h, 12 h, 24 h (left to right). (b) % completion of EGFP labeling over 24 h intervals with 
probe 6-2 (blue diamonds), 6-3 (purple squares), 6-4 (yellow triangles) and 6-5 (red 
diamonds). (c) Fluorescence microscope images of E. coli expressing N-terminal cysteine 
GST after labeling with probe 3 for 24 h. The fluorescence image was overlapped with 
the phase contract image for easy visualization. (d) 12% SDS-PAGE protein analysis of 




     Small molecule-based chemical labeling strategies for the site-specific tagging of 
proteins have provided powerful tools for the study of protein functions in intact cells. 
We have developed a simple yet highly versatile method for site-specific, covalent 
labeling of proteins inside live cells by adopting the chemo-selective native chemical 
ligation. We have shown that this strategy can be applied to bacterial as well as 
 87
mammalian cells with tolerable background labeling using a variety of small molecule 
probes, thus making it potentially useful for future bioimaging and proteomics 
applications. This strategy however is not amenable to proteins that have a pre-requisite 


































7.1 General Information 
 
     All chemicals were purchased from commercial vendors and used without further 
purification, unless otherwise noted. Either HPLC grade or distilled solvents were used in 
all the reaction. All moisture-sensitive reactions were performed under a positive pressure 
of nitrogen or argon. Concentration in vacuo was performed on a Büchi rotary evaporator   
Analytical thin layer chromatography was performed using Merck silica gel plates (0.25 
mm thickness) with fluorescent indicator UV254. Subsequent to elution, spots were 
visualized by ultraviolet illumination, iodine staining, KMnO4 staining (for alkenes, 
aldehydes), Nindhydrin staining (for primary amines), or ceric molybdate staining. Flash 
chromatography was performed using Merck silica gel (40 µM particle size) and freshly 
distilled or AR grade solvents. Analytical and preparative RP-HPLC separations were 
performed on Phenomex C18 column (250 x 4.60  mm) and Phenomex C18 (250 x 21.20 
mm) coloumns, respectively, using a Waters 600E HPLC system equipped with a waters 
600 controller and a waters 2487 UV detector. Shimadzu LCMS-IT-TOF system 
equipped with auto-sampler (cat. No. LCMS-2010EV) was used for the analysis of the 
inhibitor library. Eluents A (0.1% TFA/acetonitrile) and B (0.1% TFA/water) were used 
as the mobile phase.  1H NMR and 13C NMR spectra were recorded on a 300 MHz 
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Bruker ACF300 or Bruker Avance 300 MHz or DPX-300 NMR spectrometer. Chemical 
shifts are reported as δ in parts per million (ppm) referenced with respect to residual 
solvent (CHCl3 = 7.26 ppm, methanol-d4 =  3.3 ppm and DMSO-d6 = 2.50 ppm) or from 
internal standard tetramethylsilane (TMS = 0.00 ppm). 13C NMR spectra are reported as δ 
in units of parts per million (ppm) relative from solvent signal: CDCl3 (δ=77.0, triplet) 
and methanol-d4 (δ=49.0, singlet). The following abbreviations were used in reporting 
spectra: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of 
doublets. All enzymes were purchased from commercial sources. 
 
7.2 High-Throughput Assembly of Protein Tyrosine Phosphatases 
(PTPs) Inhibitors Using “Click Chemistry” 
 
7.2.1 Experimental details for the synthesis of PTP inhibitor library 
 
 
General procedure for the synthesis of various Propargyl phenyl ethers (2-16, 2-19 
and 2-22): Potassium carbonate (99 mmol) and benzo-18-crown-6 (3.3 mmol) were 
added to a solution of propargyl p-toluenesulfonate 2-34 (66 mmol) and hydroxyl 
acetophenone (66 mmol)  in acetonitrile (100 ml) followed by refluxing for 6 h (*in the 
case of  compound 2-21, the reaction completed quantitatively in < 30 min), after which 
the organic phase was removed under reduced pressure and taken into dichloromethane 
layer (80 ml) and extracted with NaHCO3 (2 x 40 ml), water (2 x 40 ml) and brine (1 x 40 
ml).  The organic phase was then dried with anhydrous Na2SO4, and the solvent was 
removed in vacuo to afford the crude product, which, upon further purification by flash 
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column chromatography, afforded the pure propargyl phenyl ether.  Compounds 2-16, 2-
19 and 2-22 were prepared form compounds 2-15, 2-18 and 2-21, respectively, in 86–
96% yield using above procedure. 
 
1-(4-Prop-2-ynyloxy-phenyl)-ethanone (2-16): Yield = 89%.  1H-NMR (300 MHz, 
CDCl3) δ 7.92 (d, J = 10.44Hz, 2H), 6.99 (d, J = 10.44Hz, 2H), 4.73 (d, J = 2.5Hz, 2H), 
2.54-2.53 (m, 4H).  ESI-MS: m/z [M+H]+ = 175.0. 
 
1-(5-Chloro-2-prop-2-ynyloxy-phenyl)-ethanone (2-19): Yield = 91%.  
 
1-(5-Fluoro-2-prop-2-ynyloxy-phenyl)-ethanone (2-22): Yield = 98 %.  1H-NMR (300 
MHz, CDCl3) 7.46-7.42 (dd, J = 3.15 & 3.12Hz, 1H), 7.19-7.12 (m, 1H), 7.06-7.01 (dd, J 
= 3.84 & 3.84Hz), 4.77 (d, J = 2.43Hz, 2H) 2.63 (s, 3H), 2.55 (m, 1H).  ESI-MS: m/z 
[M+H]+ = 193.2. 
 
General procedure for the synthesis of various isoxazole-3-carboxylic acid methyl 
esters (2-17, 2-20, 2-23 and 2-25): To a mixture of alkyne-derivatized acetophenone (53 
mmol) and dimethyl oxalate (53 mmol) was added freshly prepared NaOMe (0.5 M in 
MeOH, 53 mmol).  The reaction mixture was refluxed for 12 h before cooled to room 
temperature.  To the same reaction MeOH (80 ml), NH2OH.HCl (53 mmol) and a 
catalytic amount of p-TsOH.H2O were added and the resulting mixture was refluxed 
continuously for 3 days.  Upon cooling to room temperature, the precipitated compound 
was collected, washed with water and ice-cold methanol to afford the pure isoxazole-3-
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carboxylic acid methyl ester.  Compounds 2-17, 2-20, 2-23 and 2-25 were obtained from 
compounds 2-16, 2-19, 2-22 and 2-24, respectively, in 34–41% yield. 
 
5-(4-Prop-2-ynyloxy-phenyl)-isoxazole-3-carboxylic acid methyl ester (2-17): Yield = 
35%.  1H-NMR (300 MHz, DMSO-d6) δ 7.92 (d, J = 8.82Hz, 2H), 7.38 (s, 1H), 7.16 (d, 
J = 8.85Hz, 2H), 4.91 (d, J = 2.4Hz, 2H), 3.92 (s, 3H), 2.50 (m, 1H).  ESI-MS: m/z 
[M+H]+ =  258.1. 
 
5-(5-Chloro-2-prop-2-ynyloxy-phenyl)-isoxazole-3-carboxylic acid methyl ester (2-
20): Yield = 34%.  1H-NMR (300 MHz, CDCl3) 7.97 (d, J = 2.79Hz, 1H), 7.40-7.46 (dd, 
J = 2.43 & 2.79Hz, 1H), 7.21 (s, 1H), 7.07 (d, J = 9.06Hz, 1H), 4.85 (d, J = 2.10Hz, 2H), 
3.99 (s, 3H), 2.59 (m, 1H).  ESI-MS: m/z [M+H]+ =  291.8. 
 
5-(5-Fluoro-2-prop-2-ynyloxy-phenyl)-isoxazole-3-carboxylic acid methyl ester (2-
23): Yield = 36 %.  1H-NMR (300 MHz, CDCl3) δ 7.75-7.71 (dd, J = 2.79 & 2.79Hz, 
1H), 7.25 (s, 1H), 7.19-7.08 (m, 2H), 4.85 (d, J = 2.43Hz, 2H), 4.01 (s, 3H), 2.57(m, 1H).  
ESI-MS: m/z: [M+H]+ = 276.1. 
 
5-(4-Nitro-phenyl)-isoxazole-3-carboxylic acid methyl ester (2-25): Yield = 36%.  1H-
NMR (300 MHz, DMSO-d6) δ 8.39 (d, J = 9.24Hz, 2 H), 8.25 (d, J = 9.24 Hz, 2 H), 
7.81(s, 1H), 3.32(s, 3H).  
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5-(5-Chloro-2-prop-2-ynyloxy-phenyl)-1H-pyrazole-3-carboxylic acid methyl ester 
(2-29): To a mixture of acetophenone 2-19 (1.1 g, 0.53 mmol) and dimethyl oxalate (0.87 
g, 0.53 mmol) was added freshly prepared NaOMe (0.5 M in MeOH, 0.53 mmol).  The 
reaction mixture was refluxed for 12 h and then cooled to room temperature.  To the 
same reaction pot MeOH (20 ml), Hydrazinium sulfate (0.67 g, 0.53 mmol) and a 
catalytic amount of p-TsOH.H2O were added and the resulting mixture was refluxed 
continuously for 3 days before cooled down to room temperature.  The precipitated 
compound was collected, washed with water and ice-cold methanol to afford the pure 
pyrazole-3-carboxylic acid methyl ester 2-29 (0.63 g, 41% in 2 steps).  1H-NMR (300 
MHz, CDCl3) δ 7.71 (d, J = 2.43Hz, 1H), 7.28-7.32 (dd, J = 2.46 & 2.76Hz, 1H), 7.20 (s, 
1H), 7.05 (d, J = 8.7 Hz, 1H), 4.85 (d, J = 2.10Hz, 2H), 3.96 (s, 3H), 2.62 (m, 1H).  ESI-
MS: m/z [M+H]+ = 291.0 
 
5-(4-Amino-phenyl)-isoxazole-3-carboxylic acid methyl ester (2-26): Compound 2-25 
(3.5 g, 14.1 mmol) was dissolved in glacial acetic acid (100 ml) and Pd/C (0.35 g, 10% 
wt) was added.  The reaction was stirred for 4 h under hydrogen atmosphere.  At the end 
of reaction, Pd/C was filtered out and the solvent was removed completely under reduced 
pressure to yield pure amine 2-26 (2.8 g; 91%).  1H-NMR (300 MHz, DMSO-d6) δ 7.53 
(d, J = 7.23Hz, 2H), 6.93 (s, 1H), 6.66 (d, J = 7.23Hz, 2H), 3.9 (s, 3H).  ESI-MS: m/z 
[M+H]+ = 219.1. 
 
5-[4-(5,5-Dimethyl-4-oxo-hexanoylamino)-phenyl]-isoxazole-3-carboxylic acid 
methyl ester (2-27): To a solution of 2-26 (2 g, 9.2 mmol), 2-36 (1.6 g, 9.2 mmol) and 
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HATU (3.7 g, 10.1 mmol) in DMF (30 ml) was added 2,4,6-Collidine (1.3 ml, 10.1 
mmol).  The mixture was stirred for 3 h.  The solvent was removed in vacuo and the 
resulting slurry was taken into ethyl acetate (100 ml) and extracted with NaHCO3 (2 x 50 
ml), water (2 x 50 ml) and Brine (1 x 50 ml), dried with anhydrous Na2SO4 and 
concentrated in vacuo to afford a pale brownish crude product, which on flash column 
purification afforded pure 2-27 (3 g; 91%).  ESI-MS: m/z [M+23]+ = 396.9 and m/z 
[M+H]+ = 375.0. 
 
5-[4-(3-Prop-2-ynylcarbamoyl-propionylamino)-phenyl]-isoxazole-3-carboxylic acid 
methyl ester (2-28): Compound 2-27 (2.0 g) was treated with 1:1 (v/v) ratio of 30 ml 
TFA/ dichloromethane mixture for 30 min to give the free acid.  Upon removal of the 
solvent in vacuo, the acid was used without further purification.  Next, the acid (1.35 g, 
4.9 mmol) was dissolved in DMF, and EDC (1.04 g, 5.4 mmol), HOBt (0.75 g, 5.9 
mmol) and DIEA (0.95 ml, 5.4 mmol) were added.  The resulting mixture was stirred for 
30 min before propargyl amine (0.38 ml, 5.4 mmol) was carefully added using a gas-tight 
syringe.  The resulting mixture was allowed to stir in dark for 8 h.  At the end, the solvent 
was removed in vacuo and the resulting residue was taken into ethyl acetate (80 ml) 
followed by extraction with NaHCO3 (2 x 40 ml), water (2 x 40 ml) and brine (1 x 40 ml) 
and dried with anhydrous Na2SO4. Upon concentration in vacuo, the crude product was 
further purified by flash-column chromatography to furnish 2-28 (1.24 g; 74% yield).  
1H-NMR (300 MHz, DMSO-d6) δ 7.90-7.87 (d, J = 8.70Hz, 2H), 7.76-7.73 (d, J = 
8.73Hz, 2H), 7.36 (s, 1H), 3.92 (s, 3H), 3.34 (s, 2H), 3.56 (m, 4H), 2.49 (m, 1H).  ESI-
MS: m/z [M+Na] = 378.1. 
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General procedure for the hydrolysis of the methyl esters (2-A, 2-B, 2-C, 2-D & 2-
E): The methyl ester (4 mmol) was suspended in methanol (10 ml) and a NaOH solution 
(10 ml; 10 M solution) was added slowly and the reaction was stirred for 3 h before the 
pH was adjusted to ~2 using HCl (2 N solution) under cold conditions.  The resulting 
precipitate was collected, washed with cold water, dried in vacuo to furnish the desired 
acid.  Compounds 2-A, 2-B, 2-C, 2-D & 2-E were prepared starting from 2-17, 2-20, 2-
23, 2-28 and 2-29, respectively. 
 
Compound 2-A: Yield = 87%.  1H-NMR (300 MHz, DMSO-d6) δ 7.91-7.85 (d, J = 
9.6Hz, 2H), 7.26 (s, 1H), 7.16-7.14 (d, J = 8.7 Hz, 2H), 4.90 (d, J = 1.98Hz, 2H), 2.50 
(m, 1H).  ESI [M+1]+ = 244.1, ESI-MS: m/z [M+Na]+ = 266.0. 
 
Compound 2-B: Yield = 89%.  1H-NMR (300 MHz, DMSO-d6) δ 7.92-7.91 (d, J = 
2.89Hz, 1H), 7.64-7.60 (dd, J = 2.79 & 2.76Hz, 1H), 7.36-7.33 (d, J = 9.03Hz, 1H), 7.18 
(s, 1H), 5.09 (d, J = 2.1Hz, 2H), 2.51 (m, 1H).  ESI-MS: m/z [M+H]+ = 278.2. 
 
Compound 2-C: Yield = 91%.  1H-NMR (300 MHz, DMSO-d6) δ 7.76-7.72 (dd, J = 
2.76 & 3.15Hz, 1H), 7.74-7.40 (m, 1H), 7.34-7.31 (m, 1H), 7.19 (s, 1H), 5.06 (d, J = 
2.46Hz, 2H), 2.50 (m, 1H).  ESI-MS: m/z [M+H]+ = 261.0. 
 
Compound 2-D: Yield = 88 %.  1H-NMR (300 MHz, DMSO-d6) δ 7.91-7.88 (d, J = 
8.70Hz, 2H), 7.77-7.74 (d, J = 8.73Hz, 2H), 7.37 (s, 1H), 3.34 (s, 2H), 3.56 (m, 4H), 2.49 
(m, 1H).  ESI-MS: m/z [M+H]+ = 341.9. 
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Compound 2-E: Yield = 88%.  1H-NMR (300 MHz, DMSO-d6) δ 7.92 (m, 1H), 7.42 
(m, 1H), 7.25 (s, 2H), 4.99 (d, J = 2.45Hz,  2H), 2.51 (m, 1H).  ESI-MS: m/z [M-H]-1 = 
275.0. 
 
5-Bromo-pentanoyl chloride (2-31): 5-bromopentanoic acid (3 g, 17 mmol) was 
dissolved in distilled chloroform (100 ml) and redistilled thionyl chloride (2.81 ml, 34 
mmol) was slowly added in  a period of 10  min using a dropping funnel.  The reaction 
mixture was refluxed for 12 h.  Upon fractional distillation, 5-bromopentanonyl chloride 
was collected between 115o and 119 oC.  Repeated fractional distillation of the crude 
liquid afford very pure 2-31 (2.03 g; 60%) as a dull brownish liquid.  1H-NMR (300 
MHz, CDCl3) δ 3.42-3.38 (t, J = 12.21Hz, 2H), 2.96-2.92 (t, J = 13.23Hz, 2H), 1.94-1.74 
(m, 4H).  
 
General procedure for the preparation of azides (2-1 to 2-13):  The amine (1 mmol) 
was dissolved in distilled chloroform (30 ml).  The acid chloride linker (1.1 mmol) was 
slowly added at 0 oC, followed by addition of pyridine (1.1 mmol) to scavenge any 
protons generated in the reaction.  The reaction mixture was allowed to stir for 1 h at 
room temperature.  The organic layer was extracted with NaHCO3 (2 x 20 ml), water (2 x 
20 ml) and brine (1 x 20 ml), dried with anhydrous Na2SO4, then concentrated in vacuo.  
The resulting compound was pure enough to be used for the next reaction.  The product 
obtained (1 mmol) was dissolved in DMF (30 ml).  Sodium azide (1.1 mmol) was added 
and the reaction mixture was heated at 50-60 oC for 24 h.  At the end, the solvent was 
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removed in vacuo and the residue obtained was taken into ethyl acetate (40 ml) or 
dichloromethane (40 ml) layer, followed by extraction with NaHCO3 (2 x 20 ml), water 
(2 x 20 ml) and brine (1 x 20 ml). The resulting organic layer was treated with anhydrous 
Na2SO4 and concentrated in vacuo to yield the crude product which was further purified 
by flash column chromatography to afford the corresponding azide (60 to 80 % in two 
steps). 
 
Azide 2-1: Yield = 64%.  1H-NMR (300 MHz, CDCl3) δ 7.53 (d, J = 7.62Hz, 2H), 7.35 
(m, 2H), 7.17 (m, 1H), 4.18 (s, 2H).  
 
Azide 2-2: Yield = 72%.  1H-NMR (300 MHz, CDCl3) δ 7.50 (d, J = 8.04Hz, 2H), 7.32 
(m, 2H), 7.11 (m, 1H), 3.41 (m, 2H), 2.35 (m, 2H), 1.94 (m, 4H).  ESI-MS: m/z [M+H]+ 
= 219.1. 
 
Azide 2-3: Yield = 76%.  1H-NMR (300 MHz, DMSO-d6) δ 7.95-7.92 (d, J = 8.73Hz, 
2H), 7.76-7.73 (d, J = 8.73Hz, 2H), 3.83 (s, 3H), 3.66-3.64 (t, 2H), 2.71-2.66 (t, 2H).  
ESI-MS: m/z [M+H]+ = 248.3. 
 
Azide 2-4: Yield = 64%.  1H-NMR (300 MHz, CDCl3) δ 8.37 (d, J = 5.22Hz, 2H), 7.71 
(d, J = 5.19Hz, 2H), 4.11 (s, 2H).  ESI-MS: m/z [M-H]- = 176.1. 
 
Azide 2-5: Yield = 63%.  
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Azide 2-6: Yield = 67%.  1H-NMR (300 MHz, CDCl3) δ 7.24 (q, 2H), 7.04-6.98 (m, 2H), 
4.41 (d, J = 5.61Hz, 2H), 4.01 (s, 2H). 
 
Azide 2-7: Yield = 77%.  1H-NMR (300 MHz, CDCl3) δ 7.55-7.52 (d, J = 8.55Hz, 2H), 
7.29-7.26 (t, 2H), 7.09-7.05 (t, 1H), 3.62-3.58 (t, 2H), 2.59-2.55 (t, 2H).  ESI-MS: m/z 
[M+23]+ =  213.1 
 
Azide 2-8: Yield = 82%.  1H-NMR (300 MHz, DMSO-d6) δ 7.57-7.54 (d, J = 8.43Hz, 
2H), 7.34-7.31 (d, J = 8.73Hz, 2H), 5.06 (s, 1H), 4.04-3.98 (q, 2H), 3.62-3.58 (t, 2H), 
2.68 (m, 2H), 1.14-1.10 (t, 3H).  
 
Azide 2-9: Yield = 87%.  1H-NMR (300 MHz, CDCl3) δ 7.44-7.41 (d, J = 9Hz, 2H), 
6.90-6.87 (d, J = 8.55Hz, 2H), 3.81 (s, 3H), 3.75-3.71 (t, 2H), 2.62-2.58 (t, 2H). 
 
Azide 2-10: Yield = 93%.  1H-NMR (300 MHz, CDCl3) δ 7.41 (dd, J = 2.13 & 1.98Hz, 
2H), 6.85 (dd, J = 2.28 & 1.98Hz, 2H), 3.80 (s, 3H), 3.31 (t, J = 13.32Hz, 2H), 2.37 (t, J 
= 14.64Hz, 2H), 1.61-1.85 (m, 4H).  ESI-MS: m/z [M+Na]+ = 271.0. 
 
Azide 2-11: Yield = 66%.  1H-NMR (300 MHz, DMSO-d6) δ 8.01-7.97 (d, J = 11.85Hz, 
2H), 7.50-7.21 (m, 6H), 5.03 (m, 1H), 3.87 (m, 2H), 2.74-2.24 (t, 2H). 
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Azide 2-12: Yield = 92%.  1H-NMR (300 MHz, CDCl3) δ 7.44 (d, J = 3.63Hz, 1H), 7.01 
(d, J = 3.63Hz, 1H), 3.44 (t, J = 12.0Hz, 2H), 2.59 (t, J = 13.29Hz, 2H), 1.98-1.96 (m, 
4H).  ESI-MS: m/z [M+H]+= 226.0. 
 
Azide 2-13: Yield = 87%. 1H-NMR (300 MHz, CDCl3), δ 7.48-7.45 (d, 2H), 7.33-7.30 
(d, 2H), 5.14 (s, 1H), 3.73 (s, 3H), 3.31-3.26 (t, 2H), 2.38-2.33 (t, 2H), 1.77 (m, 4H). ESI 
[M+23]+ = 329.1. 
 
Azide 2-14: Yield = 59%.  ESI-MS: m/z [M-H]- = 393.0.  The synthesis of this 
compound is as previously reported.69 
 
General “click chemistry” procedure for library assembly 
Each alkyne (13.5 µmol) and azide (16.2 µmol) were dissolved in DMSO (0.1 ml) and 
taken into t-butyl alcohol (1 ml) in a 15 ml centrifuge tube.  Sodium ascorbate (1.35 
µmol, dissolved in 1 ml of water, was added, followed by copper (II) sulfate pentahydrate 
(0.135 µmol).  The resulting solution was shaken for 2 days.  A few library members 
precipitated, which were centrifuged, washed with 1:1 cold methanol/water mixture and 
dried in vacuo.  They were redissolved in DMSO and used directly in subsequent 
enzymatic assays.  Unprecipitated reaction mixtures were also pure enough and used 
directly without further purifications.  All reaction products were assessed by HPLC 




7.2.2 Biological assay for PTPs: 
Screening for Inhibition activity against different phosphatases 
The protein phosphatase activity was determined by measuring the rate of hydrolysis of 
the following fluorogenic substrate, designed and synthesized as previously reported69  
(Fig. 7.1).The inhibition of phosphatases were screened using black polypropylene flat-
bottom 384-well microtiter plates (Nunc, USA) in a total reaction volume of 50 µl/well, 
monitored with a SpectraMAXTM Gemini XS fluorescence plate reader (Molecular 
Devices, USA).  Different concentrations of inhibitors were used in the assay (26-260 
µM), where necessary.  Controls were done with 1,3-dipolar ligation reactions carried out 
without addition of Cu(I) catalyst (e.g. CuSO4 and sodium ascorbate), and showed no 
inhibition against any of the enzymes (up to 260 µM inhibitor concentration).  The assay 




Fig. 7.1 Structure of the fluorogenic substrate used in the assay 
 
PTB 1B: 
PTB 1B concentration (1 U)    = 1 µl 
Substrate S1 (mM)                   = 1 µl 
Inhibitor (0.66 mM)                 = 2 µl 
Assay Buffer (2 X )                  = 25 µl 
Double Distilled water             = 21 µl 




TCP TP concentration (0.33 U)    = 1 µl 
Substrate S1 (mM)                        = 1 µl 
Inhibitor (0.66 mM)                      = 2 µl 









Double distilled water                   = 21 µl 




YOP Concentration (1 U)              = 1 µl 
Substrate S1 (mM)                         = 1 µl 
Inhibitor (0.66-6.6 mM)                = 2 µl 
Assay Buffer (2 X)                         = 25 µl 
Double distilled water                    = 21 µl 




LAR Concentration (0.5 U)           = 1 µl 
Substrate S1 (mM)                         = 1 µl 
Inhibitor (0.66-6.6 mM)                = 2 µl 
Assay Buffer (2 X)                         = 25 µl 
Double distilled water                    = 21 µl 




λPPase Concentration (0.5 U)       = 1 µl 
Substrate S1 (mM)                         = 1 µl 
Inhibitor (0.66-6.6 mM)                = 2 µl 
Assay Buffer (2 X)                         = 25 µl 
Double distilled water                    = 21 µl 
[Assay Buffer = 25 mM Tris, pH = 7.5] 
 
PP1 
 PP1 Concentration (0.5 U)           = 1 µl 
Substrate S1 (mM)                        = 1 µl 
Inhibitor (0.66-6.6 mM)               = 2 µl 
Assay Buffer (2 X)                        = 25 µl 
Double distilled water                   = 21 µl 
[Assay Buffer = 25 mM Tris, pH = 7.5] 
 
 The enzyme was last added to start the reaction and the reaction was monitored at 
λex = 355 nm and λem  = 460 nm.  The activity was compared in the absence and presence 
of inhibitors.  The results were shown in the heat maps below (Fig. 7.2):   
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Fig. 7.2: Inhibition profiles of the 66-member library against 6 phosphatases.  Note that 
inhibitor concentrations differ with different enzymes. 
 
IC50  measurements of selected inhibitors: 
 
 Compounds 2-A13, 2-C10, 2-B1, 2-B11, 2-B4, 2-A5 were identified to be the 
relatively potent ones against PTB1B, TCPTP, YOP, LAR, λPPase, and PP1, 
respectively.  These six compounds were further investigated by the measurement of their 
IC50 values.  The IC50 values of the six compounds against all six enzymes were shown in 
previous section. The IC50 values were obtained using dose-dependent reactions by 
varying the concentrations of the inhibitor, under the same enzyme concentration.  
Briefly, a two-fold dilution series of an inhibitor, from approximately 745 µM to 1 µM 
(final concentrations) was prepared.  The reaction conditions for each enzyme were as 
listed above.  The enzymatic reactions were allowed to incubate at room temperature for 















[Inhibitor]   26 µM         53 µM         53 µM        254 µM       254 µM        254 µM 
      
     Empty well  100%              0% inhibition 
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0-60 min before being interrogated for end-point fluorescence at λex = 355 nm and λem  = 
460 nm.  The IC50 was calculated by fitting the fluorescence outputs obtained using the 
Graphpad Prism software v.4.03 (GraphPad, San Diego).  Each IC50 plots were generated 
by 6 to 8 data points.  Representative results are shown in Fig. 7.3. 
                           
 
Inhibitor B11; IC50 = 29.6 µM against PTB 1B



















          






















Inhibitor C10; IC50 = 17.51 µM against TCP TP



















          
Inhibitor A13;  IC50 = 23.29 µM against TCP TP






















In B1;  IC50 = 23.86 µM for YOP



















     
Inhibitor A6:  IC50 >750 µM against PP1



















Inhibitor B4; IC50 > 450 µM against λ PPase






















Fig. 7.3 IC50 graphs for various ‘click’ inhibitors against different enzymes. 
 
7.2.3 Chemical synthesis of the 3250-member click library 
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List of amine building blocks
 
 
Fig. 7.4 List of amine building blocks 
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Synthesis of the reductive aminated resin (2-38): PL-FMP resin (200 x 150 mg, 0.9 
mmol/g) was taken in 200 MacroKanTM  reactors each containing a RF tag. The resin was 
swelled in 1,2-dichloroethane (250 mL) for about two hours after which the solvent was 
decanted. The 200 microreactors were then distributed equally into 40 different bottles of 
capacity 50 mL containing 2% Acetic acid in 1,2-dichloroethane(30 mL). Amines (AA1-
AD4, Fig. 7.4) (5 eq) were added to the bottles, so that each bottle contains a unique 
amine. The reaction mixture was then incubated for about 3 hours after which Sodium 
triacetoxyborohydride (6 eq) was added. After shaken for another 8 hours the solution 
was decanted and the reactors were combined and washed with DCM (200 mL x 5), 
MeOH (200 mL x 2) and THF (200 mL x 3) and dried to afford the resin 2-38. 
 
Synthesis of the N-acylated resin (2-3a to 2-3e): The 200 reductive aminated resins 
were separated into 5 sets (40 different reductive aminated resins x 5 sets). To the first 
set, DCM (100 mL), DIEA (10 eq) and acid chloride, 2-i to 2-l (5 eq) were added and the 
reaction mixture was shaken for about 8 hours after which the solution was decanted and 
the resin was washed with DCM (100 mL x 3), MeOH (100 mL x 2) and THF (100 mL x 
3) and dried to afford resin 2-3a to 2-3e. 
 
General protocol for cleavage and release of azides (2-A1-2C to 2-D4-6C): Each dried 
resin was treated with an 1.5 ml solution containing TFA (50%), DCM (45%) and water 
(5%) and the mixture was shaken for 4 hours and transferred into 3 different 96-well 
plates and concentrated in vacuo to afford the below azides. Representative yield varied 
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from 50% to 80%. The azides were redissolved in DMSO (1 mL) to give 50 mM solution 
(assuming 50 % yield).  
All azides synthesized from the above protocols are of high purity (90-95%). 
Representative compounds were further characterizations, without any purification, by 
LCMS, 1H and 13C NMR.  
 
2-Azido-N-(3-fluoro-phenyl)-acetamide (2-A2-2C): 1H-NMR (500 MHz, (CD3)2SO) δ 
10.3 (S, 1h), 7.58 (d, J = 8 Hz, 1H), 7.39-7.29 (m, 1H), 7.09 (d, J = 50 Hz, 1H), 6.92 (m, 
1H), 4.06 (s, 2H). 13C-NMR (500 MHz, (CD3)2SO) δ 167.1, 163.6, 131.0, 140.1, 115.5, 
110.6, 106.6, 51.8. ESI-MS(TOF): m/z 195.060 [M + H]+. 
 
2-Azido-N-(2-phenoxy-phenyl)-acetamide (2-B1-2C) :1H-NMR (500 MHz, (CD3)2SO) 
δ 9.71 (s, 1H), 7.39 (t, 3J = 8 Hz, 3H), 7.16-7.11 (m, 3H), 7.00 (d, 3J = 8Hz, 2H), 6.89-
6.87 (m, 1H), 4.06 (s, 2H). 13C-NMR (500 MHz, (CD3)2SO) δ 156.5, 129.9, 128.9, 125.3, 
123.6, 123.5, 118.6, 118.5, 51.1. ESI-MS(TOF): m/z 269.098 [M + H]+. 
 
2-Azido-N-(3,4-dimethoxy-phenyl)-acetamide (2-B2-2C) : H-NMR (500 MHz, 
(CD3)2SO) δ 9.36 (s, 1H), 7.71 (s, 1H), 6.97 (d, 3J = 8.8 Hz, 1H), 6.66 (m, 1H), 4.14 (s, 
2H), 3.79 (s, 3H), 3.69 (s, 3H). 13C-NMR (500 MHz, (CD3)2SO) δ 166.9, 153.4, 143.9, 
127.8, 112.4, 109.0, 108.49, 56.7, 55.8, 51.8. ESI-MS(TOF): m/z 237.091 [M +H]+. 
 
 2-Azido-N-(4-pentyloxy-phenyl)-acetamide 2-B5-2C) : 1H-NMR (500 MHz, 
(CD3)2SO) δ10.06 (s, 1H), 6.96 (s, 2H), 4.00 (s, 2H), 3.74 (s, 6H), 3.62 (s, 3H). 13C-NMR 
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(500 MHz, (CD3)2SO) δ 166.0, 152.7, 134.4, 133.6, 97.0, 60.05, 55.6, 51.2. ESI-
MS(TOF): m/z 267.100 [M + H]+. 
 
2-Azido-N-(4-pentyl-phenyl)-acetamide (2-B12-2C) : 1H-NMR (500 MHz, (CD3)2SO) 
δ 10.10 (s, 1H), 7.28 (s, 1H), 7.22 (t, 3J = 8.2 Hz, 1H), 7.11 (d, 3J = 8.2 Hz, 1H), 6.66 (d, 
3J = 8 Hz, 1H), 4.02 (s, 2H), 3.73 (s, 3H). 13C-NMR (500 MHz, (CD3)2SO) δ 166.8, 
160.0, 140.0, 130.1, 112.0, 109.6, 105.5, 55.4, 51.7. ESI-MS(TOF): m/z 207.080 [M + 
H]+. 
 
2-Azido-N-(3,4-dimethyl-phenyl)-acetamide (2-C4-2C): H-NMR (500 MHz, 
(CD3)2SO) δ 9.96 (s, 1H), 7.36 (s, 1H), 7.29 (d, 3J = 8.2 Hz, 1H), 7.06 (d, 3J = 8.2 Hz, 
1H), 3.99 (s, 2H), 2.19 (s, 3H), 2.16 (s, 3H). 13C-NMR (500 MHz, (CD3)2SO) δ 165.8, 
136.3, 136.0, 131.4, 129.6, 120.4, 116.7, 51.2, 19.5, 18.7. ESI-MS(TOF): m/z 205.101 
[M+ H]+. 
 
2-Azido-N-(4-ethyl-phenyl)-acetamide (2-C7-2C): 1H-NMR (500 MHz, (CD3)2SO) δ 
10.0 (s, 1H), 7.47 (d, 3J = 8.8 Hz, 2H), 7.15 (d, 3J = 8.2 Hz, 2H), 4.00 (s, 2H), 2.55 (m, 
2H), 1.15 (t, 3J = 7.6 Hz, 3H). 13C-NMR (500 MHz, (CD3)2SO) δ 166.4, 139.5, 136.6, 
128.5, 119.8, 51.7, 28.0, 16.1. ESI-MS(TOF): m/z 205.103 [M +H]+. 
 
3-(2-Azido-acetylamino)-benzoic acid ethyl ester (2-C10-2C): 1H-NMR (500 MHz, 
(CD3)2SO) δ 10.36 (s, 1H), 8.24 (s, 1H), 7.85 (d, 3J = 8.2 Hz, 1H), 4.32 (m, 3J = 7 Hz, 
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2H), 4.07 (s, 2H), 1.32 (t, 3J = 7 Hz, 3H). 13C-NMR (500 MHz, (CD3)2SO) δ 166.6, 
165.4, 138.7, 130.4, 129.3, 124.2, 123.6, 119.6, 60.8, 51.2, 14.1.  
 
2-Azido-N-(4-heptyl-phenyl)-acetamide (2-C11-2C): 1H-NMR (500 MHz, (CD3)2SO) δ 
10.03 (s, 1H), 7.46 (d, 3J = 8.8 Hz, 2H), 7.12 (d, 3J = 8.8 Hz, 2H), 4.01 (s, 2H), 2.51 (t, 
2H), 1.52 (m, 2H), 1.24 (m, 8H), 0.85 (t, 3J = 7 Hz, 3H). 13C-NMR (500 MHz, (CD3)2SO) 
δ 165.9, 137.6, 136.0, 128.4, 119.2, 51.2, 34.4, 31.1, 30.9, 28.5, 28.4, 22.0, 13.8. ESI-MS 
(TOF): m/z 275.179 [M +H]+. 
 
N-Anthracen-1-yl-2-azido-acetamide (2-D1-2C): 1H-NMR (500 MHz, (CD3)2SO) δ 
10.40 (s, 1H), 8.48 (d, 3J = 13.8 Hz, 3H), 8.06 (t, 3J = 9.4 Hz, 3H), 7.56 (d, 3J = 9.4 Hz, 
1H), 7.47 (m, 2H), 4.14 (s, 2H). 13C-NMR (500 MHz, (CD3)2SO) δ 167.1, 135.8, 132.2, 
131.5, 129.3, 128.5, 128.1, 126.2, 125.6, 125.5, 121.2, 116.7, 114.5, 51.9. ESI-MS 
(TOF): m/z 277.099 [M + H]+.  
 
4-Azido-N-(4-fluoro-phenyl)-butyramide (2-A1-4C): 1H-NMR (300 MHz, DMSO-d6) 
δ 9.94(s, 1H), 7.57-7.54(m, 2H), 7.09-7.06 (m, 2H), 3.35-3.33(t, J = 6.62 Hz, 2H), 2.36-
2.33(m, 2H), 1.81-1.78(m, 2H). 13C-NMR (125 MHz, DMSO-d6) δ 170.12, 158.75, 
156.84, 135.56, 120.76(d), 115.20(d), 50.24, 33.07, 24.19. 
 
4-Azido-N-(3-fluoro-4-methyl-phenyl)-butyramide (2-A6-4C): 1H-NMR (300 MHz, 
DMSO-d6) δ 10.03, 7.55-7.52(m, 1H), 7.18-7.17(m, 2H), 3.40-3.37 (t, J = 6.625 Hz, 2H), 
2.51-2.50(m, 2H), 2.16(s, 3H), 1.86-1.81(q, 2H). 13C-NMR (125 MHz, CDCl3) δ 170.37, 
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161.12, 159.21, 138.54(d), 131.25(d), 118.18(d), 114.53, 105.80, 5.21, 33.13, 24.52, 
13.54. 
 
4-Azido-N-(4-chloro-phenyl)-butyramide (2-A8-4C): 1H-NMR (500 MHz, DMSO-d6) 
δ 10.02(s, 1H), 7.58-7.56 (d, J = 8.85 Hz, 2H), 7.30-7.28 (d, J = 8.8 Hz, 2H), 3.35-3.33 (t, 
J = 6.95 Hz, 2H), 2.37 (m, 2H), 1.82-1.77(m, 2H). 13C-NMR (125 MHz, DMSO-d6) δ 
170.40, 138.09, 128.48, 126.49, 120.52, 50.22, 33.16, 24.12. 
 
4-Azido-N-(4-chloro-2-methoxy-phenyl)-butyramide (2-A11-4C): 1H-NMR (500 
MHz, DMSO-d6) δ 9.29(s, 1H), 8.10(s, 1H), 7.10-7.08(m, 1H), 7.05-7.03 (m, 1H), 
3.83(s, 3H), 3.39-3.36(t, J = 6.92Hz, 2H), 2.54-2.49(m, 2H), 1.86-1.80(m, 2H). 13C-NMR 
(125 MHz, DMSO-d6) δ 170.94, 148.05, 128.58, 123.74, 123.29, 120.84, 112.85, 112.35, 
55.96, 50.21, 32.96, 24.26. 
 
4-Azido-N-(2-methoxy-phenyl)-butyramide (2-B4-4C): 1H-NMR (500 MHz, DMSO-
d6) δ 9.06 (s, 1H), 7.88-7.86(m, 1H), 7.03-6.97(m, 2H), 6.86-6.83(t, 1H), 3.8(s, 3H), 
3.35-3.32(t, J = 6.92Hz, 2H), 2.46-2.41(m, 2H), 1.80-1.77(m, 2H). 13C-NMR (125 MHz, 
DMSO-d6) δ 170.41, 149.64, 127.23, 124.26, 122.13, 120.09, 111.06, 55.55, 50.25, 
32.94, 24.38. 
 
4-Azido-N-(4-methylsulfanyl-phenyl)-butyramide (2-B7-4C): 1H-NMR (500 MHz, 
DMSO-d6) δ 9.89(s, 1H), 7.51-7.50(m, 2H), 7.17-1.16(m, 2H), 3.35-3.32 (t, J = 6.95 Hz, 
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3H), 2.38(m,3H), 2.36-2.33 (t, 2H), 1.82-1.77(q, 2H). 13C-NMR (125 MHz, DMSO-d6) δ 
170.14, 136.73, 131.42, 127.13, 119.71, 50.26, 33.14, 24.20, 15.57. 
 
4-Azido-N-(4-trifluoromethoxy-phenyl)-butyramide (2-B8-4C): 1H-NMR (500 MHz, 
DMSO-d6) δ 10.09(s, 1H), 7.66-7.64(d, J = 8.85 Hz, 2H), 7.25-7.23(d, J = 8.2 Hz, 2H), 
3.36-3.33 (t, J = 6.6, 2H), 2.38-2.35(m, 2H), 1.83-1.78(m, 2H). 13C-NMR (125 MHz, 
DMSO-d6) δ 170.49, 143.34, 138.37, 121.47, 120.30, 119.09, 50.24, 33.16, 24.15. 
 
4-Azido-N-(4-phenoxy-phenyl)-butyramide (2-B11-4C): 1H-NMR (500 MHz, DMSO-
d6) δ 9.92(s, 1H), 7.57-7.56(m, 2H), 7.32-7.29 (m, 2H), 7.05-7.02(m, 1H), 6.94-6.90(m, 
4H), 3.36-3.33(t, J = 6.92 Hz, 2H), 2.37-2.34(t, J = 7.25 Hz, 2H), 1.83-1.78 (m, 2H). 13C-
NMR (75 MHz, CDCl3) δ 170.04, 157.38, 151.47, 135.13, 129.85, 122.83, 120.70, 
119.37, 117.72, 50.26, 33.10, 24.26. 
 
4-Azido-N-(4-methoxy-phenyl)-butyramide (2-B12-4C):  1H-NMR (500 MHz, DMSO-
d6) δ 9.87(s, 1H), 3.67 (s, 3H), 3.36-3.329(m, 2H), 2.36-2.33 (t, J = 7.25 Hz, 2H), 1.82-
1.77(m, 2H). 13C-NMR (125 MHz, DMSO-d6) δ 170.31, 159.44, 140.34, 129.36, 111.32, 
108.42, 104.86, 54.86, 50.25, 33.23, 24.18.  
 
4-Azido-N-(4-tert-butyl-phenyl)-butyramide (2-C6-4C): 1H-NMR (500 MHz, DMSO-
d6) δ 9.80(s, 1H), 7.45-7.44(d, J = 8.8 Hz, 2H), 7.25-7.24(d, J = 8.2 Hz, 2H), 3.35-3.32(t, 
J = 6.62 Hz, 2H), 2.35-2.32 (t, J = 7.57 Hz, 2H), 1.82-1.76(m, 2H), 1.2 (s, 9H). 13C-NMR 
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(75 MHz, DMSO-d6) δ 170.00, 145.26, 136.58, 125.14, 118.84, 50.27, 33.89, 33.10, 
31.13, 24.28 
 
4-Azido-N-(4-ethyl-phenyl)-butyramide (2-C7-4C): 1H-NMR (300 MHz, CDCl3) δ 
7.36-7.33(d, J = 8.7 Hz, 2H), 6.85-6.82(d, J = 8.7 Hz, 2H), 4.03-3.96(m, 2H), 3.42-3.38(t, 
J = 6.27 Hz, 2H), 2.47-2.43 (t, J = 7.14 Hz, 2H), 2.01-1.97 (t, J = 6.79Hz, 2H), 1.41-
1.37(t, J = 6.79 Hz, 3H). 13C-NMR (75 MHz, CDCl3) δ 170.83, 142, 130, 122.30, 114.76, 
63.68, 50.64, 33.91 
 
5-Azido-pentanoic acid (2-ethoxy-phenyl)-amide (2-A12-5C): 1H-NMR (500 MHz, 
DMSO-d6) δ 8.87(s, 1H), 7.85(m, 1H), 7.00-6.97(m, 2H), 6.86-6.83(m, 1H), 4.06-
3.99(m, 2H), 3.34-3.32(m, 2H), 2.52-2.37(m, 2H), 1.58(m, 4H), 1.32-1.21(m, 3H). 13C-
NMR (125 MHz, CDCl3) δ 170.87, 148.98, 127.45, 124.33, 122.37, 120.07, 112.17, 
63.82, 50.38, 44.75, 35.40, 27.74, 22.39, 14.52. ESI-MS (TOF): m/z 263.148 [M + H]+. 
 
5-Azido-pentanoic acid (4-ethoxy-phenyl)-amide (2-B3-5C): 1H-NMR (300 MHz, 
DMSO-d6) δ  9.68 (s, 1H), 7.44-7.41 (d, J = 15 Hz, 2H), 6.81-6.78(d, J = 15.05 Hz, 2H), 
3.95-3.88(m, 2H), 3.33-3.28(d, J = 10.67 Hz, 2H), 2.27-2.23 (t, J = 11.5 Hz, 2H), 1.58-
1.52(m, 4H), 1.27-1.20(m, 3H). 13C-NMR (125 MHz, DMSO-d6) δ 170.27, 154.24, 
132.33, 120.55, 114.26, 63.01, 50.38, 35.55, 27.84, 22.43, 14.64. ESI-MS(TOF): m/z 
263.148 [M + H]+. 
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5-Azido-pentanoic acid (2-methoxy-phenyl)-amide (2-B4-5C): 1H-NMR (300 MHz, 
DMSO-d6) δ 8.99(s, 1H), 7.89-7.87 (d, J = 12.85, 1H), 7.04-6.96 (m, 2H), 6.87-6.81(m, 
1H), 3.77(s, 3H), 3.33-3.29 (t, J = 10.55 Hz, 2H), 2.39-2.35(t, J = 11.1 Hz, 2H, ), 1.61-
1.51(m, 4H). 13C-NMR (125 MHz, DMSO-d6) δ 170.99, 149.60, 127.30, 124.20, 122.06, 
120.10, 111.04, 55.55, 50.35, 35.35, 27.77, 22.37. ESI-MS(TOF): m/z 249.133 [M + H]+. 
 
5-Azido-pentanoic acid (3-isopropoxy-phenyl)-amide (2-B6-5C): 1H-NMR (500 MHz, 
DMSO-d6) δ 9.78 (s, 1H), 7.24 (s, 1H), 7.13-7.08(m, 2H), 6.54-6.51(m, 1H), 4.51-
4.43(m, 1H), 3.3 (t, 2H), 2.30-2.26(t, J = 11.65Hz, 2H), 1.63-1.50(m, 4H), 1.21 (s, 3H), 
1.23 (s, 3H). 13C-NMR (125 MHz, CDCl3) δ 170.85, 157.64, 140.42, 129.34, 111.11, 
110.12, 106.52, 69.06, 50.38, 35.74, 27.81, 22.23, 21.79. ESI-MS(TOF): m/z 277.163 [M 
+ H]+. 
 
5-Azido-pentanoic acid (3,4-dimethoxy-phenyl)-amide (2-B10-5C): 1H-NMR (300 
MHz, DMSO-d6) δ 9.7 (s, 1H), 7.06-7.03(d, J = 8.55Hz, 1H), 6.83-6.80(d, J = 8.52 Hz, 
1H), 3.7(s, 6H), 3.33-3.29(t, J = 6.24 Hz, 2H), 2.28-2.24(t, J = 6.73 Hz, 2H), 1.60-
1.50(m, 4H). 13C-NMR (75 MHz, DMSO-d6) δ 170.39, 148.50, 144.63, 132.96, 112.08, 
110.94, 104.33, 55.71, 55.30, 50.40, 38.63, 35.65, 27.86, 22.32. ESI-MS(TOF): m/z 
279.143 [M + H]+. 
 
5-Azido-pentanoic acid (5-chloro-2-phenoxy-phenyl)-amide (2-C2-5C): 1H-NMR 
(300 MHz, DMSO-d6) δ 9.56(s, 1H), 8.10(s, 1H), 7.37-7.32(m, 2H), 7.10-7.06(m, 2H), 
6.97-6.94 (d, J = 13.95 Hz, 2H), 6.87-6.84(d, J = 14.5 Hz, 1H), 3.24 (t, 2H), 2.36-2.31 (t, 
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J = 11.5 Hz, 2H), 1.52-1.41(m, 4H). 13C-NMR (75 MHz, DMSO-d6) δ 171.67, 156.34, 
145.81, 131.15, 129.89, 127.13, 124.11, 123.59, 122.71, 120.09, 118.30. ESI-MS(TOF): 
m/z 345.110 [M + H]+. 
 
5-Azido-pentanoic acid (3-ethyl-phenyl)-amide (2-C5-5C): 1H-NMR (500 MHz, 
DMSO-d6) δ 9.77 (s, 1H), 7.40-7.31 (m, 2H), 7.16-7.07(m, 1H), 6.83-6.77 (m, 1H), 3.33-
3.27(m, 2H), 2.52(m, 2H), 2.30-2.22(m, 2H), 1.55(m, 4H), 1.14-1.05(m, 3H). 13C-NMR 
(125 MHz, CDCl3) δ 170.77, 144.12, 139.24, 128.47, 122.44, 118.39, 116.49, 50.39, 
35.70, 28.23, 27.83, 22.29, 15.46. ESI-MS(TOF): m/z 247.153 [M + H]+ 
 
4-(5-Azido-pentanoylamino)-benzoic acid ethyl ester (2-C9-5C): 1H-NMR (500 MHz, 
DMSO-d6) δ 10.19(s, 1H), 7.87-7.84(d, J = 12.35 Hz, 2H), 7.70-7.67(d, J = 13.6 Hz, 
2H), 4.26-4.22(m, 2H), 3.33-3.29(t, J = 10 Hz, 2H), 2.36-2.32(t, J = 11.1 Hz, 2H), 1.61-
1.51(m, 4H), 1.28-1.22(m, 3H). 13C-NMR (125 MHz, CDCl3) δ 171.48, 165.29, 143.56, 
130.14, 123.95, 118.31, 60.32, 50.38, 35.78, 27.79, 22.10, 14.15. ESI-MS(TOF): m/z 
291.144 [M + H]+. 
 
6-Azido-hexanoic acid (4-fluoro-phenyl)-amide (2-A1-6C):  1H-300 MHz, DMSO d6) 
δ 9.87 (s, 1H, NH), 7.55 (m, 2H), 7.07 (m, 2H), 3.28 (t, 2H, J = 6.74 Hz), 2.25 (t, 2H, J = 
7.23 Hz), 1.51 (m, 4H), 1.31 (m, 2H); 13C-NMR (75.5 MHz, DMSO d6) δ 171.31, 
159.74, 136.06, 121.13, 115.37, 50.89, 36.49, 28.40, 26.18, 24.97. ESI-MS (TOF): m/z = 
[M+H]+  251.124  
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6-Azido-hexanoic acid (4-chloro-phenyl)-amide (2-A8-6C): 1H-NMR (300 MHz, 
DMSO d6) δ 9.95 (s, 1H, NH), 7.56 (d, 2H, J = 8.85 Hz), 7.30 (d, 2H, J = 8.88 Hz), 3.28 
(t, 2H, J = 6.82 Hz), 2.27 (t, 2H, J = 7.30 Hz), 1.51 (m, 4H), 1.33 (m, 2H); 13C-NMR 
(75.5 MHz, DMSO d6) δ 171.59, 138.62, 128.89, 126.81, 120.89, 50.88, 36.57, 28.39, 
26.15, 24.90. ESI-MS(TOF): m/z = [M+H]+  267.091 
   
6-Azido-hexanoic acid (4-chloro-2-methoxy-phenyl)-amide  (2-A11-6C): 1H- NMR 
(300 MHz, DMSO d6) δ 9.15 (s, 1H, NH), 8.06 (s, 1H), 7.10-6.95 (m, 2H), 3.79 (s, 3H, 
OMe), 3.28 (t, 2H, J = 6.80 Hz), 2.37 (t, 2H, J = 7.32 Hz), 1.52 (m, 4H), 1.31 (m, 2H); 
13C-NMR (75.5 MHz, DMSO d6) δ 172.10, 148.40, 129.09, 124.14, 123.54, 121.11, 
112.76, 56.38, 50.91, 36.19, 28.39, 26.11, 24.99. ESI-MS(TOF): m/z = [M+H]+  297.104 
 
6-Azido-hexanoic acid (2-ethoxy-phenyl)-amide (2-A12-6C):  1H- NMR (300 MHz, 
DMSO d6) δ 8.81 (s, 1H, NH), 7.85 (d, 1H, J = 7.74 Hz), 7.03-6.95 (m, 2H), 6.86-6.79 
(m, 1H), 4.03 (q, 2H, J = 6.9 Hz), 3.29 (t, 2H, J = 6.74 Hz), 2.34 (t, 2H, J = 7.32 Hz), 
1.52 (m, 4H), 1.32 (m, 2H); 13C-NMR (75.5 MHz, DMSO d6) δ 171.46, 149.31, 127.93, 
124.64, 122.67, 120.47, 112.59, 64.22, 50.93, 36.31, 28.42, 26.12, 25.12, 14.93. ESI-MS 
(TOF): m/z = [M+H]+  277.157 
 
6-Azido-hexanoic acid (4-ethoxy-phenyl)-amide (2-B3-6C): 1H- NMR (300 MHz, 
DMSO d6) δ 9.64 (s, 1H, NH), 7.42 (d, 2H, J =  9.03 Hz), 6.79 (d, 2H, J = 8.88 Hz),), 
3.92 (q, 2H, J = 7.08 Hz), 3.28 (t, 2H, J = 6.82 Hz), 2.22 (t, 2H, J = 7.39 Hz), 1.52 (m, 
4H), 1.26 (m, 2H); 13C-NMR (75.5 MHz, DMSO d6) δ 170.86, 154.60, 132.79, 120.92, 
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114.66, 63.41, 50.90, 36.45, 28.41, 26.20, 25.07, 15.04. ESI-MS(TOF): m/z = [M+H]+  = 
7.156 
 
6-Azido-hexanoic acid (2-methoxy-phenyl)-amide (2-B4-6C):  1H- NMR (300 MHz, 
DMSO d6) δ 8.97 (s, 1H, NH), 7.88 (d, 1H, J =  7.71 Hz), 6.99 (m, 2H), 6.84 (m, 1H), 
3.78 (s, 3H, OMe), 3.28 (t, 2H, J= 6.82 Hz), 2.34 (t, 2H, J = 7.23 Hz), 1.55 (m, 4H), 1.34 
(m, 2H); 13C-NMR (75.5 MHz, DMSO d6) δ 171.59, 149.96, 127.77, 124.53, 122.40, 
120.51, 111.44, 55.97, 50.94, 36.24, 28.41, 26.16, 25.12. ESI-MS(TOF): m/z = [M+H]+  
= 3.142 
 
6-Azido-hexanoic acid (3,4,5-trimethoxy-phenyl)-amide (2-B5-6C): 1H- NMR (300 
MHz, DMSO d6) δ 9.74 (s, 1H, NH), 6.94 (s, 2H), 3.68 (s, 6H, OMe), 3.58 (s, 3H, OMe), 
3.29 (t, 2H, J = 6.73 Hz), 2.23 (t, 2H, J = 7.23 Hz),1.53 (m, 4H), 1.31 (m, 2H); 13C-NMR 
(75.5 MHz, DMSO d6) δ 171.29, 153.04, 135.86, 133.56, 97.13, 60.45, 56.02, 50.90, 
36.65, 28.43, 26.19, 24.98. ESI-MS(TOF): m/z = [M+H]+  323.160 
 
6-Azido-hexanoic acid (3,4-dimethoxy-phenyl)-amide (2-B10-6C): 1H- NMR (300 
MHz, DMSO d6) δ 9.67 (s, 1H, NH), 7.26 (s, 1H), 7.03 (d, 1H, J = 8.55 Hz), 6.82 (d, 1H, 
J = 8.70 Hz), 3.68 (s, 6H, OMe), 3.29 (t, 2H, J = 6.73 Hz), 2.23 (t, 2H, J = 7.30 Hz),1.53 
(m, 4H), 1.31 (m, 2H); 13C-NMR (75.5 MHz, DMSO d6) δ 170.96, 148.88, 144.97, 
133.40, 112.49, 111.28, 104.69, 56.12, 55.69, 50.90, 36.54, 28.42, 26.20, 25.03. ESI-MS: 
m/z = [M+H]+  293.153 
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6-Azido-hexanoic acid (4-phenoxy-phenyl)-amide (2-B11-6C):   1H- NMR (300 MHz, 
DMSO d6) δ 9.84 (s, 1H, NH), 7.55 (d, 2H, J = 8.88 Hz), 7.31 (t, 2H, J = 7.56 Hz), 7.05 
(t, 1H, J = 7.39 Hz), 6.92 (m, 4H), 3.28 (t, 2H, J = 6.80 Hz), 2.26 (t, 2H, J = 7.32 
Hz),1.54 (m, 4H), 1.34 (m, 2H); 13C-NMR (75.5 MHz, DMSO d6) δ 171.22, 157.82, 
151.79, 135.66, 130.28, 123.23, 121.04, 119.81, 118.11, 50.90, 36.51, 28.41, 26.18, 
25.03. ESI-MS(TOF): m/z = [M+H]+  325.159 
Synthesis of azides using acid building blocks 
 
Fig. 7.5 List of acid building blocks. 
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Synthesis of the reductive aminated resin (2-4a to 2-4e): 
  Pre-swelled PL-FMP resin (34 x 150 mg, 0.9 mmol/g) was taken in to 5 sets (x 34) 
MacroKanTM  reactors each containing a RF tag. The reactors were taken into a 250 ml 
bottle containing 2% Acetic acid in 1,2-dichloroethane (150 mL), DIEA (8 eq) and the 
amine 6a-e (4 eq). After incubating for about 2 hours, Sodium triacetoxyborohydride (5 
eq) was added. After shaken for another 4 hours, the solution was decanted and the 
microreactors were washed with DCM (200 mL x 5), MeOH (200 mL x 2) and THF (200 
mL x 3) and dried to afford the N-acylated resins 2-4a to 2-4e  (5 sets, each contains 34 
identical reactors). 
 
Synthesis of N-acylated resin (2-39): 
To the first set of the reductive aminated resin 2-4a to 2-4e  (34 x 150 mg) was taken 
into 34 different bottles (10 mL). DMF solution (5 mL) containing PyBOP (4 eq), HOAt 
(4 eq) and DIEA (6 eq) was added followed by the addition of acid building blocks 2-
AE1-2AG10 (4 eq), (Fig. 7.5) so that each bottle had a unique acid. After shaken for 12 
hours the microreactors were decanted and combined and washed with DCM (200 mL x 
5), MeOH (200 mL x 2) and THF (200 mL x 3) and dried to afford the resin 2-39.  
 
Cleavage and release of azides (2-E1-2C to 2-G10-2C): 
The above General protocol for cleavage and release of azides, to afford the 2-E1-2C 
to 2-G10-2C. All azides synthesized from the above protocols are of high purity (90-
95%) Representative compounds were further characterizations, without any purification, 
by LCMS, 1H and 13C NMR.  
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 N-(2-Azido-ethyl)-benzamide (2-G1-3C): 1H-NMR (500 MHz, CDCl3) δ 7.79-7.77 (d, 
J = 12.20 Hz, 2H), 7.54-7.41 (m, 4H), 3.64-3.56 (m, 4H). 13C-NMR (125 MHz, CDCl3) 
132.65, 132.29, 129.21, 127.53, 51.50, 40.00. ESI-MS(TOF): m/z 191.092 [M + H]+. 
 
N-(2-Azido-ethyl)-3-fluoro-benzamide (2-G2-3C): 1H-NMR (500 MHz, CDCl3) δ 7.57-
7.51(m, 2H), 7.43-7.36(q, 4H), 7.22-7.17(m, 1H), 3.62-3.55(m, 4H). 13C-NMR (125 
MHz, CDCl3) 167.19, 136.92, 136.92, 130.84(d), 123.12(d), 119.32(d), 115.13(d), 51.22, 
40.08. ESI-MS(TOF): m/z 209.081  [M + H]+. 
 
N-(2-Azido-ethyl)-3,4-difluoro-benzamide (2-G3-3C): 1H-NMR (500 MHz, CDCl3) δ 
7.73-7.66(m, 1H), 7.58-7.55(m, 1H), 7.28-7.17(m, 1H), 3.62-3.55(m, 4H). 13C-NMR 
(125 MHz, CDCl3) 165.77, 154.19, 151.98, 131.17, 123.17(m), 117.61(m), 51.10, 40.85. 
ESI-MS(TOF): m/z 227.073 [M + H]+. 
 
N-(2-Azido-ethyl)-2,4-difluoro-benzamide (2-G4-3C): 1H-NMR (500 MHz, CDCl3) δ 
8.12-8.10(d, J = 9.85 Hz, 1H), 3.61-3.56(m, 4H). 13C-NMR (125 MHz, CDCl3) 166.09, 
164.0, 161, 133.77(d), 127.26, 117.94(d), 51.13, 40.20. ESI-MS(TOF): m/z 227.072 [M + 
H]+. 
 
N-(2-Azido-ethyl)-4-fluoro-3-trifluoromethyl-benzamide (2-G5-3C): 1H-NMR (500 
MHz, CDCl3) δ 8.14-8.10 (m, 1H), 7.02-6.94 (m, 1H), 6.90-6.86(m, 1H), 3.67-3.63(m, 
2H), 3.58-3.55(t, J = 5.67 Hz, 2H). 13C-NMR (125 MHz, CDCl3) 166.49, 163.24(d), 
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134.44(m), 117.70(d), 113.10(m), 105.12(m), 51.31, 39.97. ESI-MS (TOF): m/z 227.068 
[M + H]+. 
 
N-(2-Azido-ethyl)-4-fluoro-3-methyl-benzamide (2-G6-3C): 1H-NMR (500 MHz, 
CDCl3) δ 7.66(m, 1H), 7.59-7.57(m, 1H), 7.04-7.00(t, J = 10 Hz , 1H), 3.62-3.58(m, 2H), 
3.55-3.53(t, J = 5  , 2H), 2.40 (s, 3H). 13C-NMR (125 MHz, CDCl3) 167.60, 164.94, 
162.94, 131.35, 51.42, 40.03, 15.04. 
 
N-(2-Azido-ethyl)-2,3,4-trifluoro-benzamide (2-G7-3C):  1H-NMR (500 MHz, CDCl3) 
δ 7.87-7.82(m, 1H), 7.12-7.07 (m, 1H), 3.67-3.64(m, 2H), 3.59-3.56(t, J = 5.67 Hz, 2H). 
ESI-MS(TOF): m/z 245.060 [M + H]+. 
 
N-(2-Azido-ethyl)-2-fluoro-benzamide (2-G8-3C): 1H-NMR (500 MHz, CDCl3) 8.09-
8.06 (m, 1H), 7.50-7.46(m, 1H), 7.27(m, 1H), 7.15-7.11 (m, 1H), 3.68-3.64(m, 2H), 3.58-
3.56 (t, J = 5.67, 2H). 13C-NMR (125 MHz, CDCl3) δ 164.22, 160.26, 134.16(d), 
132.56(d), 125.43(d), 121.22, 116.74(d), 51.33, 39.94. ESI-MS(TOF): m/z 209.081 [M + 
H]+. 
 
N-(2-Azido-ethyl)-4-ethyl-benzamide (2-G10-3C):  1H-NMR (500 MHz, CDCl3) δ 
7.72-7.69(d, J = 13.9 Hz, 2H), 7.25-7.22 (d, J = 13.9 Hz, 2H), 3.63-3.50(m, 4H), 2.72-
2.64(q, 2H), 1.26-1.21(t, J = 12.7 Hz, 3H). 13C-NMR (125 MHz, CDCl3) δ 168.43, 
148.94, 131.94, 128.61, 127.62, 51.42, 39.93, 29.28, 15.79. ESI-MS (TOF): m/z 304.983 
[M + H]+. 
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Synthesis of azides using acid chloride building block 
 
Synthesis of N-acylated resin from acid chloride (2-6a to 2-6e): 
     The reductive aminated resins 2-4a; 2-4c; 2-4d; 2-4e (4 x 150 mg) were taken in a 
bottle (25 ml) containing DCM (15 ml). 2-chlorobenzoyl chloride, H (4 eq) and DIEA (5 
eq) were added. After shaken for 6 hours, the solution was decanted and the 
microreactors were washed with DCM (50 mL x 5), MeOH (50 mL x 2) and THF (50 mL 
x 3) and dried to afford the N-acylated resin 2-6a to 2-6e 
 
Cleavage and release of the azides (2-H1-2C to 2-H1-6C):  
Each dried resin was treated with an 1.5 ml solution containing of TFA (10 %) and 
DCM (90 %)  the mixture was shaken for 1 hour and transferred into 96-well plate, dried 
in vacuo, then redissolved in DMSO (1 mL) to give 50 mM solutions (assuming 50 % 
yield). All azides synthesized from the above protocols are of high purity (90-95%). 
Representative compounds were further characterizations, without any purification, by 
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Sulfonyl chloride building blocks
Fig. 7.6 List of Sulfonyl chloride building blocks 
 
Synthesis of the N-sulfonamide resin (2-7a to 2-7-e):  
The reductive aminated resin 2-4a to 2-4e (23 x 150 mg) was taken in to 23 different 
bottles (10 ml) each containing a unique Sulfonyl chloride (2-AI1 to a-AJ11) (Fig. 7.6) 
and DIEA (5 eq) in DCM (5 ml). After shaken for 6 hours, the solution was decanted and 
the microreactors were washed with DCM (200 mL x 5), MeOH (200 mL x 2) and THF 





Cleavage and release of the sulfonamide-based azides (2-I1-2C to 2-J11-6C):  
Each dried resin was treated with an 1.5 ml solution containing of TFA (10 %) and 
DCM (90 %)  the mixture was shaken for 1 hour and transferred into 2 different 96-well 
plates, dried in vacuo, then redissolved in DMSO (1 mL) to give 50 mM solutions 
(assuming 50 % yield). All azides synthesized from the above protocols are of high purity 
(90-95%). Representative compounds were further characterizations, without any 
purification, by LCMS, 1H and 13C NMR.  
 
4-Acetyl-N-(2-azidoethyl)benzenesulfonamide (2-I1-2S): 1H NMR (300 MHz, DMSO-
d6) δ 2.63 (s, 3H), 2.94-3.00 (m, 2H), 3.33 (t, J = 5.8 Hz, 2H), 7.93 (d, J = 8.4 Hz, 2H), 
8.13-8.16 (m, 3H). 13C NMR (75 MHz, DMSO-d6) δ 27.0, 42.1, 50.1, 126.8, 129.0, 
139.5, 144.0, 197.3. 
 
Synthesis of azides using chloroformate building block 
 
Synthesis of carbamate resin (2-8a, 2-8d, 2-8d) 
     The reductive aminated resins 2-4a, 2-4d, 2-4e (3 x 150 mg) were taken in a bottle (25 
ml) containing DCM (15 ml). Benzylchloro formate and DIEA (5 eq) were added. After 
shaken for 6 hours, the solution was decanted and the microreactors were washed with 
DCM (50 mL x 5), MeOH (50 mL x 2) and THF (50 mL x 3) and dried to afford the 




Cleavage and release of the azides (2-L1-2C to 2-L1-6C):  
     Each dried resin was treated with an 1.5 ml solution containing of TFA (10 %) and 
DCM (90 %)  the mixture was shaken for 1 hour and transferred into 96-well plate, dried 
in vacuo, then redissolved in DMSO (1 mL) to give 50 mM solutions (assuming 50 % 
yield). All azides synthesized from the above protocols are of high purity (90-95%; see 
Appendix for detailed structures, ID and characterizations). Representative compounds 
were further characterizations, without any purification, by LCMS, 1H and 13C NMR. 
 
General procedure for the synthesis of various Propargyl phenyl ethers (2-42, 2-43, 
2-49, 2-50, 2-51):  Potassium carbonate (99 mmol) and benzo-18-crown-6 (3.3 mmol) 
were added to a solution of propargyl p-toluenesulfonate (66 mmol) and hydroxyl 
acetophenone (66 mmol) in acetonitrile (100 ml) followed by refluxing for 6 h, after 
which the organic phase was removed under reduced pressure and taken into 
dichloromethane layer (80 ml) and extracted with NaHCO3 (2 x 40 ml), water (2 x 40 ml) 
and brine (1 x 40 ml). The organic phase was then dried with anhydrous Na2SO4, and the 
solvent was removed in vacuo to afford the crude product, which, upon further 
purification by flash column chromatography, afforded the pure Propargyl phenyl ether. 
Compounds 2-42, 2-43, 2-49, 2-50, 2-51 were obtained from compounds 2-40, 2-41, 2-
46, 2-47, 2-48 respectively, in 67–90% yield. 
 
1-(3,5-dibromo-2-(prop-2-ynyloxy)phenyl)ethanone (2-42): Pale yellow solid. Yield = 
67 %. 1H-NMR (300 MHz, CDCl3) δ 7.84 (d, J = 2.46 Hz, 1H), 7.71 (d, J = 2.46 Hz, 1H), 




1-(4-fluoro-2-(prop-2-ynyloxy)phenyl)ethanone (2-43): Yellow solid. Yield = 88%. 
1H-NMR (300 MHz, CDCl3) δ 7.85 – 7.79 (m, 1H), 6.82 – 6.72 (m, 2H), 4.80 (d, J = 2.46 
Hz, 2H), 2.61 – 2.59 (m, 4H);  13C-NMR (75 MHz, CDCl3) δ 197.6, 167.6, 164.2, 158.5, 
132.7 (JCF = 10.9 Hz), 125.0 (JCF = 3.3 Hz), 108.6 (JCF = 21.3 Hz), 101.0 (JCF = 26.2 
Hz), 76.7, 56.5, 31.8; ESI-MS: m/z [M-H]- = 191.2. 
 
1-(3-methoxy-4-(prop-2-ynyloxy)phenyl)ethanone (2-49): White solid. Yield = 90%. 
1H-NMR (300 MHz, CDCl3) δ 7.57 – 7.53 (m, 2H), 7.04 (d, J = 8.22 Hz, 1H), 4.82 (d, J 
= 2.46 Hz, 2H), 3.92 (s, 3H), 2.59 – 2.57 (m, 4H);  13C-NMR (75 MHz, CDCl3) δ 196.7, 
150.8, 149.4, 131.4, 122.7, 112.3, 110.5, 76.5, 76.4, 56.5, 55.9, 26.1 ESI-MS: m/z 
[M+H]+ = 205.2. 
 
1-(2-(prop-2-ynyloxy)phenyl)ethanone (2-50): Pale yellow solid. Yield = 63 %. 1H-
NMR (300 MHz, CDCl3) δ 7.81 – 7.73 (m, 1H), 7.50 – 7.44 (m, 1H), 7.08 – 7.02 (m, 
2H), 4.81 (d, J = 2.46 Hz, 2H), 2.64 (s, 3H), 2.54 (t, J = 2.46 Hz, 1H); ESI-MS: m/z 
[M+Na]+ = 197.0. 
 
General procedure for the synthesis of various isoxazole-3-carboxylic acid methyl 
esters (2-44, 2-45, 2-52, 2-53, 2-54):  
To a mixture of alkyne-derivatized acetophenone (53 mmol) and dimethyl oxalate (53 
mmol) was added freshly prepared NaOMe (0.5 M in MeOH, 53 mmol). The reaction 
mixture was refluxed for 12 h before cooled to room temperature. To the same reaction 
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MeOH (80 ml), NH2OH.HCl (53 mmol) and a catalytic amount of p-TsOH.H2O were 
added and the resulting mixture was refluxed continuously for 3 days. Upon cooling to 
room temperature, the precipitated compound was collected, washed with water and ice-
cold methanol to afford the pure isoxazole-3-carboxylic acid methyl ester. Compounds 2-
44, 2-45, 2-52, 2-53, 2-54 were obtained from compounds 2-42, 2-43, 2-49, 2-50, 2-51 
respectively, in 34–44% yield.  
 
Methyl 5-(3,5-dibromo-2-(prop-2-ynyloxy)phenyl)isoxazole-3-carboxylate (2-42): 
Pale brown powder. Yield = 35%. 1H-NMR (300 MHz, DMSO-d6) δ 8.12 (d, J = 2.13 
Hz, 1H), 8.07 (d, J = 2.31 Hz, 1H), 7.37 (s, 1H), 4.81 (d, J = 2.13 Hz, 2H), 3.94 (s, 3H), 
3.61 (t, J = 2.30 Hz, 1H); 13C-NMR (75 MHz, DMSO-d6) δ 165.7, 159.6, 156.6, 150.6, 
137.6, 129.8, 124.1, 119.6, 118.2, 105.1, 80.1, 77.7, 60.6, 53.0; ESI-MS: m/z = N.A. 
(didn’t show up in both +ve and –ve modes, probably due to difficult ionization). 
 
Methyl-5-(4-fluoro-2-(prop-2-ynyloxy)phenyl)isoxazole-3-carboxylate (2-43): Off- 
white solid. Yield = 38%. 1H-NMR (300 MHz, DMSO-d6) δ 8.0233 – 7.99 (m, 1H), 7.27 
(dd, J = 11.3 Hz, J = 2.39 Hz, 1H), 7.15 (s, 1H), 7.09 – 7.03 (m, 1H), 5.12 (d,  J = 2.31 
Hz, 2H), 3.94 (s, 3H), 3.76 (t, J = 2.22 Hz, 1H);  ESI-MS: m/z [M+H]+ = 274.7. 
 
Methyl 5-(5-chloro-2-(prop-2-ynyloxy)phenyl)isoxazole-3-carboxylate (2-49): Yellow 
solid. Yield = 34%. 1H-NMR (300 MHz, DMSO-d6) δ 7.97 (d, J = 2.79 Hz, 1H), 7.46 – 
7.40 (dd, J = 9.29 Hz, J = 2.61 Hz, 1H), 7.21 (s, 1H), 7.07 (d, J = 9.06 Hz, 1H) 4.85 (d,  J 
= 2.10 Hz, 2H), 3.99 (s, 3H), 2.59 (t, J = 2.10 Hz, 1H); ESI-MS: m/z [M+H]+ = 291.8. 
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5-(2-Methyl-4-prop-2-ynyloxy-phenyl)-isoxazole-3-carboxylic acid methyl ester (2-
50):  Pale brown solid. Yield = 44 %.  1H-NMR (300 MHz, DMSO-d6) δ 7.73-7.70(d, J 
= 8.37 Hz, 1H), 7.07(s, 1H), 7.00-6.97(m, 2H), 4.87-4.86(d, J = 2.2 Hz, 2H), 3.9 (s, 3H), 
3.58-3.57 (t, J = 4.44 Hz, 1H), 2.45(s, 3H). 13C-NMR (75 MHz, DMSO-d6) δ 171.12, 
160.02, 158.78, 156.26, 138.23, 130.01, 118.95, 117.64, 112.89, 102.29, 78.89, 78.54, 
55.57, 52.84, 21.14. ESI-MS: m/z = N.A. (didn’t show up in both +ve and –ve modes, 
probably due to difficult ionization).  
 
Methyl 5-(2-(prop-2-ynyloxy)phenyl)isoxazole-3-carboxylate (2-51): Dark brown 
solid. Yield = 42 %. 1H-NMR (300 MHz, DMSO-d6) δ 7.94 (dd, J = 7.74 Hz, J = 1.65 
Hz, 1H), 7.56 – 7.53 (m, 1H), 7.32 (d, J = 8.22 Hz, 1H), 7.20 – 7.15 (m, 2H), 5.31 (d,  J = 
2.46 Hz, 2H), 3.93 (s, 3H), 3.66 (t, J = 2.46 Hz, 1H);  ESI-MS: m/z = N.A. (didn’t show 
up in both +ve and –ve modes, probably due to difficult ionization).  
 
General procedure for the hydrolysis of the methyl esters (2-F, 2-G, 2-H, 2-I, 2-J):  
The methyl ester (4 mmol) was suspended in methanol (10 ml) and a NaOH solution (10 
ml; 10 M solution) was added slowly and the reaction was stirred for 3 h before the pH 
was adjusted to ~2 using HCl (2 N solution) under cold conditions. The resulting 
precipitate was collected, washed with cold water, dried in vacuo to furnish the desired 
acid. Compounds 2-F, 2-G, 2-H, 2-I, 2-J were prepared starting from 2-44, 2-45, 2-52, 2-
53, 2-54 respectively.  
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5-(3,5-dibromo-2-(prop-2-ynyloxy)phenyl)isoxazole-3-carboxylic acid (2-F): Brown 
powder. Yield = 92%. 1H-NMR (300 MHz, DMSO-d6) δ 8.13 (d, J = 2.46 Hz, 1H), 8.08 
(d, J = 2.28 Hz, 1H), 7.31 (s, 1H), 4.82 (d, J = 2.28 Hz, 2H), 3.63 (t, J = 2.39 Hz, 1H); 
13C-NMR (125 MHz, DMSO-d6) δ 165.2, 160.6, 157.9, 150.6, 137.4, 129.7, 124.3, 
119.6, 118.1, 105.2, 100.0, 80.0, 77.7, 60.5; ESI-MS: m/z [M-H]- = 400.0.  
 
5-(4-fluoro-2-(prop-2-ynyloxy)phenyl)isoxazole-3-carboxylic acid (2-G): Pale brown 
solid. Yield = 92%. 1H-NMR (300 MHz, DMSO-d6) δ 7.95 (t, J = 7.65 Hz, 1H), 7.21 (d, 
J = 11.19 Hz, 1H), 7.08 (s, 1H), 7.00 (t, J = 8.48 Hz, 1H), 5.08 (s, 2H), 3.71 (s, 1H); 13C-
NMR (75 MHz, DMSO-d6) δ 165.8 (d, JCF = 2.18 Hz), 166.2, 162.5, 160.9, 157.7, 155.5 
(d, JCF = 10.9 Hz), 129.0 (d, JCF = 10.4 Hz), 112.0 (d, JCF = 3.3 Hz), 108.7 (d, JCF = 21.8 
Hz), 103.2, 102.0 (d, JCF = 26.2 Hz), 79.3, 78.1, 56.9; ESI-MS: m/z [M+H]+ = 262.1.  
 
5-(3-methoxy-4-(prop-2-ynyloxy)phenyl)isoxazole-3-carboxylic acid (2-H): White 
powder. Yield = 96%. 1H-NMR (300 MHz, DMSO-d6) δ 7.53 (br s, 2H), 7.38 (s, 1H), 
7.19 (d, J = 8.88 Hz, 1H), 4.91 (d, J = 1.47 Hz, 2H), 3.90 (s, 3H), 3.62 (s, 1H); 13C-NMR 
(75 MHz, DMSO-d6) δ 170.9, 161.0, 157.7, 149.5, 148.6, 119.9, 118.6, 113.9, 109.4, 
100.0, 78.9, 78.7, 56.1, 55.9; ESI-MS: m/z [M+H]+ = 274.7. 
 
5-(2-Methyl-4-prop-2-ynyloxy-phenyl)-isoxazole-3-carboxylic acid (2-I): Brown 
solid. Yield = 93%.  
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5-(2-(prop-2-ynyloxy)phenyl)isoxazole-3-carboxylic acid (2-J): Dull white solid. Yield 
= 92%. 1H-NMR (300 MHz, DMSO-d6) δ 7.94 (dd, J = 7.88 Hz, J = 1.64 Hz, 1H), 7.59 – 
7.53 (m, 1H), 7.32 (d, J = 8.22 Hz, 1H), 7.19 (t, J = 7.56 Hz, 1H) 7.15 (s, 1H), 5.06 (d, J 
= 2.46 Hz, 2H), 3.68 (t, J = 2.22 Hz, 1H); ESI-MS: m/z [M-H]- = 242.1. 
 
2.3.3 General Procedure for the High-throughput ‘click’ assembly  
 
    A total of 10 different alkynes (2-A to 2-J) and 325 azides (Azides synthesized by the 
above solid-phase method as well as few azides synthesized from the solution phase) 
were subjected to Cu(I) catalyzed 1,3-dipolar cycloaddition which to assemble the 3250 
member library. The library was assembled in 14-different 384 well plates. 
 
Synthesis of the 3250 member click library:  
 
          The optimized condition for the alkyne-alkyne click reaction is given in the Table 
7.1. Alkyne solution (25 mM, 10 µL) was dispensed into each well of the 384-well plate 
using a Multi-drop Combi dispenser (Thermo Scientific) followed by the transfer of azide 
solutions (50 mM, 7 µL) from the 96-well storage plate to the first quadrant of the 384-
well reaction plate using a Sciclone ALH 3000 Liquid Handler Workstation (Caliper Life 
Sciences). Similarly other azides were transferred from the 96-well storage plates to the 
rest of the three quadrants of the 384-reation plate. t-BuOH (43 µl ) and catalyst mix±(40 
µl) were added to each well in the reaction plate using the bulk liquid dispenser. The 384-
well plate was carefully sealed using a silicone based cap-mat and shaken for 2 days. The 
solvent was dried in vacuo and the resulting residue was redissolved in DMSO (100 
µL/well). The ‘click’ products were analyzed by LC-MS to determine the quality and 
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identity (See Appendix). Representative members were also characterized by 1H NMR 
analysis and the data is presented below. The concentration of the product in each well is 
calculated to be 2.5 mM based on the assumption that all alkynes were reacted 
quantitatively. The compounds were stored in -20o C.  
            
 ±Catalyst mix is a mixture of CuSO4 solution (25 mM, 2 µL) and Sodium ascorbate (50 
mM, 5 µL) in water (33 µL).      
 
 





1 Alkyne (in DMSO) 1 25 mM 10 
2 Azide   (in DMSO) 1.4 50 mM 7 
3 CuSO4.5 H2O (in Water) 0.2 25 mM 2 
4 Sodium ascorbate ( in Water) 0.5 50 mM 5 
5 t-BuOH - - 43 
6 Water - - 33 
 








yl)methoxy)phenyl)isoxazole-3-carboxylic acid (2-A5-2C-W2): 1H NMR (300 MHz, 
DMSO-d6) δ 4.34 (m, 2H), 5.23 (s, 2H), 5.45 (s, 2H), 6.97-7.01 ( m,1H), 7.03 (s, 1H), 
7.08-7.13 (m, 2H), 7.33-7.41 (m, 1H), 7.44- 7.48 (dd, 1H, J= 11.34Hz, J= 2.31Hz), 7.93-
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yl)methoxy)phenyl)isoxazole-3-carboxylic acid (2-I-2-A6-2C): 1H NMR (300 MHz, 
DMSO-d6) δ 2.17 (s, 3H), 5.36 (s, 2H), 5.47 (s, 2H), 6.98-7.01 (m, 1H), 7.03 (s, 1H), 
7.17-7.24 (m, 2H), 7.45-7.52 (m, 2H), 7.96 (m, 1H), 8.33 (s, 1H), 10.59 (s, 1H); ESI-MS 
(IT-TOF) m/z = [M+H] +  470.1295  
 
5-(4-fluoro-2-((1-(2-(4-(methylthio)phenylamino)-2-oxoethyl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)isoxazole-3-carboxylic acid (2-I-2-B7-2C): 1H NMR (300 MHz, 
DMSO-d6) δ 2.45 (s, 3H), 5.35 (s, 2H), 5.46 (s, 2H), 6.98-7.01 (m, 1H), 7.03 (s, 1H), 
7.24 (d, 2H, J= 8.70 Hz), 7.49-7.55 (m, 3H), 7.93-7.99 (m, 1H), 8.33 (s, 1H), 10.48 (s, 
1H) ); ESI-MS (IT-TOF) m/z = [M+H] +  484.1053  
 
5-(4-fluoro-2-((1-(2-oxo-2-(4-(trifluoromethoxy)phenylamino)ethyl)-1H-1,2,3-triazol-
4-yl)methoxy)phenyl)isoxazole-3-carboxylic acid (2-I-2-B8-2C):  1H NMR (300 MHz, 
MeOH-d4) δ 5.39 (s, 2H), 5.44 (s, 2H), 6.88-6.95 (m, 1H), 7.05 (s, 1H), 7.23-7.25 (m, 
2H), 7.28-7.29(m,1H), 7.66-7.69 (m, 2H), 7.95-8.00 (m, 1H), 8.26 (s, 1H) ); ESI-MS (IT-
TOF) m/z = [M+H] +  522.1054  
 
5-(4-fluoro-2-((1-(2-(4-methoxyphenylamino)-2-oxoethyl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)isoxazole-3-carboxylic acid (2-I-2-B9-2C): 1H NMR (300 MHz, 
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DMSO-d6) δ 3.75 (s, 3H), 5.33 (s, 2H), 5.46 (s, 2H), 6.88-6.91 (d, 2H, J= 8.88 Hz), 7.01-
7.09 (m, 2H), 7.45-7.49 (m, 3H), 7.93-7.99 (m, 1H), 8.32 (s, 1H), 10.34 (s, 1H) ); ESI-
MS (IT-TOF) m/z = [M+H] +  468.1424  
 
5-(2-((1-(2-(3,4-dimethoxyphenylamino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methoxy)-
4-fluorophenyl)isoxazole-3-carboxylic acid (2-I-2-B10-2C): 1H NMR (300 MHz, 
DMSO-d6) δ 3.71 (s, 6H), 5.33 (s, 2H), 5.47 (s, 2H), 6.89-6.91 (d, 1H, J= 8.70 Hz), 7.02-
7.05 (m, 3H), 7.29 (s, 1H), 7.45-7.50 (dd, 1H, J= 11.34Hz, J= 2.31 Hz), 7.94-7.97 (m, 
1H), 8.32 (s, 1H), 10.35 (s, 1H); ESI-MS (IT-TOF) m/z = [M+H] +  498.1454  
 
5-(4-fluoro-2-((1-(2-oxo-2-(4-phenoxyphenylamino)ethyl)-1H-1,2,3-triazol-4-
yl)methoxy)phenyl)isoxazole-3-carboxylic acid (2-I-2-B11-2C): 1H NMR (300 MHz, 
DMSO-d6) δ 5.36 (s, 2H), 5.47 (s, 2H), 6.95-7.13 (m, 7H), 7.33-39 (m, 2H), 7.45-7.50 
(dd, 1H, J= , J= Hz), 7.54-7.58 (m, 2H), 7.97 (m, 1H), 8.33 (s, 1H), 10.51 (s, 1H); ESI-
MS (IT-TOF) m/z = [M+H] +  530.1579  
 
5-(4-Fluoro-2-{1-[(4-pentyl-phenylcarbamoyl)-methyl]-1H-[1,2,3]triazol-4-
ylmethoxy}-phenyl)-isoxazole-3-carboxylic acid (2-I-2-C8-2C): 1H NMR (300 MHz, 
DMSO-d6) δ 0.82-0.87 (m, 3H), 1.22-1.32 (m, 6H), 1.48-1.58 (m, 2H), 5.34 (s, 2H), 5.4 
(s, 2H), 6.98-7.01 (m, 1H), 7.05 (s, 1H), 7.14 (d, 2H, J= 8.37 Hz), 7.45-7.50 (m, 3H), 




7.3 Solid-Phase Assembly and in situ screening of Protein Tyrosine 
Phosphatases inhibitors 
 
7.3.1 Experimental details of the synthesis of PTP traceless library 
 
 
    Synthesis of linkers: 
 
 
        To a solution of bromoalkynoic acid (15 mmol) in dichloromethane were added 
benzyl alcohol (15 mmol), DMAP (3 mmol) and EDC (16.5 mmol) at ice cold condition. 
The solution was stirred for 15 min at room temperature, after which the organic phase 
was extracted with extracted with NaHCO3 (2 x 50 mL), water (2 x 50 mL) and brine (1 x 
30 mL). The organic phase was separated and then dried using anhydrous Na2SO4 and the 
solvent was removed in vacuo to afford the crude product, which, upon further 
purification by flash column chromatography afforded the pure product. 3-9a and 3-9b 
were obtained from 6-bromohexanoic acid and 8-bromooctanoic acid respectively in 
good yields. 
 
Benzyl-6-bromohexanoate (3-9a): Yield = 89%. 
1
H-NMR (300 MHz, CDCl3) δ 7.35-
7.39 (m, 5H), 5.10 (s, 2H)< 3.38-3.33 (t, J = 6.72 Hz , 2H), 2.38-2.33 (t, J = 7.4 Hz, 2H), 
1.88-1.79 (m, 2H), 1.71-1.60(m, 2H), 1.49-1.39(m, 2H). 13C-NMR (300 MHz, CDCl3) δ 
173.14, 135.98, 128.50, 128.15, 66.11, 33.97, 33.41, 32.31, 27.5, 24.01. 
 
Benzyl-8-bromooctanoate (3-9b):  Yield = 83%. 
1
H-NMR (300 MHz, CDCl3) δ 7.33-
7.28 (m, 5H), 5.10 (s, 2H), 3.38-3.33 (t, J = 6.6 Hz 2H), 2.36-2.31 (t, J = 7.6 Hz, 2H), 
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1.85-1.76 (m, 2H), 1.63-1.42 (m, 2H), 1.39-1.29 (m, 6H). 13C-NMR (300 MHz, CDCl3) δ 
173.44, 136.11, 128.14(m), 66.04, 34.18, 33.83, 32.66, 28.84, 28.34, 27.92, 24.78. 
 
Synthesis of Warhead: 
 
1-(4-Benzyloxy-phenyl)-ethanone (3-2): To a solution of 4-hydroxyacetophenone 3-1 
(0.11 mol, 15 g) in acetone (150 ml) were added K2CO3 (0.22 mol, 30 g) and benzyl 
bromide (0.12 mol, 14.4 ml). The resulting suspension was refluxed for 12 hrs. After 
which the leftover K2CO3 was removed by filtration. On removal of acetone under 
vacuum, the residue obtained was dissolved in Dichloromethane (200 ml) and extracted 
with water (3 x 150 ml) and brine (1 x 100ml). The organic layer was dried over 
anhydrous sodium sulfate and the solvent was removed under vacuum. The resulting 
crude solid was suspended in Hexane: Ethyl acetate mixture (9:1) and heated to boiling. 
On slow cooling shiny white crystals precipitated out which were filtered and washed 
with hexane and dried to afford 3-2 (20.68 g, 83 %). 1H-NMR (300 MHz, CDCl3) δ 7.94-
7.90 (d, J = 9.54 Hz, 2H), 7.44-7.38 (m, 5H), 7.01-6.97(d, J = 11.67 Hz, 2H), 5.12 (s, 
2H), 2.54 (s, 2H). 13C-NMR (300 MHz, CDCl3) δ 197, 167.9, 136.09, 130.54-130.42(d), 
128.62, 128.17, 127.40, 114.46, 70.04-69.91(d), 21.88. ESI-MS: m/z [M+H]+
 
=  227.1 
 
5-(4-Benzyloxy-phenyl)-isoxazole-3-carboxylic acid methyl ester (3-3): To a mixture 
of benzyl-derivatized acetophenone 3-2 (20g, 80 mmol) and dimethyl oxalate (10.38g, 88 
mmol) was added freshly prepared NaOMe (0.5 M in MeOH, 84 mmol). The reaction 
mixture was refluxed for 12 h and then cooled to room temperature. To the same reaction 
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flask MeOH (80 ml), NH2OH.HCl (6.1g, 88 mmol) and a catalytic amount of p-
TsOH.H2O were added and the resulting mixture was refluxed continuously for 3 days. 
Upon cooling to room temperature, the precipitated compound was collected, washed 
with water and ice-cold methanol to afford the pure isoxazole-3-carboxylic acid methyl 
ester 3-3 (12.57g, 42% in 2 steps). 1H-NMR (300 MHz, DMSO-d6) δ 7.91-7.87 (d, J = 
8.85 Hz, 2H), 7.49-7.35 (m, 5H), 7.32 (s, 1H), 7.20-7.17 (d, J = 8.88 Hz, 2H), 5.20 (s, 
2H), 3.92 (s, 3H). ESI-MS: m/z [M+Na]+
 
= 332.1 and m/z [2M+Na]+  = 640.9      
 
5-(4-Benzyloxy-phenyl)-isoxazole-3-carboxylic acid (3-4): To a vigorously stirred 
suspension of 3-3 (10.8g, 35mmol) in MeOH (100 ml) was added NaOH (100ml, 10 N) 
and allowed to stir for 4 hours after which MeOH was removed under reduced pressure. 
To the resulting suspension, water (100 ml) was added and the pH was adjusted to ~ 2 
using 2N HCl solution. The white precipitate formed was filtered, washed with ice-cold 
water and dried to afford the acid 3-4 (9.58g, 93%), which was used without further 
purification. 1H-NMR (300 MHz, DMSO-d6) δ 7.91-7.88 (d, J = 8.37 Hz, 2H), 7.49-7.35 
(m, 5H), 7.26 (s, 1H), 7.20-7.17 (d, J = 1.4 Hz, 2H), 5.2 (s, 2H). 13C-NMR (300 MHz, 
DMSO-d6) δ 171.18, 161.30, 160.61, 158.06, 136.92, 128.85-127.91(m), 119.46, 99.76, 




5-(4-Benzyloxy-phenyl)-isoxazole-3-carboxylic acid tert-butyl ester (3-5): To the 
solution of the acid 3-4 (9g, 30.5 mmol) in THF (100 ml) were added t-BuOH (6.7 g, 
91.5 mmol), EDC (8.74 g, 45.75 mmol) and DMAP (1.86 g, 15.25 mmol) at 0oC. After a 
few minutes a cloudy suspension was formed, on adding DCM (40 ml) to the suspension 
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a clear solution was formed. The resulting clear solution was allowed to stir for 12 hours 
at room temperature. The solvents were removed under reduced pressure and the 
resulting crude mass was directly  purified using flash chromatography to afford 3-5 
(8.24g, 77%). 1H-NMR (300 MHz, CDCl3) δ 7.73-7.70 (d, J =10.89 Hz, 2H), 7.44-7.33 
(m, 5H), 7.06-7.03 (d, J = 8.7 Hz, 2H), 6.72 (s, 1H), 5.11 (s, 2H), 1.63 (s, 9H). 13C-NMR 
(300 MHz, CDCl3) δ 171.33, 160.59,159.21, 158.06, 136.28, 128.66-127.44(m), 119.81, 
115.38, 98.59, 83.48, 70.12, 28.06.  ESI-MS: m/z [M+Na]+
 
= 374.0 and m/z [2M+Na]+  = 
724.9.
   
 
 
5-(4-Hydroxy-phenyl)-isoxazole-3-carboxylic acid tert-butyl ester (3-6): To a solution 
of benzyl ether 3-5 (8g, 23mmol), in methanol-THF (1:1) was slowly added Pd/C power 
(0.8g, 10 % wt). The reaction was stirred for 4 h under hydrogen atmosphere. After 
which, Pd/C was filtered out and the solvent was removed completely under reduced 
pressure to yield pure derivatized phenol 3-6 in quantitative yield. 1H-NMR (300 MHz, 
DMSO-d6) δ 7.78-7.54 (d, J = 8.7 Hz, 2H), 7.14 (s, 1H), 6.93-6.90 (d, J = 8.7 Hz, 1.57 
(s, 9H). 13C-NMR (300 MHz, CDCl3) δ 171.74, 160.39, 159.05, 158.05, 128.06, 117.63, 
116.40, 98.80, 83.43, 28.01 ESI-MS: m/z [M+Na]+
 
= 283.9 and m/z [2M+Na]+  = 545.1.  
 
General procedure for the synthesis of the phenyl ethers (3-7a and 3-7b): Potassium 
carbonate (22 mmol) and catalytic amount of dibenzo-18-crown-6 were added to a 
solution of bromo-benzylalkynolate (2.5mmol) and derivatized phenol 3-6 (11 mmol) in 
acetonitrile (100 ml) followed by refluxing for 3 h, after which the organic phase was 
removed under reduced pressure and taken into dichloromethane layer (80 ml) and 
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extracted with water (2 x 40 ml) and brine (1 x 40 ml). The organic phase was then dried 
with anhydrous Na2SO4, and the solvent was removed in vacuo to afford the crude 
product, which, upon further purification by flash column chromatography, afforded the 
pure ether. Compounds 3-7a and 3-7b were prepared from compound 3-9a and 3-9b 
respectively on treatment with compound 3-6. 
 
5-[4-(5-Benzyloxycarbonyl-pentyloxy)-phenyl]-isoxazole-3-carboxylic acid tert-butyl 
ester (3-7a): Yield = 94%. 1H-NMR (300 MHz, CDCl3) δ  7.72-7.69 (d, J = 8.7 Hz, 2H), 
7.35 (m, 5H), 6.96-6.93 (d, J = 8.88 Hz, 2H), 6.71 (s, 1H),  5.12 (s, 2H), 4.01-3.97 (t, J = 
6.04 Hz, 2H), 2.43-2.38 (t, J = 7.48 Hz, 2H), 1.90-1.79 (m, 4H), 1.63 (s, 9H), 1.63-1.43 
(m, 2H). 13C-NMR (300 MHz, CDCl3) δ 173.28, 171.39, 160.86, 159.18, 157.99, 135.96, 
128.48-128.13(m), 127.44, 119.39, 114.90, 98.40, 83.41, 67.76, 66.10, 34.09, 28.71, 
28.01, 27.54, 25.51, 24.46, 23.99. ESI-MS: m/z [M+H]+ = 465.8, [M+Na]+
 
= 488.1  and 
m/z [2M+Na]+  =  953.0 
 
5-[4-(7-Benzyloxycarbonyl-heptyloxy)-phenyl]-isoxazole-3-carboxylic acid tert-butyl 
ester (3-7b): Yield = 63%. 1H-NMR (300 MHz, CDCl3) δ  7.73-7.70 (d, J = 8.7 Hz, 2H), 
7.35 (m, 5H), 6.97-6.95 (d, J = 8.7 Hz, 2H), 6.72 (s, 1H), 5.12 (s, 2H), 4.01-3.97 (t, J = 
6.43 Hz, 2H), 2.39-2.34 (t, J = 7.48 Hz, 2H), 1.83-1.66 (m, 4H), 1.63(s, 9H), 1.47-





General procedure for the benzyl ester hydrogenolysis (3-A and 3-B):  
To a solution of benzyl ester (5g, 11mmol) in THF, was slowly added Pd/C (0.5g, 10 % 
wt). The reaction was stirred for 4 h under hydrogen atmosphere. After which, Pd/C was 
filtered out and the solvent was removed completely under reduced pressure to yield pure 
the acid derivative in quantitative yield. Hydrogenolysis of compounds 3-7a and 3-7b 
gave the products 3-A and 3-B respectively. 
 
5-[4-(5-Carboxy-pentyloxy)-phenyl]-isoxazole-3-carboxylic acid tert-butyl ester (3-
A): Yield = 98%. 1H-NMR (300 MHz, CDCl3) δ 7.73-7.70 (d, J = 9.03 Hz, 2H), 6.98-
6.95 (d, J = 8.7 Hz, 2H), 6.73 (s, 1H), 4.04-3.99 (t, J = 6.27 Hz, 2H), 2.43-2.38 (t, J = 
7.48 Hz, 2H), 1.93-1.68 (m, 4H), 1.63 ( s, 9H), 1.59-1.47 (m, 2H). 13C-NMR (300 MHz, 
CDCl3) δ 179.61, 171.43, 160.90, 159.21, 158.01, 127.28, 119.44, 114.95, 98.45, 83.48, 
67.78, 33.87, 28.74, 28.03, 25.49, 24.33. ESI-MS: m/z [M-1]-= 374.1 and m/z [2M-1]-  = 
749.0. 
 
5-[4-(7-Carboxy-heptyloxy)-phenyl]-isoxazole-3-carboxylic acid tert-butyl ester (3-
B): Yield = 98%. 1H-NMR (300 MHz, CDCl3) δ 7.73-7.7 (d, J = 8.88 Hz, 2H), 7.26(s, 
1H), 6.98-6.95 (d, J = 8.88 Hz, 2H), 4.02-3.98 (t, J = 6.42 Hz, 2H), 2.39-2.34 (t, J = 7.39 
Hz, 2H), 1.83-1.76 (m, 2H), 1.66 (m, 2H), 1.63 (s, 9H), 1.52-1.39 (m, 6H). 13C-NMR 
(300 MHz, CDCl3) δ 179.90, 172.19, 161.72, 161.72, 159.97, 158.75, 128.21, 120.9, 
115.67, 99.15, 84.20, 68.80, 34.57, 29.73, 29.64, 28.77, 26.49, 25.27. ESI-MS: m/z [M-
H]-
 
= 402.2 and m/z [2M-1]-  = 805.1. 
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General procedure for the activation of acid to acid chloride (3-8a and 3-8b): 
A solution of the carboxylic acid (6.6mmol) in freshly distilled dichloromethane (25 ml) 
was added DIEA (13.2mmol) followed by the slow addition of  fresh oxalyl chloride (6.6 
mmol) using an air-tight syringe at 0oC. After the completion of the addition, the reaction 
mixture was allowed to stir at room temperature for another 4 h. The completion of the 
reaction was monitored by TLC. The reaction mixture was used as such for further solid-
phase coupling reaction without any further purification. The acid chlorides 3-8a and 3-
8b were prepared from acids 3-A and 3-B respectively.  
 
Solid-phase assembly of the PTP inhibitors 
 
 The construction of the PTP inhibitor library was achieved by IRORI® split-and-pool 
directed sorting technology. Final products were released from the solid phase by our 
optimized TFA cleavage protocol. 
Synthesis of the reductive aminated resin (3-10): 
 PL-FMP resin (70 x ~30 mg, 0.9 mmol/g) was taken in 70 MacroKanTM  reactors each 
containing a RF tag. The resin was swelled in 1,2-dichloroethane (200 mL) for about two 
hours after which the solvent was decanted. The 70 microreactors were then distributed 
equally into 35 different bottles of capacity 15 mL containing 2% acetic acid in 1,2-
dichloroethane (6 mL). Amines (3-a1 to 3-a35) (5 eq) were added to the bottles, so that 
each bottle contains a unique amine. The reaction mixture was then incubated for about 3 
hours after which sodium triacetoxyborohydride (6 eq) was added. After shaken for 
another 8 hours the solution was decanted and the reactors were combined and washed 
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with DCM (150 mL x 5), MeOH (150 mL x 2) and THF (200 mL x 3) and dried to afford 
resin 3-10. 
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Fig. 7.7 List of 35 different amines used for the reductive amination 
 
 
Synthesis of the N-acylated resin (3-11a and 3-11b): 
 
           The 70 reductive aminated resins were separated into 2 sets (35 different reductive 
aminated resins x 2 sets). To the first set DCM (50 mL) and DIEA (5 eq) were added and 
cooled using an ice-bath. The reaction mixture consisting of acid chloride, 3-8a (6.6 
mmol) was then slowly added to the bottle under a stream of argon. The reaction mixture 
was shaken for 12 h at room temperature after which the solution was decanted and the 
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resin was washed with DCM (100 ml x 3), MeOH (100 mL x 2) and THF (100 mL x 3) 
and dried to afford resin 3-11a. Similarly the second set of resin on acylation with 3-8b 
gave the resin 3-11b. 
 
Protocol for the cleavage and release of the inhibitors from the solid-support (3-A1 
to 3-A35 and 3-B1 to 3-B35): 
      Each dried resin was treated with a 1.3 mL solution containing TFA (50%), DCM (45 
%) and water (5%) and the mixture was shaken for 3.5 hours and transferred into a 96-
well plates and concentrated in vacuo to afford the compounds 3-A1 to 3-A35 and 3-B1 
to 3-B25. Representative yield varied from 50% to 90%. The compounds were then 
redissolved in DMSO. Most of the compounds synthesized from the above protocols are 
of high purity (90-95%). Representative compounds were further characterized without 
any purification by LCMS and 1H NMR. 
 
NMR Characterization of few Final products: 
 
 
Compound 3-A1: 1H-NMR (300 MHz, DMSO-d6) δ 10.02 (s, 1H), 7.87-7.86 (d, J = 8.7 
Hz, 2H), 7.64-7.60 (d, J = 8.88 Hz, 2H), 7.35-7.32 (d, J = 8.88 Hz, 2H), 7.24 (s, 1H), 
7.10-7.07 (d, J = 8.7 Hz, 2H), 4.08-4.04 (t, J = 6.24 Hz, 2H), 2.37-2.32 (t, J = 7.23 Hz, 
2H),  1.87-1.72 (m, 2H), 1.69-1.59(m, 2H), 1.51-1.41 (m, 2H). 
 
Compound 3-A2: 1H-NMR (300 MHz, DMSO-d6) δ 9.99 (s, 1H), 7.87-7.84 (d, J = 8.7 
Hz, 2H), 7.56-7.52 (d, J = 12.84 Hz, 1H), 7.23 (s, 1H), 7.18-7.16 (m, 2H), 7.09-7.06 (d, J 
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= 8.88 Hz, 2H), 4.08-4.04 (t, J = 6.39 Hz, 2H), 2.35-2.30 (t, J = 7.23 Hz, 2H), 2.16 (s, 
3H), 1.76 (m, 2H), 1.68-1.61 (m, 2H), 1.48-1.43 (m, 2H). 
 
Compound 3-A3: 1H-NMR (300 MHz, DMSO-d6) δ 9.94 (s, 1H), 7.87-7.84 (d, J = 8.7 
Hz, 2H), 7.63-7.58 (m, 2H), 7.22 (s, 1H), 7.15-7.07 (m, 4H), 4.08-4.04 (t, J = 6.42 Hz, 
2H), 2.35-2.27 (t, J = 7.42 Hz, 2H), 1.77 (m, 2H), 1.66 (m, 2H), 1.51-1.41 (m, 2H). 
 
Compound 3-A12: 1H-NMR (300 MHz, CDCl3) δ 9.95 (s, 1H), 8.42-8.39(d, J = 8.01 
Hz, 1H), 7.81(m, 1H), 7.69-7.66(d, J = 7.65 Hz, 1H), 7.37-7.32(m, 2H),7.15-7.10(m, 
2H), 7.02-6.99(m, 3H), 6.95-6.92(d, J = 8.34 Hz, 1H), 6.87-6.84(d, J = 7.65  Hz, 1H),  
6.7(m, 1H), 3.97(m, 2H), 2.47-2.39(m, 2H), 1.81-1.70(m, 4H), 1.67-1.53 (m, 2H), 0.88-
0.83(m, 2H).  
 
Compound 3-A16:  1H-NMR (300 MHz, DMSO-d6) δ 10.09 (s, 1H), 7.87-7.84(d, J = 
8.55 Hz, 2H), 7.71-7.84 (d, J = 8.88 Hz, 2H), 7.31-7.28 (d, J = 8.85 HZ, 2H), 7.24 (s, 
1H),  7.10-7.07 (d, J = 8.7 Hz, 2H), 4.08-4.04 (t, J = 6.24 Hz, 2H), 2.38-2.32 (t, J = 7.41 
Hz, 2H), 1.77 (m, 2H), 1.64 (m, 2H), 1.51-1.42 (m, 2H). 
 
Compound 3-A17: 1H-NMR (300 MHz, CDCl3) δ 7.74-7.69(m, 1H), 7.47-7.44(m, 2H), 
7.24-7.22 (m, 3H), 6.97-6.91(m, 2H). 6.79-6.78(m, 1H), 4.39(m, 2H), 3.47(t, J = 6.26 Hz, 
2H), 2.61(s, 3H), 2.30(m, 2H), 1.70(m, 2H). 
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Compound 3-A23: 1H-NMR (300 MHz, CDCl3) δ 7.99-7.96 (d, J = 7.65 Hz, 1H), 7.89-
7.83(m, 2H), 7.65-7.63(d, J = 8.37 Hz, 2H), 7.57-7.50(m, 2H), 7.44-7.42(m, 2H), 6.91-
6.88(d, J = 8.7 Hz, 2H), 6.73(s, 1H), 4.93-4.91(d, J = 5.22 Hz, 2H), 3.98-3.94(t, J = 6.27 
Hz, 2H), 2.35-2.27(m, 2H), 1.84-1.68(m, 2H), 1.56-1.45(m, 2H), 0.88-0.83(m, 2H).  
 
Compound 3-A27:  1H-NMR (300 MHz, DMSO-d6) δ 10.21(s, 1H), 7.91-7.84 (m, 4H), 
7.74-7.71(d, J = 8.7 Hz, 2H), 7.24 (s, 1H), 7.09-7.06 (d, J = 8.88 Hz, 2H), 4.31-4.24(q, 
2H), 4.08-4.02(t, J = 6.24 Hz, 2H), 2.41-2.36(t, J = 7.23, 2H), 1.75(m, 2H), 1.65 (m, 2H), 
1.52-1.43(m, 2H), 1.33-1.26(t, J = 7.05 Hz, 3H). 
 
Compound 3-A30: 1H-NMR (300 MHz, DMSO-d6) δ 9.78(s, 1H), 7.87-7.84(d, J = 8.73 
Hz, 2H), 7.49-7.46 (d, J = 8.37 Hz, 2H), 7.24 (s, 1H), 7.09-7.07 (d, J = 8.4 Hz, 4H), 4.08-
4.04(t, J = 6.42 Hz, 2H), 2.34-2.29 (t, J = 7.23 Hz, 2H), 1.77 (m, 2H), 1.66 (m, 2H), 1.57-
1.41(m, 4H), 1.32-1.18 (m, 6H), 0.87-0.83(t, J = 6.9 Hz, 3H).  
 
Compound 3-A31:  1H-NMR (300 MHz, DMSO-d6) δ 9.70 (s, 1H), 7.87-7.84 (d, J = 
8.73 Hz, 2H), 7.35-7.28(m, 2H), 7.24 (s, 1H), 7.09-7.06 (d, J = 9.06 Hz, 2H), 7.03-
7.01(d, J = 8.22 Hz, 2H), 4.07-4.03(t, J = 6.43 Hz, 2H), 2.33-2.23 (t, J = 7.22 Hz, 2H), 
2.17-2.15(m, 6H), 1.76 (m, 2H), 1.65 (m, 2H), 1.50-1.40 (m, 2H). 
 
Compound 3-B4: 1H-NMR (300 MHz, DMSO-d6) δ 9.85 (s, 1H), 7.30 (m, 1H), 7.24 (s, 
1H), 7.21-7.07 (m, 3H), 6.61-6.49 (d, J = 6.9 Hz, 1H), 4.06-4.02(t, J = 6.42 Hz, 2H), 3.70 
(s, 3H), 2.32-2.27(t, J = 7.2 Hz, 2H), 1.73 (m, 2H), 1.59 (m, 2H), 1.35 (m, 6H). 
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Compound 3-B6:  1H-NMR (300 MHz, DMSO-d6) δ 9.92 (s, 1H), 7.87-7.84(d, J = 8.73 
Hz, 2H), 7.62-7.58(m, 2H), 7.23(s, 1H), 7.15-7.07(m, 4H), 4.06-4.02(t, J = 6.43 Hz, 2H), 
2.32-2.27(t, J = 7.22 Hz, 2H), 1.74(m, 2H), 1.60(m, 2H), 1.36(m, 6H). 
 
Compound 3-B9: 1H-NMR (300 MHz, DMSO-d6) δ 9.68(s, 1H), 7.87-7.84(d, J = 8.7 
Hz, 2H), 7.35 (m, 1H), 7.31-7.28(m, 1H), 7.24(s, 1H), 7.09-7.06(d, J = 8.88 Hz, 2H), 
7.02-7.00 (d, J = 8.22 Hz, 1H), 4.06-4.02(t, J = 6.42 Hz, 2H), 2.26-2.22(t, J = 7.23 Hz, 
2H), 2.16-2.14(m, 6H), 1.73(m, 2H), 1.59(m, 2H), 1.35(m, 6H). 
 
Compound 3-B10: 1H-NMR (300 MHz, DMSO-d6) δ 9.70 (s, 1H), 7.87-7.84 (d, J = 8.7 
Hz, 2H), 7.48-7.45(d, J = 9.03 Hz, 2H), 7.23 (s, 1H), 7.09-7.06(d, J = 8.88 Hz, 2H), 6.85-
6.81(d, J = 9.03 Hz, 2H), 4.06-4.01(t, J = 6.45Hz, 2H), 3.99-3.92(q, 2H), 2.29-2.24(t, J = 
7.23 Hz, 2H), 1.73(m, 2H), 1.59(m, 2H), 1.40-1.23(m, 9H). 
 
Compound 3-B16: 1H-NMR (300 MHz, DMSO-d6) δ 9.87 (s, 1H), 7.87-7.84(d, J = 8.73 
Hz, 2H), 7.56-7.54(d, J = 8.7 Hz, 2H), 7.23-7.19(m, 3H), 7.09-7.06(d, J = 8.88 Hz, 2H), 
4.06-4.02(d, J = 6.42 Hz, 2H), 2.32 (m, 2H), 1.73(m, 2H), 1.62(m, 2H), 1.35(m, 6H). 
 
Compound 3-B17:  1H-NMR (300 MHz, DMSO-d6) δ 10.07(s, 1H), 7.86-7.83 (d, J = 
8.7 Hz, 2H), 7.70-7.67 (d, J = 9.06 Hz, 2H), 7.30-7.27 (d, J = 8.4 Hz, 2H), 7.20 (s, 1H), 
7.09-7.06 (d, J = 8.85Hz, 2H), 4.06-4.02(t, J = 6.49 Hz, 2H), 2.60 (s, 3H), 2.32-2.27(t, J 
= 7.41 Hz, 2H), 1.73 (m, 2H), 1.61 (m, 2H), 1.36 (m, 6H). 
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Compound 3-B21: 1H-NMR (300 MHz, DMSO-d6) δ 9.96(s, 1H), 7.93 (s, 1H), 7.87-
7.84 (d, J = 8.88 Hz, 2H), 7.79-7.74(m, 2H), 7.54-7.51(m, 2H), 7.15 (m, 1H), 7.09-
7.06(d, J = 8.88Hz, 2H), 6.99-6.96(m, 1H), 4.06-4.02(t, J = 6.40 Hz, 2H), 3.92-3.87(m, 
2H), 2.36-3.31(m, 2H), 1.74(m, 2H), 1.63(m, 2H), 1.38(m, 6H).  
 
Compound 3-B23: 1H-NMR (300 MHz, DMSO-d6) δ 8.32 (m, 1H), 8.07-8.46(m, 1H), 
7.95-7.92 (m, 1H), 7.87-7.83(m, 3H), 7.57-7.52(m, 2H), 7.49-7.42 (m, 2H), 7.24 (s, 1H), 
7.09-7.06 (d, J = 8.7 Hz, 2H), 4.73-4.71 (d, J = 5.58 Hz, 2H), 4.04-4.00(t, J = 6.42 Hz, 
2H), 2.18-2.13 (t, J = 7.24 Hz, 2H), 1.69 (m, 2H), 1.55 (m, 2H), 1.28 (m, 6H). 
 
 
7.3.2 Protocol for the Biological Screening: 
 
        The activity of phosphatases was assayed by measuring the rate of hydrolysis of the 
fluorogenic substrate, 6, 8-difluoro-methylumbelliferyl phosphate (DIFMUP) in 25 µl 
reaction volumes in black polypropylene flat-bottom 384-well microtiter plates (Greiner, 
Germany). For IC50 studies of the 70-member library against PTP1B, dose-dependent 
reactions were set up by varying the concentrations of the inhibitor, under the same 
enzyme and substrate concentration. Briefly, a two-fold dilution series of an inhibitor, 
from approximately 400 µM to 3.125 µM (final concentrations) was prepared. The 
reaction condition is as shown below.  
 
PTB 1B (2.4 µg/ml) = 5 µl  
DIFMUP (20 µM) = 5 µl  
Inhibitor (Varied) = 5 µl  
Assay Buffer (1X) = 10 µl  
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[Assay buffer = 25 mM HEPES, 150mM NaCl and 0.1 mg/ml BSA, pH = 7.5].  
Negative controls were performed in the absence of enzyme and positive controls were 
carried out in the presence of enzyme but without inhibitor.  
 
The enzymatic reactions were allowed to incubate at room temperature for 30 min before 
being initiated by the addition of DIFMUP. The enzymatic reactions were immediately 
monitored with a Tecan F200 fluorescence plate reader (Tecan, Germany), at λex = 355 
nm and λem = 460 nm for a period of 15 min. The IC50 was calculated by fitting the 
fluorescence outputs obtained using the Graphpad Prism software v.4.03 (GraphPad, San  
Diego) From the preliminary screening results, six representative compounds were 
identified and their IC50 values against PTP1B were again investigated independently.  
Each IC50 plots were generated by averaging the duplicates from two independent assays 







Fig. 7.8 Graphs for determining IC50 values of selected library members against PTP1B. 
The selected members were assayed in duplicate and the results were averaged from two 
independent experiments followed by obtaining the plots with Graphpad Prism software 




Selectivity profiles of selected PTP1B inhibitors 
 
For selectivity assays, a panel of PTP enzymes from different PTP-subfamilies was 
chosen. These include TCPTP, YopH and LMWPTP. The IC50 values of the selected 
library members were determined as previously described for PTP1B.  Dose-dependent 
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reactions were set up by varying the concentrations of the inhibitors; from approximately 
100 µM to 3.125 µM (final concentrations). The optimized assay conditions (amount of 
enzyme needed to reach a fluorescence output of ~30000 in 15 min) of the different 




Enzyme (2.4 µg/ml) = 5 µl  
DIFMUP (20 µM) = 5 µl  
Inhibitor (Varied) = 5 µl  
Assay Buffer (1X) = 10 µl  




Enzyme (5.0 µg/ml) = 5 µl  
DIFMUP (20 µM) = 5 µl  
Inhibitor (Varied) = 5 µl  
Assay Buffer (1X) = 10 µl  




Enzyme (20 µg/ml) = 5 µl  
DIFMUP (20 µM) = 5 µl  
Inhibitor (Varied) = 5 µl  
Assay Buffer (1X) = 10 µl  




7.4 Versatile Microwave-Assisted Strategies for the Synthesis of Azide 
fragments 
 












Fig. 7.9 List of alcohol blocks used in route A 
 To PS-TsCl resin (0.134 mmol) swelled in Dichloromethane (DCM) (3 ml) was added 
the alcohol (4-a to 4-j) (Fig. 7.9) (0.7 mmol) and Pyridine (1.5 ml). The reaction mixture 
was shaken for 12 hours, after which the reaction solvents were drained and the resin was 
washed with DCM (3 x 25 ml), DMF (3 x 25 ml), DMF/H2O (1:1, 2 x 25 ml), THF (3 x 
25 ml), DCM (2 x 25 ml) and dried under vacuum to afford the tosylated resin (4-1a to 4-
10a). The dried tosylated resin (4-1a to 4-10a) was transferred into microwave reaction 
vessel followed by the addition of DMF (2 ml) and NaN3 (1.34 mmol).  The resin was 
microwave irradiated for 30 min after which the resin and the solid residue were filtered 
off, the DMF layer was taken in to DCM/Ether (20 ml). The organic layer was extracted 
with water (5 x 10 ml) and brine (1 x 10 ml) dried with anhydrous Na2SO4 and 






Fig. 7.10 List of azides synthesized from PS-TsCl resin 
 
             
1-(2-Azido-ethyl)-4-methoxy-benzene (4-1): Yield = 64 %.  1H-NMR (500 MHz, 
CDCl3) δ 7.14-7.13 (d, J = 5.31Hz, 2H), 6.89-6.85 (d, J = 5.31 Hz, 2H), 3.79 (s, 3H), 
3.48-3.45(t, J = 4.35 Hz, 2H), 2.85-2.82(t, J = 4.35 Hz, 2H). 13C-NMR: (75 MHz, CDCl3) 
δ 158.50, 130.06, 129.72, 114.09, 55.26, 52.71, 34.50. 
 
((2-(2-azidoethoxy)ethoxy)methyl)benzene (4-2): Yield = 80%. 1H-NMR (300 MHz, 
CDCl3) δ 7.35 – 7.28 (m, 5H), 4.58 (s, 2H), 3.70 – 3.64 (m, 6H), 3.40 (t, J = 5.09 Hz, 
2H). 13C-NMR: (75 MHz, CDCl3) δ 138.18, 128.35, 127.68, 127.58, 73.31, 70.73, 70.03, 
69.50, 50.72. 
 
1-(2-azidoethoxy)-2-chlorobenzene (4-3): Yield = 70%. 1H-NMR (300 MHz, CDCl3) δ 
7.40 – 7.37 (m, 1H), 7.26 – 7.19 (m, 1H), 6.98 – 6.91 (m, 2H), 4.19 (t, J = 5.10 Hz, 2H), 
3.64 (t, J = 5.01 Hz, 2H). 13C-NMR: (500 MHz, CDCl3) δ 153.96, 130.55, 127.70, 
123.39, 122.23, 113.76, 68.10, 30.33. 
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2-(azidomethyl)-1,3-dichlorobenzene (4-4): Yield = 20%. 1H-NMR (300 MHz, CDCl3) 
δ 7.37 – 7.34 (m, 2H), 7.25 – 7.19 (m, 1H), 4.67 (s, 2H). 
  
(2-azidoethyl)benzene (4-5): Yield = 89%. 1H-NMR (300 MHz, CDCl3) δ 7.35 – 7.21 
(m, 5H), 3.50 (t, J = 7.23 Hz, 2H), 2.90 (t, J = 7.23 Hz, 2H). 13C-NMR: (75 MHz, CDCl3) 
δ 138, 128.62, 128.41, 126.51, 52.21, 35.07. 
 
1-Azidomethyl-naphthalene (4-6): Yield = 10%. 1H-NMR (300 MHz, CDCl3) δ 8.05 – 
7.46 (m, 7H), 4.78 (s, 2H). 
 
(3-Azido-butyl)-benzene (4-7): Yield = 0%. (No Reaction) 
 
(2-azidoethoxy)benzene (4-8): Yield = 92%. 1H-NMR (300 MHz, CDCl3) δ 7.32 – 7.27 
(m, 2H), 7.01 – 6.91 (m, 3H), 4.15 (t, J = 5.01 Hz, 2H), 3.59 (t, J = 5.01 Hz, 2H). 13C-
NMR: (500 MHz, CDCl3) δ 158.24, 129.55, 121.38, 114.67, 66.89, 30.32. 
 
(4-Azido-butyl)-benzene (4-9): Yield = 61%. 1H-NMR (300 MHz, CDCl3) δ 7.31 – 7.16 
(m, 5H), 3.28 (t, J = 6.50 Hz, 2H), 2.64 (t, J = 7.23 Hz, 2H), 1.76 – 1.59 (m, 4H). 13C-
NMR: (300 MHz, CDCl3) δ 128.41, 125.94, 60.40, 35.40, 30.91, 21.05. 
 
9-Azidomethylanthracene (4-10): Yield = 60 %. 1H-NMR (300 MHz, CDCl3) δ 8.34-
8.28(m, 3H), 8.07-8.04(m, 2H), 7.82-7.79(m, 2H), 7.63-7.49(m, 2H).13C-NMR: (75 
MHz, CDCl3) δ 134.83, 130.0, 127.93, 127.55, 125.91, 124.22, 30.39.  
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MW-assisted solution-phase approaches 
 
General procedure for the conversion of alcohols (4-a, 4-b, 4-d, 4-g and 4-k to 4-p) in 
























4-m 4-n 4-o 4-p
List of the alcohols building blocks
 
 
Fig. 7.11 List of alcohol blocks used in tosylation  
 
 
           Commercially available alcohol (4-a, 4-b, 4-d, 4-g, 4-k to 4-p) (2 mmol) (Fig. 
7.11) and p-toluenesulfonyl chloride (2.1 mmol) were dissolved in anhydrous diethyl 
ether (10 ml) and cooled to -5 ºC. Finely powdered KOH (20 mmol) was then added 
slowly in small portions over a 15-min period. The reaction mixture was further stirred 
for 4 h, after which the reaction mixture was quenched with water (10 ml) in an ice-bath. 
The organic layer was separated and the aqueous layer was extracted twice with ether (2 
x 15 ml). The combined organic extracts were washed with brine (1 x 15 ml) and dried 
over Na2SO4. The solvent was removed under reduced pressure to afford 























4-6b 4-8b 4-9b 4-10b
List of the tosylates synthesized
 
 
Fig. 7.12 List of tosylates synthesized 
 
 
2-(4-methoxyphenyl)ethyl 4-methylbenzenesulfonate (4-1b): Yield = 89%.  
 
2-(2-benzyloxyethoxy)ethyl 4-methylbenzenesulfonate (4-2b): Yield = 96%. 1H-NMR 
(300 MHz, CDCl3) δ 7.80-7.78 (d, J = 8.01 Hz, 2H), 7.32-7.29(m, 7H), 4.53(s, 2H), 4.19-
4.15(t, J = 4.87 Hz, 2H), 3.71-3.57(m, 6H), 2.42(s, 3H). 13C-NMR (75 MHz, CDCl3) δ 
145.41, 138.75, 133.62, 130.44, 129.02, 128.59, 128.35, 128.28, 73.89, 71.43, 69.98, 
69.90, 69.31, 22.24. 
 
2,4-dichlorobenzyl 4-methylbenzenesulfonate (4-3b): Yield = 96%.  1H-NMR (300 
MHz, CDCl3) δ 7.80 (d, J = 8.22 Hz, 2H), 7.35 – 7.31 (m, 4H), 7.23 – 7.20 (m, 1H), 5.12 
(s, 2H), 2.45 (s, 3H). 
 
2,6-dichlorobenzyl 4-methylbenzenesulfonate (4-4b): Yield = 88%.  1H-NMR (300 
MHz, CDCl3) δ 7.85 (d, J = 8.22 Hz, 2H), 7.34 (d, J = 8.04 Hz, 2H), 7.30 – 7.19 (m, 3H), 
5.32 (s, 2H), 2.45 (s, 3H). 
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2-chlorobenzyl 4-methylbenzenesulfonate (4-5b): Yield = 76%.  1H-NMR (300 MHz, 
CDCl3) δ 7.82 (d, J = 8.40 Hz, 2H), 7.40 – 7.21 (m, 6H), 5.16 (s, 2H), 5.16 (s, 3H). 
 
2-methylbenzyl 4-methylbenzenesulfonate (4-6b): Yield = 96%.  1H-NMR (300 MHz, 
CDCl3) δ 7.79 (d, J = 8.22 Hz, 2H), 7.32 (d, J = 8.04 Hz, 2H), 7.26 – 7.13 (m, 5H), 5.08 
(d, J = 2.31 Hz, 2H), 2.45 (s, 3H), 2.25 (s, 3H). 
 
1-methyl-3-phenylpropyl (4-methylbenzene)sulfonate (4-7b): Crude Yield = 60%. 
 
4-methylbenzyl 4-methylbenzenesulfonate (4-8b): Yield = 99%.  1H-NMR (300 MHz, 
CDCl3) δ 7.79 (d, J = 8.22 Hz, 2H), 7.32 (d, J = 8.04 Hz, 2H), 7.26 – 7.13 (m, 5H), 5.08 
(d, J = 2.31 Hz, 2H), 2.45 (s, 3H), 2.25 (s, 3H). 
 
3,5-dimethoxybenzyl 4-methylbenzenesulfonate (4-9b): Yield = 93%.  1H-NMR (300 
MHz, CDCl3) δ 7.79 (d, J = 8.37 Hz, 2H), 7.32 (d, J = 8.04 Hz, 2H), 6.39 – 6.36 (m, 3H), 
4.98 (s, 2H), 3.74 (s, 6H), 2.44 (s, 3H). 
 
3-phenylpropyl 4-methylbenzenesulfonate  (4-10b): Yield = 93%. 1H-NMR (300 MHz, 
CDCl3) δ 7.81-7.78(d, J = 8.37Hz, 2H), 7.36-7.33(d, J = 8.01 Hz, 2H), 7.28-7.15 (m, 
3H), 7.08-7.06(d, J = 6.96 Hz 2H), 4.06-5.01(t, J = 6.09 Hz, 2H), 2.67-2.62(t, J = 7.66 
Hz, 2H), 2.5(s, 3H), 2.01-1.91(p, 2H). 13C-NMR (75 MHz, CDCl3) δ 145.39, 141.03, 
130.51, 129.12, 129.06, 128.57, 126.80, 70.26, 22.30. 
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General procedure for the MW-assisted conversion of tosylates (4-1b to 4-10b) into 
azides (4-1, 4-2, 4-4, 4-7 and 4-11 to 4-16): 
 
 Tosylate (4-1b to 4-10b) (0.4 mmol) was dissolved in DMF (2 ml) and NaN3 (0.8 mmol) 
was suspended into it. The reaction mixture was pre-stirred for 30 seconds in a sealed 
microwave reactor and was allowed to run at 80 °C for 10 minutes under microwave 
irradiation, after which the reaction mixture was poured into water (10 ml) and ether (10 
ml). The layers were separated and the aqueous layer was extracted with ether (2 x 10ml). 
The combined ether extracts were washed with brine (1 x 10ml) and dried over Na2SO4, 
filtered and concentrated under reduced pressure to obtain spectroscopically pure product 
(4-1, 4-2, 4-4, 4-7, 4-11 to 4-16, 83-98% yield) (Fig 7.13) which were suitable for the 
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Fig. 7.13 List of azides synthesized via tosylates 
 
1-(2-Azidoethyl)-4-methoxybenzene (4-1): Yield = 93%. 7.13-7.11(d, J = 8.55 Hz, 2H), 
6.86-6.83(d, J = 8.55 Hz, 2H), 3.77(s, 3H), 3.46-3.42(t, J = 7.24 Hz, 2H), 2.84-2.79(t, J = 
7.23, 2H). 13C-NMR (75 MHz, CDCl3) δ 159.03, 130.29, 114.60, 55.75, 53.23, 35.01. 
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[2-(2-Azido-ethoxy)ethoxymethyl]-benzene (4-2):  Yield = 89%. 
 
1-(azidomethyl)-2,4-dichlorobenzene (4-11): Yield = 96%. 1H-NMR (300 MHz, 
CDCl3) δ 7.44 – 7.42 (m, 1H), 7.35 – 7.28 (m, 2H), 4.46 (s, 2H). 13C-NMR (75 MHz, 
CDCl3) δ 134.8, 134.3, 131.9, 130.6, 129.6, 127.4, 51.6. 
 
2-(azidomethyl)-1,3-dichlorobenzene (4-4): Yield = 98%. 1H-NMR (300 MHz, CDCl3) 
δ 7.37 – 7.34 (m, 2H), 7.25 – 7.19 (m, 1H), 4.67 (s, 2H). 13C-NMR (75 MHz, CDCl3) δ 
136.3, 131.4, 130.2, 128.5, 49.1 
 
1-(azidomethyl)-2-chlorobenzene (4-12): Yield = 93%. 1H-NMR (300 MHz, CDCl3) δ 
7.46 – 7.37 (m, 2H), 7.32 – 7.24 (m, 2H), 4.48 (s, 2H). 13C-NMR (75 MHz, CDCl3) δ 
133.8, 133.3, 130.0, 129.8, 129.7, 127.2, 52.3. 
 
1-(azidomethyl)-2-methylbenzene (4-13): Yield = 89%. 1H-NMR (300 MHz, CDCl3) δ 
7.28 – 7.22 (m, 4H), 4.35 (s, 2H), 2.37 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 136.8, 
130.7, 130.5, 129.3, 128.6, 126.2, 53.1, 19.0. 
 
3-azidobutyl-benzene (4-7): Crude Yield = 60%.  
 
1-(azidomethyl)-4-methylbenzene (4-14): Yield = 93%. 1H-NMR (300 MHz, CDCl3) δ 
7.25 – 7.18 (m, 4H), 4.29 (s, 2H), 2.37 (s, 3H). 13C-NMR (75 MHz, CDCl3) δ 129.4, 
129.3, 128.5, 128.2, 54.5, 21.1. 
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1-(azidomethyl)-3,5-dimethoxybenzene (4-15): Yield = 96%. 1H-NMR (300 MHz, 
CDCl3) δ 6.46 – 6.38 (m, 3H), 4.27 (s, 2H), 3.80 (s, 6H). 13C-NMR (75 MHz, CDCl3) δ 
161.1, 137.6, 106.1, 100.2, 55.4, 54.9. 
 
(3-Azidopropyl- benzene (4-16): Yield = 91%.  1H-NMR (300 MHz, CDCl3) δ 7.40-
7.35(m, 2H), 7.30-7.25(m, 3H), 3.36-3.32 (t, J = 6.82 Hz, 2H), 2.80-2.75(t, J = 7.56 Hz, 
2H), 2.03-1.93(p, 2H). 13C-NMR (75 MHz, CDCl3) δ 141.37, 129.01, 128.95, 126.63, 
51.12, 33.25, 30.94. 
 
General procedure for the conversion of alcohols (4-a, 4-b, 4-e to 4-g, 4-q to 4-u) in 
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Fig. 7.14 List of alcohols used for mesylation 
 
            
 To a solution of the alcohol (4-a, 4-b, 4-e to 4-g, 4-q to 4-u) (2 mmol) (Fig. 7.14) in 
DCM (10 ml) was added mesyl chloride (6 mmol) under ice-cold condition followed by 
the addition of TEA (4 mmol). The reaction mixture was stirred typically from 10 min to 
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one hour depending on the alcohol used. Then reaction mixture was poured into water 
(10 ml). The layers were separated and the aqueous layer was extracted twice with DCM 
(2 x 15 ml). The combined DCM extracts were washed with NaHCO3 (2 x 15 ml), H2O (1 
x 15ml), brine (1 x 15 ml) and then dried over Na2SO4, filtered and concentrated under 
reduced pressure to obtain pure product. Alcohol (4-a, 4-b, 4-q, 4-e, 4-g, 4-s, 4-u) gave 
exclusively the respective mesylate (4-1c to 4-3c, 4-5c, 4-7c, 4-8c, 4-10c) whereas 
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Fig. 7.15 List of mesylates/chlorides synthesized 
 
4-methoxyphenethyl methanesulfonate (4-1c): Yield = 90%. 1H-NMR (300 MHz, 
CDCl3) δ 7.15 (d, J = 8.34 Hz, 2H), 6.86 (d, J = 8.70 Hz, 2H), 4.38 (t, J = 6.96 Hz, 2H), 
3.79 (s, 3H), 3.02 (t, J = 6.96 Hz, 2H), 2.85 (s, 3H). 
 
2-(2-benzylox-ethoxy-ethyl methanesulfonate (4-2c): Yield = 89%. 1H-NMR (300 
MHz, CDCl3) δ 7.33-7.27(m, 5H), 4.53(s, 2H), 4.36-4.33(m, 2H), 3.71-3.78(m, 2H), 
3.68-3.60(m, 6H), 2.98(s, 3H). 
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3,4,5-trimethoxy-benzyl methanesulfonate (4-3c): Yield = 77%. 1H-NMR (300 MHz, 
CDCl3) δ 6.62(s, 2H), 4.52(s, 2H), 3.88(s, 6H), 3.84(s, 3H). 
 
3-(chloromethyl)-2-methylbiphenyl (4-4c): Yield = 82%. 1H-NMR (300 MHz, CDCl3) 
δ 7.37 – 7.20 (m, 8H), 4.58 (s, 2H), 4.68 (s, 2H), 2.31 (s, 3H); 13C-NMR (75 MHz, 
CDCl3) δ 143.3, 141.8, 136.1, 134.8, 130.7, 129.3, 129.1, 128.1, 126.9, 125.8, 45.5, 16.1. 
 
2-phenethyl methanesulfonate (4-5c): Yield = 91%. 1H-NMR (300 MHz, CDCl3) δ 
7.36-7.23 (m, 5H), 4.44-4.39(t, J = 6.54 Hz, 2H), 3.07-3.02(t, J = 6.96 Hz, 2H), 2.82(s, 
3H). 13C-NMR (75 MHz, CDCl3) δ 136.94, 129.56, 129.27, 127.63, 70.98, 37.77, 36.14. 
 
1-Chloromethyl-naphthalene (4-6c): Yield = 81%. 1H-NMR (300 MHz, CDCl3) δ 8.13-
8.10(d, J = 8.37 Hz, 1H), 7.86-7.79(m, 2H), 7.59-7.46 (m, 3H), 7.41-7.35(m, 1H), 5.00(s, 
2H). 
 
1-methyl-3-(phenyl)-propyl methanesulfonate (4-7c): Yield = 72%. 1H-NMR (300 
MHz, CDCl3) δ 7.22-7.18(2H), 7.04-7.00(m, 3H), 4.41(m, 1H), 3.05(s, 3H), 2.61(m, 2H), 
1.79 (m, 2H), 1.38(d, 2H). 
 
cyclohexyl methanesulfonate (4-8c): Yield = 84%. 1H-NMR (300 MHz, CDCl3) δ 4.73-
4.64(septet, 1H), 3.00 (s, 3H), 1.97 (m, 2H), 1.79(m, 2H), 1.70-1.50(m, 3H), 1.46-
1.26(m, 3H). 
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1-(chloromethyl)-2-methoxybenzene (4-9c): Yield = 90%. 1H-NMR (300 MHz, CDCl3) 
δ 7.33 – 7.25 (m, 2H), 6.94 – 6.85 (m, 2H), 4.63 (s, 2H), 3.83 (s, 3H). 
 
2-(4-fluoro-phenyl)-ethyl methanesulfonate (4-10c): Yield = 91%.  1H-NMR (300 
MHz, CDCl3) δ 7.36-7.23 (m, 5H), 4.44-4.39(t, J = 6.54 Hz, 2H), 3.07-3.02(t, J = 6.96 
Hz, 2H), 2.82(s, 3H). 
 
General procedure for the MW assisted conversion of chlorides/mesylates (4-1c to 4-
10c) in to azides (4-1 to 4-2, 4-5 to 4-7 and 4-17 to 4-21) 
 
 To a solution of chloride/mesylate (1.7 mmol) in DMF (2 ml) was added NaN3 (3.4 
mmol). The reaction mixture was pre-stirred for 30 seconds in a sealed microwave 
reactor and was microwave irradiated for 10-15 min at 80o (10-15 min), after which the 
reaction mixture was poured into water (10 ml) and ether (15 ml). The aqueous layer was 
extracted with ether (2 x 15 ml). The combined ether extracts were washed with NaHCO3 
(2 x 15 ml), water (1 x 15 ml) and brine (1 x 15 ml) and dried over Na2SO4, filtered and 
concentrated under reduced pressure to obtain a spectroscopically pure azide product (4-
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Fig. 7.16 List of azides synthesized via mesylation 
 
1-(2-azidoethyl)-4-methoxybenzene (4-1): Yield = 99%. 1H-NMR (300 MHz, CDCl3) δ 
7.13 (d, J = 8.73 Hz, 2H), 6.85 (d, J = 8.70 Hz, 2H), 3.78 (s, 3H), 3.45 (t, J = 7.14 Hz, 
2H), 2.83 (t, J = 7.14 Hz, 2H); 13C-NMR (75 MHz, CDCl3) δ 158.5, 130.1, 129.7, 114.1, 
55.2, 52.7, 34.5 
 
  [2-(2-Azido-ethoxy)-ethoxymethyl]-benzene (4-2): Yield = 87%. 1H-NMR (300 MHz, 
CDCl3) δ 7.35 – 7.28 (m, 5H), 4.58 (s, 2H), 3.70 – 3.64 (m, 6H), 3.40 (t, J = 5.09 Hz, 
2H). 13C-NMR: (75 MHz, CDCl3) δ 138.18, 128.35, 127.68, 127.58, 73.31, 70.73, 70.03, 
69.50, 50.72. 
 
5-(azidomethyl)-1,2,3-trimethoxy-benzene (4-17): Yield = 89%.  1H-NMR: (300 MHz, 
CDCl3) δ 6.53(s, 2H), 4.28(s, 2H), 3.88(s, 6H), 3.85(s, 3H). 
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3-(azidomethyl)-2-methylbiphenyl (4-18): Yield = 95%. 1H-NMR (300 MHz, CDCl3) δ 
7.34 – 7.16 (m, 8H), 4.38 (s, 2H), 4.68 (s, 2H), 2.21 (s, 3H); 13C-NMR (75 MHz, CDCl3) 
δ 143.2, 141.7, 134.2, 134.0, 130.3, 129.2, 128.4, 128.0, 126.9, 125.6, 53.6, 16.2. 
 
(2-Azidoethyl)-benzene (4-5): Yield = 93%.  1H-NMR (300 MHz, CDCl3) δ 7.41-
7.27(m, 5H), 3.56-3.51(t, J = 7.3 Hz, 2H), 2.96-2.91(t, J = 7.3 Hz, 2H), 2.96-2.92(t, J = 
7.14Hz, 2H). 13C-NMR: (75 MHz, CDCl3) δ 139, 129.53, 129.28, 127.28, 52.92, 35.83. 
 
1-(azidomethyl)-naphthalene (4-6): Yield = 81%. 1H-NMR: (300 MHz, CDCl3) δ 8.02-
7.00(d, J = 8.01 Hz, 7.89-7.82(m, 2H), 7.5807.53(m, 2H), 7.44-7.42(m, 2H), 4.73(m, 
2H). 
 
3-azidobutyl-benzene (4-7): Yield = 82%. 1H-NMR: (300 MHz, CDCl3) δ 7.27-7.23(m, 
2H), 7.18-7.14(m, 3H), 3.41-3.35(s, 1H), 2.74-2.59(m, 2H), 1.80-1.69(m, 2H), 
1.2501.22(d, J = 6.63Hz, 3H). 13C-NMR: (300 MHz, CDCl3) δ 162.43, 141.23, 128.47, 
128.39, 126.02, 57.14, 37.88, 32.30, 19.37. 
 
Azidocyclohexane (4-19): Yield = 96%. 1H-NMR: (300 MHz, CDCl3) δ 3.36-3.30(m, 
1H), 1.91-1.89(m, 2H), 1.77-1.75(m, 2H), 1.59-1.56(m, 1H), 1.43-1.21(m, 5H). 13C-
NMR: (300 MHz, CDCl3) δ 59.97, 31.68, 25.35, 24.29 
 
1-(azidomethyl)-2-methoxybenzene (4-20): Yield = 92%. 1H-NMR (300 MHz, CDCl3) 
δ 7.33 – 7.22 (m, 2H), 6.96 – 6.88 (m, 2H), 4.33 (s, 2H), 3.82 (s, 3H).  
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1-(2-Azido-ethyl)-4-fluoro-benzene (4-21): Yield = 94%.  1H-NMR (300 MHz, CDCl3) 
δ 7.41-7.27(m, 5H), 3.56, 2.96-2.91(t, J = 7.3Hz, 2H), 2.96-2.92(t, J = 7.14 Hz, 2H). 
 
General procedure for the Microwave assisted click reaction:  
 
     Alkyne (0.018 mmol) was dissolved in small volume of DMSO (0.1 ml) and diluted 
with t-BuOH:Water (1:1) (1 ml), followed by the addition of the azide (0.020 mmol), 
Sodium ascorbate (0.014 mmol) and CuSO4.5H2O (0.007 mmol). The mixture was 
microwave irradiated at 80oC for 40 min. After which the reaction mixture was analyzed 
by HPLC, which indicated the complete conversion of the starting materials to yield the 
triazole product. Triazole products 4-T1 and 4-T3 were prepared in quantitative yields 
from azides 4-2 and 4-6 respectively. 
 
Procedure for the general click reaction: 
 
     Alkyne 2-A (0.018 mmol) was dissolved in small volume of DMSO (0.1 ml) and 
diluted with DCM:Water (1:1) (1 ml), followed by the addition of the azide 4-17 (0.020 
mmol), Sodium ascorbate (0.0036 mmol) and CuSO4.5H2O (0.0018 mmol). The mixture 
was shaken for 2 days after which it was analyzed by LC-MS, which indicated the 
complete conversion formation of the triazole product 4-T2. ESI-MS: m/z [M+H]+ = 
479.149. 
 
7.5 Activity-based fingerprinting of Enzymes 
 
 







General procedure for synthesis of (5-23) with different amino acids: 
 
 
The desired side chain-protected amino acid (1 mmol), containing either an N-α-Fmoc or 
N-α-Boc group, and HATU (0.456 g, 1.2 mmol) was dissolved in DMF.  2,4,6-Collidine 
(159 µl, 1.2 mmol) was added dropwise via a syringe.  The resulting solution was 
agitated for 10 min before compound 5-22 (0.181 g, 1 mmol) was added.  The mixture 
was further agitated for another 12 h, after which the DMF was removed in vacuo and the 
residue was taken into ethyl acetate (50 ml).  The organic layer was washed with 
NaHCO3 (2 x 30 ml), water (2 x 30 ml) and brine (2 x 30 ml) and dried over anhydrous 
Na2SO4.  The organic layer was then concentrated under reduced pressure to afford a 
yellow oily product.  Purification of this compound by flash chromatography (silica gel, 
ethyl acetate/hexane = 3:1) furnished 5-23a to 5-23p typically as a pale white solid. 
            
{4-[Boc-Ala-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-23a): Yield = 82%; 
1H-NMR (300 MHz, CDCl3) 7.44 (d, J = 8.43 Hz, 2H), 7.26 (d, 2H), 5.11 (s, 1H), 4.37 
(s, 1H), 3.71 (s, 3H), 1.43 (m, 12H); ESI-MS: m/z 353.1[M + H]+. 
 
{4-[Boc-Ile-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-23b): Yield = 87%; 
ESI-MS: m/z 417.3 [M + Na]+ 
 
[4-(Boc-Phe-amino)-phenyl]-hydroxy-acetic acid methyl ester (5-23c): Yield = 80%; 
1H-NMR (300 MHz, CDCl3) δ 7.48-7.12 (m, 9H), 5.12 (s, 1H), 4.95 (m, 1H), 3.77 (s, 
3H), 3.18 (m, 2H), 1.41 (s, 9H); ESI-MS: m/z 429.2 [M + H]+. 
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{4-[Fmoc-Asp(tBu)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-23d): Yield 
= 81%; ESI-MS: m/z 597.4 [M + Na]+. 
 
{4-[Fmoc-Lys(Boc)amino]-phenyl}-hydroxy-acetic acid methyl ester (5-23e): Yield = 
84%; 1H-NMR (300 MHz, CDCl3) δ 8.91 (s, 1H), 7.72 (d, J = 7.6 Hz, 2H), 7.50 (m, 4H), 
7.42 (m, 6H), 5.99 (s, 1H),  5.12 (s, 1H), 4.36 (m, 2H), 4.13 (m, 2H), 3.69 (m, 3H), 3.05 
(m, 2H), 1.90 (m, 1H), 1.70 (m, 1H), 1.41 (m, 11H), 1.26 (m, 2H); ESI-MS: m/z 654.3 
[M + Na]+. 
 
{4-[Fmoc-Thr(tBu)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-23f): Yield 
= 84%; 1H-NMR (300 MHz, CDCl3) δ 7.76 (d, 2H), 7.58 (m, 4H), 7.33 (m, 6H), 6.08 (m, 
1H), 5.15 (s, 1H), 4.42 (m, 2H), 4.24 (m, 1H), 3.77 (m, 1H), 3.75 (s, 3H), 1.35 (s, 9H), 
1.26 (m, 3H); ESI-MS: m/z 583.3 [M + Na]+. 
 
{4-[Fmoc-Tyr(tBu)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-23g): Yield 
= 82%; 1H-NMR (300 MHz, CDCl3) 7.75 (d, J = 7.62 Hz, 2H), 7.38 (m, 4H), 7.27 (m, 
6H), 7.19 (m, 2H), 6.89 (d, J = 8.04 Hz, 2H), 5.12 (s, 1H), 4.92 (s, 1H), 4.41 (m, 2H), 
4.19 (m, 1H), 3.73 (s, 3H), 3.19 (m, 2H), 1.3(s, 9H); ESI-MS: m/z 623.4[M + H]+. 
 
{4-[Fmoc-Glu(OBut-t)amino]-phenyl}-hydroxy-acetic acid methyl ester (5-23h): 
Yield = 85%; 1H-NMR (300 MHz, CDCl3) δ 8.86 (s, 1H), 7.74 (d, J = 7.6 Hz, 2H), 7.54 
(m, 4H), 7.30 (m, 6H), 6.08 (s, 1H),  5.14 (s, 1H), 4.38 (m, 3H), 4.18 (m, 1H), 3.71 (m, 
3H), 2.41 (m, 2H), 2.04 (m, 2H), 1.44 (m, 9H); ESI-MS: m/z 611.1 [M + Na]+. 
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{4-[Fmoc-Asn(Trt)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-23i): 
 Yield = 84%. ESI-MS: m/z 761.6 [M + H]+ 
 
{4-[Fmoc-Gln(Trt)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-23j): Yield = 
84%; 1H-NMR (300 MHz, CDCl3) δ  7.73 (d, J = 7.23 Hz, 2H), 7.47 (m, 4H), 7.26 (m, 
21H), 5.84 (s, 1H), 4.36 (m, 2H), 4.16 (m, 2H), 3.69 (m, 3H), 2.41 (m, 2H), 2.07 (m, 2H); 
ESI-MS: m/z 774.2 [M + H]+. 
 
{4-[Fmoc-Trp(Boc)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-23k): Yield 
= 80%; ESI-MS: m/z 712.8 [M + Na]+. 
 
{4-[Fmoc-Val-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-23l): Yield = 86%; 
1H-NMR (300 MHz, CDCl3) δ 7.71 (d, 2H), 7.52 (m, 4H), 7.26 (m, 6H), 5.12 (s, 1H),  
4.38 (m, 2H), 4.21 (m, 1H),  4.11 (m, 1H), 3.68 (s, 3H), 2.13 (m, 1H), 1.02 (d, 6H); ESI-
MS: m/z 525.7[M + Na]+. 
 
{4-[Fmoc-His(Trt)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-23m): Yield 
= 86%. 1H-NMR (300 MHz, CDCl3) δ 7.75 (d, 2H), 7.51 (m, 4H), 7.29 (m, 21H), 7.02 
(m, 1H), 6.68 (m, 1H), 5.16 (s, 1H), 4.65 (m, 1H), 4.38 (m, 2H), 4.12 (m, 1H), 3.71 (m, 
3H), 3.16(m, 2H); ESI-MS: m/z 782.9 [M + H]+. 
 
{4-[Fmoc-Ser(tBu)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-23n): Yield 
= 83%; 1H-NMR (300 MHz, CDCl3) δ 7.75 (d, 2H), 7.60 (m, 4H), 7.38 (m, 6H), 5.16 (s, 
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1H), 4.44 (m, 2H), 4.24 (m, 1H), 4.10 (m, 1H), 3.71 (s, 3H), 3.48 (m, 2H), 1.23 (s, 9H); 
ESI-MS: m/z 547.3[M + H]+. 
 
{4-[Fmoc-Leu-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-23o): Yield = 
88%; 1H-NMR (300 MHz, CDCl3) δ 7.73 (d, 2H), 7.55 (m, 4H), 7.28 (m, 6H), 5.13 (s, 
1H), 4.40 (m, 2H), 4.23 (m, 1H), 4.14 (m, 1H), 3.69 (s, 3H), 1.71 (m, 3H), 0.91 (m, 6H); 
ESI-MS: m/z 539.1[M + Na]+. 
 
{4-[Fmoc-Cys(Trt)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-23p): Yield 
= 82%; ESI-MS: m/z 717.6[M + Na]+. 
 
 
General procedure for synthesis of (5-24) with different amino acids: 
 
Depending upon the α-amino protecting group, 20% Piperidine in DMF or 50% TFA in 
DMF (5 ml) was added to compound 5-23 (0.5 mmol) and the resulting solution was 
stirred for 30 min.  Following removal of the solvent in vacuo, the residue was dissolved 
in anhydrous DCM and a mixture of acetic anhydride (0.153 g, 1.5 mmol) and DIEA 
(0.194 g, 1.5 mmol) was added.  After 5 min, the DCM was removed and the residue was 
purified by flash chromatography (silica gel, ethyl acetate/hexane = 3:1) to furnish 5-24a 






{4-[Acetyl–Ala-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-24a): 
Yield = 56%;  1H-NMR (300 MHz, CDCl3) δ 7.44 (d, 2H), 7.26 (d, 2H), 5.11 (s, 1H), 
4.67 (s, 1H), 3.71 (s, 3H), 2.03 (s, 3H), 1.42 (m, 3H); ESI-MS: m/z 295.4 [M + H]+. 
 
{4-[Acetyl–Ile-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-24b): Yield = 
54%; ESI-MS: m/z 359.3 [M + H]+. 
 
[4-(Acetyl-Phe-amino)-phenyl]-hydroxy-acetic acid methyl ester (5-24c): Yield = 
45%; 1H-NMR (300 MHz, CDCl3) δ 7.48-7.12 (m, 9H), 5.12 (s, 1H), 4.95 (m, 1H), 3.77 
(s, 3H), 3.18 (m, 2H), 1.99 (s, 3H); ESI-MS: m/z 370.9 [M+H]+. 
 
{4-[Acetyl-Asp(O-But)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-24d): 
Yield = 53%; 1H-NMR (300 MHz, CDCl3) δ 7.51 (d, 2H), 7.32 (d, 2H), 5.11 (s, 1H), 4.89 
(m, 1H), 3.69 (s, 3H), 2.85 (m, 2H), 2.00 (s, 3H), 1.49 (s, 9H); ESI-MS: m/z 395.1 [M + 
H]+. 
 
{4-[Acetyl-Lys(Boc)amino]-phenyl}-hydroxy-acetic acid methyl ester (5-24e): Yield 
= 53%; 1H-NMR (300 MHz, CDCl3) δ 7.45 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.43 Hz, 2H 
), 5.12 (s, 1H), 4.53 (m,1H), 3.67 (s, 3H), 3.00 (m, 2H), 2.03 (s, 3H), 1.90 (m, 2H), 1.41 
(m, 11H), 1.26 (m, 2H); ESI-MS: m/z 452.1 [M+H]+. 
 
{4-[Acetyl-Thr(t-But)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-24f): 
Yield = 56%; 1H-NMR (300 MHz, CDCl3) δ 7.48 (d, 2H), 7.31 (d, 2H), 5.13 (s, 1H), 4.46 
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(m, 1H), 3.98 (m, 1H), 3.71 (s, 3H), 2.03 (s, 3H), 1.39 (s, 9H), 1.28 (s, 3H); ESI-MS: m/z 
380.1 [M + H]+. 
 
{4-[Acetyl–Tyr(Bu-t)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-24g): 
Yield = 50%; 1H-NMR (300 MHz, CDCl3) δ 7.36 (d, J = 8.40 Hz, 2H), 7.22 (d, J = 8.01 
Hz, 2H), 7.11 (d, J = 8.01 Hz, 2H), 6.85 (d, J = 8.01 Hz, 2H), 5.11 (s, 1H), 4.99 (m, 1H), 
3.68 (s, 3H), 3.17 (m, 2H), 1.9 (s, 3H), 1.24 (s, 9H); ESI-MS: m/z 465.4 [M + Na]+. 
 
{4-[Acetyl-Glu(OBut-t)amino]-phenyl}-hydroxy-acetic acid methyl ester (5-24h): 
Yield = 50%; 1H-NMR ( 300 MHz, CDCl3) δ 7.49 (d, J = 8.43 Hz, 2H), 7.37 (d, J = 8.43 
Hz, 2H),  5.12 (s, 1H), 4.56 (m, 1H), 3.67 (s, 3H), 2.31 (m, 4H), 2.04 (s, 3H), 1.44 (s, 
9H); ESI-MS: m/z 409.2 [M+H]+. 
 
{4-[Acetyl–Asn(Trt)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-24i): Yield 
= 53%; ESI-MS: m/z 580.5 [M + H]+. 
 
{4-[Acetyl-Gln(Trt)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-24j): Yield 
= 54%; 1H-NMR (300 MHz, CDCl3) δ 7.73 (d, J = 78.23 Hz, 2H), 7.49 (m, 2H), 7.27 (m, 
15H), 5.83 (s, 1H), 4.41 (m, 1H), 3.67 (m, 3H), 2.02 (s, 3H), 2.43 (m, 2H), 2.12 (m, 2H); 
ESI-MS: m/z 594.9 [M + H]+. 
 
{4-[Acetyl–Trp(Boc)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-24k): Yield 
= 49%. 
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{4-[Acetyl–Val-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-24l): Yield = 
55%; ESI-MS: m/z 323.1 [M + H]+. 
 
{4-[Acetyl–His(Trt)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-24m): Yield 
= 53%; ESI-MS: m/z 601.7 [M +1]+.  
 
{4-[Acetyl-Ser(tBu)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-24n): Yield 
= 53%; 1H-NMR (300 MHz, CDCl3) δ 7.37 (d, J = 8.43 Hz, 2H), 7.29 (s, J = 8.43 Hz, 
2H), 5.16 (s, 1H), 4.61 (m, 1H), 3.70 (s, 3H), 3.49 (m, 2H), 2.06 (s, 3H), 1.24 (S, 9H); 
ESI-MS: m/z 367.1[M + H]+. 
 
{4-[Acetyl-Leu-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-24o):  Yield = 
53%;  1H-NMR (300 MHz, CDCl3) δ 7.48 (d, 2H), 7.35 (d, 2H), 5.13 (s, 1H),  4.53 (m, 
1H), 3.68 (s, 3H), 2.0 (s, 3H), 1.70 (m, 3H), 0.90 (m, 6H); ESI-MS: m/z 359.1[M + Na]+.  
 
{4-[Acetyl–Cys(Trt)-amino]-phenyl}-hydroxy-acetic acid methyl ester (5-24p): Yield 
= 47%. 
 
General procedure for synthesis of compound 5-27: 
 
     To a solution of compound 5-24 (0.1 mmol) in methanol (9 ml), 0.1 M LiOH (3 ml) 
was added and the mixture was stirred at room temperature.  After 3 h, the resulting 
mixture was concentrated under reduced pressure.  Following addition of 1 M HCl 
solution (10 ml), the product was extracted with 20 ml of ethyl acetate or 
dichloromethane and the organic layer was washed with 1 M HCl (2 x 15 ml), water (2 x 
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15 ml), and brine (2 x 15 ml), and dried over anhydrous Na2SO4 followed by 
concentration in vacuo to afford 5-25 typically as a dull solid, which was used for 
subsequent steps without further purification.   
A Fmoc-mono-protected diamine linker, 5-28 (44 mg, 0.12 mmol) as shown below and 
synthesized as previously described,44 was added to a flask containing compound 5-25 
dissolved in DMF (15 ml).  Subsequently, HOBt (18 mg, 0.12 mmol) and EDC (23 mg, 
0.12 mmol) were added and the reaction was allowed to proceed at 0 °C for 30 min with 
stirring.  At the end of this period, the reaction mixture was warmed to room temperature 
and further stirred for an additional 8 h, after which aqueous NH4Cl was added and the 
product was extracted with ethyl acetate.  The combined organic extract was washed with 
1 M HCl (2 x 50 ml), water (2 x 50 ml) and brine (2 x 50 ml), followed by drying over 
anhydrous Na2SO4 and concentration under reduced pressure to furnish the crude product 
5-26.  Without further purification, this compound was dissolved in CH2Cl2 (12 ml) at 0 
°C and (diethylamino)sulfur trifluoride (0.033 ml, 0.3 mmol) was added dropwise.  The 
reaction temperature was then increased to 25 °C.  After stirring for 30 min, the solvent 
was removed and the residue was taken into ethyl acetate (50 ml).  The organic layer was 
washed with NaHCO3 (2 x 30 ml), water (2 x 30 ml) and brine (2 x 30 ml) followed by 
drying over anhydrous Na2SO4 and concentration under reduced pressure to afford the 
crude product, which was further purified by flash chromatography (silica gel, 
hexane/ethyl acetate = 1:3) to afford 5-27a to 5-27p.  
 
Compound 5-27a (Ala):  Yield = 63%; 1H-NMR (300 MHz, CDCl3) δ 7.71 (d, 2H), 7.56 
(m, 4H), 7.29 (m, 6H), 5.68 (d, J = 48.6 Hz, 1H), 5.37 (m, 1H), 4.70 (m, 2H), 4.40 (m, 
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1H), 3.58 (s, 10 H), 3.36 (m, 2H), 2.01 (s, 3H), 1.43 (m, 3H); ESI-MS: m/z 657.2 [M + 
Na]+. 
 
Compound 5-27b (Ile): Yield = 63%; ESI-MS: m/z 676.8 [M + H]+. 
 
Compound 5-27c (Phe): Yield = 53%; 1H-NMR (300 MHz, CDCl3) δ 7.75 (d, J = 7.2 
Hz, 2H), 7.68 (m, 4H), 7.36 (m, 6H), 5.70 (d, J = 48.6 Hz, 1H), 5.35 (m, 1H), 4.54 (m, 
1H), 4.39 (m, 2H), 4.20 (m, 2H), 3.53 (m, 10H), 3.38 (m, 2H), 2.46 (m, 2H), 2.10 (m, 
2H), 2.01 (s, 3H), 1.45 (m, 9H); ESI-MS: m/z 733.3 [M + Na]+. 
 
Compound 5-27d (Asp): Yield = 63%; ESI-MS: m/z 758.1 [M + Na]+. 
 
Compound 5-27e (Lys): Yield = 66%; 1H-NMR (300 MHz, CDCl3) δ 7.75 (d, J = 7.2 
Hz, 2H), 7.58 (m, 4H), 7.36 (m, 6H), 5.70 (d, J = 48.5 Hz, 1H), 5.33 (m, 1H), 4.59 (m, 
2H), 4.40 (m, 1H), 3.61 (m, 10H), 3.37 (m, 2H), 3.09 (m, 2H), 2.04 (s, 3H), 1.90 (m, 2H), 
1.43 (m, 13H); ESI-MS: m/z 814.4 [M + Na]+. 
 
Compound 5-27f (Thr): Yield = 64%; 1H-NMR (300 MHz, CDCl3) δ 7.73 (d, 2H), 7.39 
(m, 10H), 5.69 (d, J = 48.4 Hz, 1H), 5.38 (m, 1H), 4.49 (m, 2H), 4.21 (m, 1H), 3.98 (m, 
1H), 3.61 (m, 10H), 3.34 (m, 2H), 2.02 (s, 3H), 1.39 (s, 9H), 1.29 (m, 3H); ESI-MS: m/z 
744.4 [M + Na]+. 
 
Compound 5-27g (Tyr): Yield = 63%; ESI-MS: m/z 806.1[M + Na]+. 
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Compound 5-27h (Glu): Yield = 60%; 1H-NMR (300 MHz, CDCl3) δ 7.75 (d, J = 7.2 
Hz, 2H), 7.58 (d, J = 7.7 Hz, 2H), 7.31 (m, 12H), 7.06 (m, 1H), 5.70 (d, J = 48.5 Hz, 1H), 
5.43 (m, 1H), 4.41 (m, 2H), 4.20 (m, 1H), 3.63 (m, 10H), 3.37 (m, 2H), 3.07 (m, 2H), 
2.04 (s, 9H); ESI-MS: m/z 771.3 [M + Na]+. 
 
Compound 5-27i (Asn): Yield = 64%; ESI-MS: m/z 943.8 [M + H]+. 
 
Compound 5-27j (Gln): Yield = 67%; 1H-NMR (300 MHz, CDCl3) δ 7.72 (d, 2H), 7.58 
(m, 4H), 7.27 (m, 21H), 5.72 (d, J = 48.5 Hz, 1H), 5.37 (m, 1H), 4.69 (m, 2H), 4.38 (m, 
1H), 3.58 (s, 10H), 3.34 (m, 2H), 2.00 (s, 3H), 2.44 (m, 2H), 2.1 (m, 2H); ESI-MS: m/z 
935.1 [M + H]+. 
 
Compound 5-27k (Trp): Yield = 63%; 1H-NMR (300 MHz, CDCl3) 7.75 (d, 2H),  7.57 
(m, 4H), 7.39 (m, 6H), 7.20 (m, 2H), 7.01 (d, 2H), 6.90 (m, 1H), 5.71 (d, J = 48.6 Hz, 
1H),  5.39 (m, 1H), 4.59 (m, 2H), 4.39 (m, 1H), 3.62 (m, 10H), 3.38 (m, 2H), 3.18 (m, 
2H), 2.02 (s, 3H), 1.25 (s, 9H); ESI-MS: m/z 872.3 [M + Na]+. 
 
Compound 5-27l (Val): Yield = 59%; ESI-MS: m/z 663.4 [M + H]+. 
 
Compound 5-27m (His): Yield = 60%; ESI-MS: m/z 944.1 [M + H]+. 
 
Compound 5-27n (Ser): Yield = 61%; ESI-MS: m/z 706.9[M + H]+. 
 
 172
Compound 5-27o (Leu): Yield = 64%; 1H-NMR (300 MHz, CDCl3) δ 7.70 (d, 2H), 7.56 
(m, 4H), 7.35 (m, 6H), 5.79 (d, J = 48.5 Hz, 1H), 5.34 (m, 1H), 4.41 (m, 2H), 4.21 (m, 
1H), 3.60 (m, 10H), 3.38 (m, 2H), 2.00 (s, 3H), 1.71 (m, 3H), 0.91 (m, 6H); ESI-MS: m/z 
699.8 [M + Na]+. 
 
Compound 5-27p (Cys): Yield = 64%; ESI-MS: m/z 932.3 [M + Na]+. 
 
General procedure for synthesis of the Probes (5-1 to 5-16): 
 
     To compound 5-27 (0.05 mmol), 20% piperidine in DMF (3 ml) was added and the 
resulting solution was stirred for 30 min.  After which the solvent was removed under 
reduced pressure to yield a residue, which upon taken into DMF (3 ml), was added Cy3-
NHS (32.4 mg, 0.06 mmol) and DIEA (10 µl, 0.06 mmol).  The reaction mixture was 
stirred at room temperature for 18 h followed by concentration under reduced pressure to 
give the crude product as syrup.  Following de-protection by treatment with 50% 
TFA/DCM for 30 min, the resulting product was further purified by reverse-phase HPLC 
(CH3CN/H2O/0.01% TFA; 15/85  60/40 gradient in 60 min) to give the desired product 
(Probes 5-1 to 5-16). The products were analyzed by NMR and MS analysis. The results 
of the MS analysis are shown in Table 7.2. 
 
Probe 5-1 (Ala): Yield =75%; 1H-NMR (300 MHz, CDCl3) δ 8.36 (m, 1H), 7.74 (m, 
2H), 7.37 (m, 6H), 7.25 (m, 2H), 7.13 (m, 2H), 6.48 (m, 2H), 5.74-5.58 (d, J = 48.6 Hz, 
1H), 4.62 (m, 1H), 3.98 (m, 2H), 3.56 (m, 12H), 3.40 (m, 2H), 2.01 (m, 3H), 1.90 (m, 19 
H); ESI-MS: m/z 838.5 [M - I]+. 
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Probe 5-2 (Ile):  Yield = 70 %; 1H-NMR (300 MHz, CDCl3) δ 8.37 (m, 1H), 7.75 (m, 
2H), 7.37 (m, 6H), 7.25 (m, 2H), 7.12 (m, 2H), 6.44 (m, 2H), 5.74-5.58 (d, J = 48.5 Hz, 
1H), 4.57 (m, 1H), 4.08 (m, 2H), 3.60 (m, 12H), 3.41 (m, 2H), 2.50 (m, 1H), 2.03 (m, 
3H), 1.71 (m, 18), 0.92 (m, 6H); ESI-MS: m/z 880.5 [M - I]+. 
 
Probe 5-4 (Asp):  Yield = 71%; 1H-NMR (300 MHz, CDCl3) δ 8.36 (m, 1H), 7.55 (d, 
2H), 7.26 (m, 6H), 7.17 (m, 2H), 7.14 (m, 2H), 6.39 (m, 2H), 5.73-5.57 (d, J = 48.5 Hz, 
1H), 4.94 (m, 1H), 3.59 (m, 2H), 3.53 (m, 12H), 3.31 (m, 2H), 2.84 (m, 2H), 2.17 (s, 3H), 
1.7 (m, 16H); ESI-MS: m/z 882.4 [M - I]+. 
 
Probe 5-6 (Thr): Yield = 72%; 1H-NMR (300 MHz, CDCl3) δ 8.37 (m, 1H), 7.63 (m, 
2H), 7.37 (m, 6H), 7.26 (m, 2H), 7.14 (m, 2H), 6.41 (m, 2H), 5.76-5.59 (d, J = 48.4 Hz, 
1H), 4.94 (m, 1H), 4.71 (m, 1H), 3.90 (m, 2H), 3.58 (m, 12H), 3.43 (m, 2H), 2.16 (s, 3H), 
1.69 (m, 16H), 1.28 (m, 3H); ESI-MS: m/z 868.5 [M - I]+. 
 
Probe 5-7 (Tyr): Yield = 72%; 1H-NMR (300 MHz, CDCl3) δ 8.35 (m, 1H), 7.58 (m, 
2H), 7.31 (m, 2H) 7.25 (m, 6H), 7.12 (m, 2H), 6.80 (m, 2H), 6.51 (m, 2H), 6.45 (m, 2H), 
5.58-5.74 (d, J = 48.5 Hz, 1H), 4.67 (m, 1H), 3.98 (m, 2H), 3.55 (m, 12H), 3.41 (m, 2H), 
3.21 (m, 2H), 2.21 (s, 3H), 1.97 (m, 16H); ESI-MS: m/z 930.5 [M - I]+.   
 
Probe 5-9 (Asn): Yield = 71%; 1H-NMR (300 MHz, CDCl3) δ 8.37 (m, 1H), 7.67 (m, 
2H), 7.37 (m, 8H), 7.94 (m, 2H), 6.49 (m, 2H), 5.58-5.74 (d, J = 48.4 Hz, 1H), 4.90 (m, 
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1H), 4.00 (m, 2H), 3.60 (m, 12H), 3.32 (m, 2H), 2.49 (m, 2H), 2.10 (s, 3H), 1.71 (m, 
16H); ESI-MS: m/z 880.5 [M - I]+. 
 
Probe 5-10 (Gln):  Yield = 72%; 1H-NMR (300 MHz, CDCl3) δ 8.36 (m, 1H), 7.72 (m, 
2H), 7.37 (m, 8H), 7.13 (m, 2H), 6.47 (m, 2H), 5.75 (d, J = 48.5 Hz, 1H), 4.62 (m, 1H), 
3.98 (m, 2H), 3.59 (m, 12 H), 3.34 (m, 2H), 2.29 (m, 2H), 2.18 (m, 2H), 2.04 (s, 3H), 
1.74 (m, 16H); ESI-MS: m/z 895.4 [M - I]+.  
 
Probe 5-11 (Trp): Yield = 72%;  1H-NMR (300 MHz, CDCl3) δ 8.36 (m, 1H), 7.65 (m, 
2H), 7.47 (m, 10H), 7.34 (m, 2H), 7.14 (m, 2H), 6.98 (m, 1H), 6.54 (m, 2H), 5.73-5.57 
(d, J = 48.6 Hz, 1H), 4.86 (m, 1H), 4.10 (m, 2H), 3.52 (m, 12H), 3.30 (m, 2H), 3.01 (m, 
2H), 1.98 (s, 3H), 1.70 (m, 16H); ESI-MS: m/z 953.4 [M - I]+. 
 
Probe 5-12 (Val):  Yield = 74%; 1H-NMR (300 MHz, CDCl3) δ 8.33-8.41 (m, 1H), 7.68-
7.71 (m, 2H), 7.40-7.33 (m, 8H), 7.27 (m, 2 H), 6.41 (m, 2H), 5.59-5.75 (d, J = 48.5 Hz, 
1H), 4.39-4.51 (m, 1H), 3.99 (m, 2H), 3.64 (m, 12H), 3.31 (m, 2H), 2.29 (m, 1H), 2.04 (s, 
3H), 1.74 (m, 16H), 0.97 (m, 6H); ESI-MS: m/z 866.4 [M - I]+.  
 
Probe 5-13 (His): Yield = 72%; 1H-NMR (300 MHz, CDCl3) δ 8.39 (m, 1H), 7.71 (m, 
3H), 7.38 (m, 6H), 7.19 (m, 2H), 7.13 (m, 3H), 6.36 (m, 2H), 5.76-5.60 (d, J = 48.6 Hz, 
1H), 4.94 (m, 1H),  4.00 (m, 2H), 3.58 (m, 12H), 3.15 (m, 2H), 2.95 (m, 2H), 2.09 (s, 
3H), 1.72 (m, 16H); ESI-MS: m/z 904.5 [M - I]+.   
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Probe 5-14 (Ser): Yield = 69%; 1H-NMR (300 MHz, CDCl3) δ 8.37 (m, 1H), 7.66 (m, 
2H), 7.36 (m, 6H), 7.22 (m, 2H), 7.12 (m, 2H), 6.40 (m, 2H), 5.59-5.75 (d, J = 48.5 Hz, 
1H), 4.63 (m, 1H), 4.12 (m, 2H), 3.97 (m, 2H), 3.59 (m, 12H), 3.37 (m, 2H), 2.05 (s, 3H), 
1.71 (m, 16H); ESI-MS: m/z 854.5 [M - I]+. 
 
Probe 5-15 (Leu): Yield = 73%; 1H-NMR (300 MHz, CDCl3) δ 8.37 (m, 1H), 7.75 (m, 
2H), 7.38 (m, 6H), 7.24 (m, 2H), 7.12 (m, 2H), 6.44 (m, 2H), 5.58-5.74 (d, J = 48.5 Hz, 
1H), 4.58 (m, 1H), 4.10 (m, 2H), 3.61 (m, 12H), 3.40 (m, 2H), 2.04 (m, 3H), 1.71 (m, 
19H), 0.91 (m, 6H); ESI-MS: m/z 880.5 [M - I]+. 
 
Probe 5-16 (Cys): Yield = 71%; 1H-NMR (300 MHz, CDCl3) δ 8.37 (m, 1H), 7.70 (d, 
2H), 7.38 (m, 6H), 7.25 (m, 2H), 7.17 (m, 2H), 6.41 (m, 2H), 5.75-5.59 (d, J = 48.5 Hz, 
1H), 4.76 (m, 1H), 3.99 (m, 2H), 3.53 (m, 12H), 3.39 (m, 2H), 3.21 (m, 2H), 2.04 (s, 3H), 


















Ala 838.50 837.47 Asn 880.50 880.48 
Ile 880.50 879.52 Gln 895.40 894.49 
Phe 914.40 913.30 Trp 953.40 952.51 
Asp 882.40 881.46 Val 866.30 866.40 
Lys 894.60 894.53 His 904.50 903.60 
Thr 868.50 867.48 Ser 854.50 853.47 
Tyr 930.50 929.50 Leu 880.50 879.52 
Glu 895.60 895.48 Cys 870.50 869.44 
 
Table 7.2 Summary of ESI-MS results of the probes 5-1 to 5-16. 
 
 
7.5.2 Gel-Based Labeling Experiments with 16 Probes: 
 
     Stock solutions of proteins were prepared as ~ 2 mg/ml solutions in distilled water, 
desalted with a NAP5 column (Amersham, USA) and stored at -20 oC until use.  Since 
the different proteins, as obtained from commercial sources, contain different amount of 
salts, the final absolute weights of the protein in the estimated 2 mg/ml stock solution 
likely differ to some degree (as determined by coomassie staining of the proteins upon 
separation on a SDS-PAGE gel).  Furthermore, the relative catalytic activity of each 
commercial protein also differs as well.  Both factors render the quantitation of our 
labeling reactions across different proteins less relevant.  Consequently, the relative 
fluorescence labeling in each protein is more meaningful when the labeling of the same 
protein against different probes is compared.  The labeling of different proteins by the 
 177
same or different probes may only be used as a qualitative measure.  The stock solutions 
of the 16 probes were prepared as 200 µM solutions in methanol and stored at -20 oC.  
Fluorescence imaging was carried out using the Typhoon 9200 scanner (Amersham, 
USA). 
 
(Enzyme) Concentration-dependent labeling  
 
Probe 5-5 (2 µM) was incubated with different concentration of trypsin using the 
procedure as described above.  The sample was then resolved on a 12% gel and 
visualized by fluorescence scanning.  It was found (Fig. 7.17) that as low as 1 ng of the 
enzyme could be detected with µM of the probe 5-5. 
               
 [Trypsin]/ng   
                                        0.5  1.0  2.0  5.0  10   20  50 100 200 
                                       
 




(Probe) Concentration-dependent labeling 
 
Reactions containing 0.02 mg/ml of trypsin were treated with varied concentrations of 
Probe 5-5 (0.05-2 µM) using the above descried procedure.  The resulting samples were 
resolved on a 12% gel and visualized by fluorescence scanning.  As shown in Fig 7.18, as 
low as 0.1 µM of the probe is needed for protein labeling to be detected.           
 
 [Probe 5-5] (µM) 
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     Thirteen different proteases were individually labeled with Probes 5-1 to 5-16 as 
described above.  The resulting gel-based profiles (Fig. 7.19) were used to generate 
fingerprints of the enzymes as shown. With trypsin as a representative, a unique activity-
based fingerprinting profile of the enzyme against all probes was thus generated.  Based 
on the relative intensity of the labeled enzymes by each probe, a dendrogram were 
constructed using the programs Tree View™ and Cluster™ developed by Eisen and 
coworkers. The thirteen proteases were hierarchically clustered based on the similarity of 
their fingerprint profiles, and shown by the tree structure on the left of the dendrogram 
(Fig. 5.4).  The degree of similarity of protease was indicated as a function of height of 
the lines connecting profiles.  
 































































Fig. 7.19  SDS-PAGE of 13 different proteases labeled with Probes 5-1 to 5-16.  Each 
lane in the gel represents labeling by a different probe (from left to right; shown with 
three-letter amino acid code): Ala, Ile, Phe, Asp, Lys, Thr, Tyr, Glu, Asn, Gln, Trp, Val, 
His, Ser, Leu, Cys. 
 
 
7.5.3 Chemical Synthesis of the PTP probes 
 
p-Hydroxymandelic acid (5-19): A solution of phenol (11.3 g , 0.12 mol), glyoxalic acid 
(7.4 g, 0.1 mol), and NaOH (8 g) was dissolved in 80 ml of water and heated to 40˚C for 
8 hrs. Then the reaction solution was brought to a pH of 6 using 1N HCl then the 
unconverted phenol was extracted with benzene (3 x 100 ml). The aqueous solution was 
acidified to a pH of 1.5 using 1N HCl and extracted with ethyl acetate (10 x 50 ml) and 
washed with brine (1 x 100 ml). The organic layer was dried over anhydrous Na2SO4 and 
concentrated to 30% of the weight and left to crystallize over night at 0 ˚C to afford pure 
5-19 (12.1 g, 60%) in the form of  solid prisms. 1H-NMR (300 MHz, DMSO) δ 7.25 (d, J 
= 3.0 Hz, 2H), 6.84 (d, J = 3.0 Hz, 2H). MS (ESI): m/z 191.4 [(M+23)]+. 
    
[2-(2-{2-[2-hydroxy-2-(4-hydroxyphenyl)-acetylamino]-ethoxy}-ethoxy-ethyl] 
carbamic acid tert-butyl ester (5-20): To a solution of amine (10 g, 0.059mol) in dry 
DMF were added EDC (13.6g, 0.071 mol), HOBt (9.94 g, 0.065 mol) and compound 5-
19 (14.65 g, 0.059mol) under ice cold condition. The resulting solution was further 
stirred for 24 hrs at RT. Upon removal of the solvent in vacuo, the residue was taken in to 
ethyl acetate and washed with water (2 x 80 ml) and brine (2 x 80 ml). The organic layer 
was dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford a 
crude mixture, which was further purified by flash chromatography (silica gel, ethyl 
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acetate 100% ) to afford 5-20 (18.78 g, 80 %) as a dull brown  highly viscous oil. 1H-
NMR (300 MHz, CDCl3) δ 7.09(d, J = 3, 2H), 6.63(d, J = 2, 2H), 4.89(s, 1H), 3.54-3.39 
(m, 10 H), 3.21-3.19(t, 2H), 1.38 (s, 9H). MS (ESI): m/z 421.3 [(M+23)]+. 
 
Compound 5-21: To a solution of 5-20 (7 g, 17.6 mmol) in dry DCM was added TEA 
(4.8 ml, 44 mmol) and diethyl chlorophosphate (2.4 ml, 17.6 mmol) at 0 oC. The resulting 
solution was further stirred for 24 hrs at RT. The reaction was then quenched with water 
and washed with saturated NaHCO3   (2 x 60 ml), water (2 x 60 ml) and brine (2 x 60 ml). 
The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced 
pressure and further purified by flash chromatography (silica gel, 
dichloromethane/ethanol = 8:2) to afford 5-21 (7.47 g, 80 %) as a dull brown viscous 
liquid.  1H-NMR (300 MHz, CDCl3) δ 7.26(d, J = 3 Hz, 2H), 6.98 (d, J = 3 Hz, 2H), 
4.85(s,1H), 4.07-3.98  (p, 4H), 3.42 (s, 4H), 3.38-3.34 (t, 4H), 3.31-3.27 (t, 2H), 3.14-
3.09 (m,2H), 1.29 (3, 9H), 1.21-1.16 (t, 6H). MS (ESI): m/z 557.2 [(M+23)]+. 
 
Compound 5-22: Compound 5-21 (5 g, 9.36 mmol) was dissolved in dry DCM and 
DAST (3.67 ml, 28 mmol) was slowly added under ice cold condition. The mixture was 
allowed to stir for further 1 hour at RT. Then the reaction mixture was washed with cold 
water and dried with anhydrous Na2SO4. The organic layer was concentrated under 
reduced pressure and further purified by flash chromatography to afford 5-22 (4.01 g, 
78%) as a dark brown oily liquid. 1H-NMR (300 MHz, CDCl3) δ 7.39 (d, J = 2.8 Hz, 
2H), 7.19 (d, J = 3 Hz, 2H), 5.78 (s, 1H), 5.61 (s, 1H), 4.21-4.10 (p, 4H), 3.56-3.47 (m, 
8H), 3.26-3.24 (m, 2H), 1.38 (s, 9H), 1.27-1.31 (t, 6H) MS (ESI): m/z 559.2 [(M+23)]+. 
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Compound 5-23: Compound 5-22 (4 g, 7.46 mmol) was added to a 40 ml solution of 1:1 
DCM:TFA mixture and stirred for 30 minutes after which it was evaporated under 
reduced pressure to afford  the amine 5-23 (2.93 g, 90 %). It was used with out further 
purification. 1H-NMR (300 MHz, CDCl3) δ 7.45(d, J = 4.29 Hz, 2H), 7.19(d, J = 2.68 Hz, 
2H) 5.87(s, 1H), 5.71(s, 1H), 4.30-4.2(p, 4H), 3.62-3.59(m, 8H), 3.53-3.45 (m, 2H), 1.36-
1.31 (t, 6H). MS (ESI): m/z 437.2 [(M+1)]+. 
 
Compound 5-24: To a solution of 5-23 (2.93 g, 6.72 mmol) in dry DMF was added EDC 
(1.55g, 8.06 mmol),  HOBt (1.13g, 7.39 mmol) and Fmoc-Lys(Boc)-OH (3.15 g, 6.72 
mmol) under ice cold condition and stirred for further 12 hrs at RT. The solvent was 
evaporated at reduced pressure and the residue was taken in to DCM and washed with 
NaHCO3 (2 x 30 ml), water (2 x 30 ml) and brine (2 x 30 ml). The organic layer was 
dried over anhydrous Na2SO4 and concentrated under reduced pressure and further 
purified by flash column (silica gel, dichloromethane/ethanol = 9.5:0.5) to afford 5-24 
(4.52g, 76%) as a dull  brownish white solid. 1H-NMR (300 MHz, CDCl3) δ 7.74(d, J = 
2.4 Hz, 2H), 7.55(d, J = 2.27 Hz, 2H), 7.41-7.37 (t, 2H), 7.21-7.28 (t, 2H), 7.19-7.21 (m, 
4H), 5.83 (s, 1H), 5.67 (s, 1H), 5.29 (s, 1H), 4.25-4.15 (p, 4H), 4.2 (s, 1H), 3.73-3.64 (m, 
8H), 3.58 (s, 4H) 1.45-1.30 (m, 23H). MS (ESI): m/z 887.0 [(M+1)]+. 
 
 Compound 5-25: Compound 5-24 (4.52 g, 5.1mmol) was added into 40 ml of 1:1 DCM: 
TFA solution and stirred for an hour. After which the solvent was evaporated under 
reduced pressure to afford compound 5-25 and used without further purification. 1H-
NMR (300 MHz, solvent MS (ESI): m/z 787.3 [(M+1)]+. 
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Compound 5-26: To a solution of 5-26 (1g, 1.27mmol) in dry DMF was added Biotin-
NHS (0.43 g, 1.27mmol) and DIEA (0.66 ml, 3.81 mmol) and stirred for 12 h at RT. 
Upon removal of the solvent in vacuo, the resulting solution was taken into DCM and 
washed with saturated NaHCO3 (2 x 30 ml), water (2 x 30 ml) and brine (2 x 30 ml). The 
organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo to afford a 
light brownish white solid which was further purified by flash chromatography (Silica 
gel, dichloromethane/ethanol = 9.5 : 0.5) to afford compound 5-26 ( 0.84 g, 66%).  1H-
NMR (300 MHz, CDCl3) δ 7.87 (d, J = 2.54 Hz), 7.47 (d, J = 2.7 Hz), 7.43-7.36 (m, 2H), 
7.29-7.34 (m, 2H), 7.55-7.22 (d, J = 3.0 Hz, 2H), 6.36 (broad, 2H), 5.94 (s, 1H), 5.78 (s, 
1H), 4.32-4.11 (m, 6H), 3.61-3.58 (m, 8H), 3.28-3.20 (m, 2H ), 3.01-2.87 (m, 2H), 2.01-
2.06 (t, 2H), 1.69-1.41 (m, 6H), 1.36-1.19 (m, 12H). (ESI): m/z 1035.5 [(M+23)]+. 
 
Compound 5-27: Compound 5-26 (0.84g, 0.83 mmol) was added to 30 ml of  20 % 
piperidine in DMF and allowed to stir for 30 minutes, Upon concentration in vacuo 
followed by short flash chromatography purification (Silica gel, dichloromethane/ethanol 
= 8:2) afford compound 5-27 (0.62  g, 91%). MS (ESI): m/z 1012 [(M+1)]+. 
 
Compound 5-28: To a solution of compound 5-27 (0.62 g) in dry DMF was added Cy3-
NHS (0.41g, 0.76mmol) and DIEA (0.39 ml, 2.28 mmol) and stirred for 12 h at RT, upon 
evaporation of the solvent in vacuo and purification by flash chromatography (silica gel, 
dichloromethane/ethanol = 9:1) afford compound 5-28 (0.31 g, 34%). 1H-NMR (300 
MHz, CDCl3) δ 8.46-8.35 (t, 1H), 7.49 (d, J = 2.52 Hz, 2H), 7.31(d,  J = 2.56 Hz), 7.23-
7.14 (m, 8H), 6.40 (m, 2H), 5.83 (s, 1H), 5.67 (s, 1H), 5. 4.59-4.49 (m, 3H), 4.23-4.16 (p, 
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4H), 4.05 (broad, 1H), 4.09 (t, 3H), 3.63-3.58 (m, 8H), 3.27-3.15 (m, 4H, 2.30-2.24 (m, 
2H), 1.37 (t, 6H).MS (ESI): m/z 1215.7 [(M+1)]+.  
 
Final probe 5-17: To a solution of compound 5-27 (0.2 g, 0.16mmol) in dry DCM was 
added TMSI (0.08 ml, 0.56 mmol) under ice cold condition and allowed to stir for 3.5 hrs 
at RT. After which the reaction was quenched with 10 % TEA in water (10 ml) and 
extracted with Chloroform (3 x 10 ml). The aqueous layer was separated and 
concentrated in vacuo to afford a red solid. Which was further  purified by reverse phase 
HPLC to afford pure compound 5-17 (0.041 g, 22%) as a dark red solid. 1H-NMR (300 
MHz, CD3OD) δ 8.56-8.47 (t, 1H), 7.52 (d, J = 2.54 Hz, 2H), 7.35(d, J = 2.54 Hz), 7.32-
7.23 (m, 8H), 6.43 (d,  J = 4.42 Hz, 2H), 5.81 (s, 1H), 5.65 (s, 1H), 5.0 (s, 1H) 4.43-4.47 
(t, 2H), 4.24-4.26 (m, 1H), 4.12 (t, 3H), 3.45-3.43 (m, 8H), 3.16-3.09 (m, 4H), 2.92-2.90 
(m, 1H), 2.87-2.84 (t, 3H),  2.64-2.68 (d, J = 4.3 Hz, 1H), 2.36-2.34 (m, 2H), 1.84-1.21 
(m, 18H),  1.13-1.09 (m, 2H). (MS (ESI): m/z 1159.6 [(M+1)]+. 
 
7.6 Bioimaging using small molecule probes 
 
 
7.6.1 Experimental Details of the Synthesis 
 
7-Hydroxycoumarin-4-acetic acid (6-9):  Resorcinol (5 g, 45 mmol) was dissolved in 
50 ml of 70% H2SO4 under ice-cold conditions, and the solution was allowed to stir for 
30 minutes. Acetone carboxylic acid (6.6 g, 45 mmol) was added in 5 portions. The 
mixture was allowed to stir further for 4 hrs, before pouring onto crushed ice pieces. The 
precipitate formed was washed with water, ethyl acetate and dried overnight under 
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reduced pressure to afford compound 6-9 as a pure white solid  (9 g, 91%). 
1
H NMR (300 
MHz, DMSO) δ 7.53 (d, J = 9.1 Hz, 1H), 6.80 (dd, J = 8.7 & 2.1 Hz, 1H), 6.73 (d, J = 2.1 
Hz, 1H), 6.22 (s, 1H), 3.82 (s, 2H). 13C-NMR (60 MHz, DMSO) δ 170.56, 161.10, 
158.16, 154.94, 150.05, 127.65, 126.58, 112.93, 111.90, 102.23, 39.30. MS (ESI): m/z 
221.0 [(M+1)]+ 
 
7-Acetoxycoumarin-4-acetic acid (6-10): To compound 6-9 (1 g, 4.53 mmol) was added 
25 ml of acetic anhydride and 5 ml of pyridine, and the reaction was allowed to stir at RT 
for 30 minutes. Upon removal of solvent in vacuo, the residue was taken into ethyl 
acetate and washed with 1 N HCl (2 x 30 ml), water (2 x 30 ml) and brine (2 x 30 ml). 
The organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo to afford 
10 (30% yield). 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 8.9 Hz, 1H), 7.23 (d, J = 5.6 
Hz, 1H), 7.24(s, 1H), 6.47(s, 1H), 2.94 (s, 2H), 2.33 (s, 3H). MS (ESI): m/z 263.0 
[(M+H)]+  
 
Acetic acid 4-[9-benzyl sulfanylcarbonylmethyl-carbamoyl)-methyl]-2-oxo-2H-
chromen-7-yl ester (6-1): To a solution of 6-10 (0.162 g, 0.62 mmol) in dry THF was 
added EDC (0.13 g, 0.68 mmol) and HOBt (0.104 g, 0.68 mmol). The reaction was 
stirred for 30 minutes under ice-cold conditions, followed by addition of 6-24 (0.135 g, 
0.62 mmol) dissolved in minimal amount of DMF. The resulting solution was stirred 
further for 6 hours at RT. Upon removal of the solvent in vacuo, the resulting mixture 
was taken into ethyl acetate and washed with 1 N HCl (2 x 30 ml), water (2 x 30 ml) and 
brine (2 x 30 ml). The organic layer was dried over anhydrous Na2SO4 and concentrated 
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in vacuo to afford a white solid, which was further purified by flash chromatography 
(silica gel, dichloromethane/ethanol = 9:1) to afford 6-1 (0.15 g, 56%). 1H NMR (300 
MHz, CDCl3) δ 7.67 (d, J = 9.0 Hz, 1H), 7.27-7.23 (m, 7H), 6.38 (s, 1H), 4.1 (s, 2H), 
3.73 (s, 2H), 2.91 (s, 2H), 2.32 (s, 3H). MS (ESI): m/z 448.0 [(M+Na)]+. 
 
4-(3,6-diacetoxy-3H-xanthen-9-yl)-isophthalic acid (6-13): Resorcinol 6-11 (5.7 g, 52 
mmol) was dissolved in 50 ml of CH3SO3H. To this solution, trimellitic anhydride (5 g, 
26 mmol) was added, and the reaction was heated at 80-85 ºC for 12 hours. The highly 
viscous solution was cooled to RT then poured into 10 volumes of ice-cold water. The 
resulting precipitate was collected and dried in vacuo to give compound 6-12 as a crude 
yellow solid which was used without further purifications. Compound 6-12 was dissolved 
in 50 ml of acetic anhydride and 10 ml of pyridine. The solution was heated at 85 ºC for 
15 minutes. The resulting solution was poured into ice-cold water to give the crude 
precipitate of 6-13, which, upon recystallization with DCM, afforded pure 6-13 as white 
crystals (5.17 g, 53%). 1H-NMR (300 MHz, CDCl3) δ 8.75 (s, 1H), 8.38 (d, J = 8.04 Hz, 
1H), 7.29 (d, J = 8.04, 1H), 7.15-7.09 (m, 2H), 6.85-6.81 (m, 4H), 2.31 (s, 6H). 1H-NMR 
(60 MHz, CDCl3) δ 168.71, 167.46, 165.85, 155.48, 152.12, 150.69, 133.24, 132.47, 





acid (FL) (6-2):  To a solution of 6-13 (0.424 g, 0.92 mmol) in dry THF was added EDC 
(0.176 g, 0.92 mmol) and HOBt (0.14 g, 0.92 mmol). The solution was stirred for 30 
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minutes under ice-cold conditions, followed by addition of 6-24 (0.2523 g, 1.16 mmol) 
dissolved in minimal amount of DMF. The resulting solution was stirred further for 6 
hours at RT. Upon removal of the solvent in vacuo, the residue was taken into ethyl 
acetate and washed with 1 N HCl (2 x 30 ml), water (2 x 30 ml) and brine (2 x 30 ml). 
The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced 
pressure to afford a crude mixture, which was further purified by flash chromatography 
(silica gel, dichloromethane/methanol = 9:1) to afford 6-2 (0.32 g, 56%). 1H -NMR (300 
MHz, CDCl3 δ 8.52 (s, 1H), 8.22 (d, J = 8.04 Hz, 1H), 7.25-7.21 (m, 6H), 7.12-7.09 (m, 
2H), 6.81-6.75 (m, 4H), 4.39 (d, J = 5.61 Hz, 2H), 4.15 (s, 2H), 2.3 (s, 6H). 13C-NMR (60 
MHz, DMSO) δ 196.52, 168.78, 168.37, 165.84, 155.31, 152.20, 151.42, 136.72, 134.08, 
129.58, 127.74, 127.50, 127.33, 126.45,125.61, 124.50, 123.91, 115.53, 110.46, 82.09, 
49.48, 32.90, 20.98. MS (ESI): m/z 623.9 [(M+1)]+. 
 
5-Carboxy-tetramethylrhodamine (6-15):  Trimellitic anhydride (1.00 g, 5.2 mmol) 
and 3-dimethylaminophenol, 6-14 (0.72 g, 10.5 mmol) was refluxed in toluene (50 ml) 
for 12 hours. Upon cooling to RT, the resulting precipitate was collected by filtration, and 
further purified by flash chromatography (silica gel, dichloromethane/methanol/acetic 
acid = 8:1.9:0.1) to afford pure 6-15 as a dark purple solid (0.811 g, 36%). 1H -NMR 
(300 MHz, CDCl3) δ 8.52 (s, 1H), 8.12 (d, J = 8.61 Hz, 1H), 7.59 (d, J = 7.62 Hz, 1H), 




Amino thioacetic acid S-benzyl ester of 5-carboxy-tetramethylrhodamine (TMR) (6-
3):  To a solution of 6-15 (0.05 g, 0.116 mmol) in dry THF was added EDC (0.022 g, 
0.116 mmol) and HOBt (0.018 g, 0.116mmol). The solution was stirred for 30 minutes 
under ice-cold conditions, followed by addition of 6-24 (0.025 g, 0.116 mmol) dissolved 
in minimal amount of DMF. The resulting solution was stirred further for 6 hours at RT. 
Upon removal of the solvent in vacuo, the residue was taken into ethyl acetate and 
washed with 1 N HCl (2 x 30 ml), water (2 x 30 ml) and brine (2 x 30 ml). The organic 
layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to 
afford a crude mixture, which was further purified by flash chromatography (silica gel, 
dichloromethane/ethanol = 9:1) to afford 6-3 (0.024 g, 35%) as a dark purple solid. 1H -
NMR (300 MHz, CD3OD) δ 8.78 (s, 1H), 8.27 (d, J = 8.01 Hz, 1H), 7.55 (d, J = 7.83 Hz, 
1H), 7.28 (d, J = 6.45, 2H), 7.20-7.26 (m, 5H), 7.09-6.99 (m, 4H), 4.40 (s, 2H), 4.15 (s, 
2H), 3.30 (s, 12H). MS (ESI): m/z 594.2 [(M+1)]+.  
 
Acetoxynapthofluorescein (6-18): Trimellitic anhydride (1.93 g, 10 mmol) was 
dissolved in methanesulfonic acid (1 M). 6-16 (3.2 g, 20 mmol) was added and the 
solution was heated at 100 
o
C for 12 hrs. Upon cooling to RT, the solution was poured 
into 8 volumes of ice-cold water. The resulting red precipitate was collected and dried in 
vacuo to give crude 6-17, which was used directly without further purifications. MS 
(ESI): m/z 477.4 [(M+1)]
+
. Crude 6-17 was dissolved in 50 ml of acetic anhydride and 10 
ml of pyridine. The resulting mixture was heated at 80-90 0C for 15 minutes. Upon 
concentration to dryness, the residue was taken into ethyl acetate and washed with 1 N 
HCl (2 x 50 ml), water (2 x 50 ml) and brine (2 x 50 ml). The organic layer was dried 
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over anhydrous Na2SO4, and concentrated in vacuo to give crude 6-18 (46% yield for 2 
steps based on the crude product), which was confirmed by MS ((ESI): m/z 561.0 
[(M+1)]+ and used without further purifications.  
 
Amino thioacetic acid S-benzyl ester of acetoxynapthofluorescein (CF) (6-4):  To a 
THF solution of crude 6-18 (0.065 g, 0.116 mmol), obtained from above reaction, was 
added EDC (0.022 g, 0.116 mmol) and HOBt (0.018 g, 0.116 mmol). The solution was 
stirred for 30 minutes under ice-cold conditions, followed by addition of 6-24 (0.025 g, 
0.116 mmol) dissolved in minimal amount of DMF. The resulting solution was stirred 
further for 6 hours at RT. Upon removal of the solvent in vacuo, the residue was taken 
into ethyl acetate and washed with 1 N HCl (2 x 30 ml), water (2 x 30 ml) and brine (2 x 
30 ml). The organic layer was dried over anhydrous Na2SO4 and concentrated under 
reduced pressure to afford a crude mixture, which was further purified by reverse phase 
HPLC to afford pure 6-4 (0.025 g, 30% yield). 1H-NMR (300 MHz, CDCl3) δ 8.62  
(s, 1H), 8.22(d, J = 6.42 Hz, 1H), 8.14-8.11 (m, 2H), 7.64 (s, 2H), 7.48 (d, J = 8.03 Hz, 
1H), 7.31-7.27 (m, 9H), 7.19 (d, J = 7.62 Hz, 2H), 4.2 (d, J = 6.0 Hz, 2H), 4.01 (s, 2H), 
2.37 (s, 6H). MS (ESI): m/z 724.1 [(M+1)]+ 
 
5-(2-Oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoylamino]-thioacetic acid S-
benzyl ester (6-5):  Biotin 6-19 (0.156 g, 0.64 mmol) was dissolved in 40 mL of dry 
THF. To this solution was added EDC (0.123 g, 0.64 mmol) and HOBt (0.098 g, 0.64 
mmol) under ice-cold conditions. The reaction was allowed to stir for 30 minutes, 
followed by addition of 6-24 (0.139 g, 0.64 mmol) dissolved in minimal amount of DMF. 
The resulting solution was allowed to stir overnight at RT. Upon removal of the solvent 
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in vacuo, the residue was taken into ethyl acetate and washed with 1 N HCl (2 x 30 ml), 
water (2 x 30 ml) and brine (2 x 30 ml). The organic layer was dried over anhydrous 
Na2SO4 and concentrated under reduced pressure to afford 6-5 (0.110 g, 42%). 
1H-NMR 
(300 MHz, DMSO) δ 7.31-7.28 (m, 5H), 6.40-6.35 (broad, 2H), 4.37-4.32 (m, 2H), 4.22 
(d, J = 5.61 Hz, 2H), 4.09 (s, 2H), 3.1-3.0 (m, 1H), 2.88-2.78 (m, 2H), 2.19-2.14 (m, 2H), 
1.60-1.48 (m, 6H). MS (ESI): m/z 408.0 [(M+1)]+.  
 
(4-Benzoyl-benzoylamino)-thioacetic acid S-benzyl ester (6-6):  To a solution of 6-20 
(0.136 g, 0.6 mmol) in dry THF (40 ml) was added EDC (0.115 g, 0.6 mmol) and HOBt 
(0.092 g, 0.6 mmol). The solution was stirred for 30 minutes under ice-cold conditions, 
followed by addition of 6-24 (0.136 g, 0.6 mmol) dissolved in minimal amount of DMF. 
The resulting solution was stirred further for 6 hours at RT. Upon removal of the solvent 
in vacuo, the residue was taken into ethyl acetate and washed with 1 N HCl (2 x 30 ml), 
water (2 x 30 ml) and brine (2 x 30 m). The organic layer was dried over anhydrous 
Na2SO4 and concentrated under reduced pressure to afford a white solid, which was 
further purified by flash chromatography (silica gel, dichloromethane/ethanol = 9.5:0.5) 
to afford 6-6 (0.157 g, 68%). 1H-NMR (300 MHz, CDCl3) δ 7.94-7.91 (m, 2H), 7.76-7.73 
(m, 4H), 7.61-7.56 (m, 1H), 7.48-7.43 (m, 2H), 7.27-7.20 (m, 5H), 4.37 (d, J = 5.64 Hz, 
2H), 4.12 (s, 2H). 13C-NMR (60 MHz, CDCl3) 195.88, 194.66, 166.68, 140.39, 138.69, 
136.66, 134.20, 132.89, 131.82, 131.17, 130.05, 129.99, 128.99, 128.80, 128.23, 128.16, 
127.45, 127.38, 127.10, 49.39, 33.00. MS (ESI): m/z 389.47 [(M+1)]+. 
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2-Nitrobenzyl tosylate (6-22): 2-Nitrobenzyl alcohol (1 g, 6.5 mmol) was dissolved in 
40 ml of dry DCM and 1.36 ml of triethylamine. p-Toluenesulfonyl chloride (1.24 g, 6.5 
mmol) was added and the solution was stirred for 2 hours before quenching with water. 
The organic layer was separated and washed with 1 N HCl(1 x 50 ml), water (1 x 50 ml), 
2 N NaOH (1 x 50 ml), water (1 x 50 ml) and brine (1 x 50 ml). The organic layer was 
dried over anhydrous Na2SO4 and concentrated under reduced pressure to give a dull 
white solid, which was further purified by flash chromatography (silica gel, 
dichloromethane/ethanol = 9.5:0.5) to give 2-nitrobenzyl tosylate, 6-22 (1.57 g, 79%). 
1H-NMR (300 MHz, CDCl3) δ 8.08-7.99 (dd, J = 9.21 & 8.04 Hz, 1H), 7.81 (d, J = 8.4 
Hz, 1H), 7.72-7.62 (m, 3H), 7.50 (d, J = 8.85 Hz, 1H) 7.33 (d, J = 8.43 Hz, 2H), 4.93 (s, 
2H), 2.42 (s, 3H). 13C-NMR (60 MHz, CDCl3) δ 149.33, 146.12, 137.71, 135.27, 134.11, 
133.09, 132.69, 132.57, 128.12, 123.89, 42.72, 20.64. MS (ESI): m/z 329.9 [(M+Na)]+.  
 
“Caged” Fluorescein (C2FL) (6-23): Crude 6-12 was first purified by recrystallization. 
The recrystallized product (0.602 g, 1.6 mmol) was dissolved in 30 ml of DMF 
containing K2CO3 (1.1 g, 5 mmol). 2-nitrobenzyl tosylate (0.492 g, 1.6 mmol) was added 
to the solution and the reaction was heated at 60 ºC for 6 hours in a RBF covered with 
Aluminium foil to maintain dark conditions. After 6 hrs, the solvent was removed in 
vacuo and the residual mixture was washed with 1 N HCl, water and brine followed by 
drying in anhydrous Na2SO4 and concentration under reduced pressure to afford 6-23 
(0.64 g, 62%). The work up was strictly done in dark. 1H-NMR (300 MHz, CDCl3) δ 8.44 
(s, 1H), 8.16 (d, J = 8.11 Hz, 1H), 8.00-7.97 (m, 2H), 7.75-7.85 (m, 2H), 7.60-7.56 (m, 
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4H), 7.45 (d, J = 8.10 Hz, 1H), 7.35 (d, J = 7.86 Hz, 2H), 7.22-7.10 (m, 4H), 5.51 (s, 4H). 
MS (ESI): m/z 647.0 [(M+1)]+. 
 
Amino thioacetic acid S-benzyl ester of C2FL (6-7): The reaction and workups were 
carried out in dark. To a solution of 6-23 (0.084 g, 0.13 mmol) in dry THF was added 
EDC (0.027 g, 0.143 mmol) and HOBt (0.022 g, 0.143 mmol). The solution was stirred 
for 30 minutes under ice-cold conditions, followed by addition of 6-24 (0.028 g, 0.13 
mmol) dissolved in minimal amount of DMF. The resulting solution was stirred further 
for 6 hours at RT. Upon removal of the solvent in vacuo, the residue was taken into ethyl 
acetate and washed with 1 N HCl (2 x 30 mm), water (2 x 30 ml) and brine (2 x 30 ml). 
The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced 
pressure to afford a crude mixture, which was further purified by flash chromatography 
(silica gel, dichloromethane/ethanol = 9.8:0.2) to afford 6-7 (0.040 g, 38%). 1H-NMR 
(300 MHz, CDCl3) δ 8.38 (s, 1H), 8.29 (d, J = 8.13 Hz, 1H), 8.08-8.11 (m, 2H), 7.99-
7.90 (m, 2H), 7.71-7.68 (m, 4H), 7.65 (d, J = 8.10 Hz, 1H), 7.60-7.49 (m, 6H), 7.25 (s, 
5H), 5.29 (s, 4H), 4.68 (s, 2H), 4.19 (s, 2H). MS (ESI): m/z 810.1 [(M+1)]+. 
 
7.6.2 Fluorescence and in vitro labeling experiments  
 
     10 µl each of the stock solutions of probes 6-1, 6-2, 6-3 and 6-4 (1 mM in DMSO) 
was added to 100 µl of 1 mM K2CO3 solution, and the mixture was allowed to stand at 
RT for > 5 min for the deacylation reaction to occur, resulting in the release of very 
strong fluorescence in the solution. 10 µl of the solution was subsequently diluted with 
100 µl of distilled water, and the resulting solution was transferred to a black 96-well 
microtitre plate (Nunc, USA), where the excitation and the emission spectra of the probes 
 192
were recorded using a SpectraMax™ GeminiXS fluorescence microplate reader 
(Molecular Devices, USA).  
 
In vitro Protein labeling procedures With N-terminal cysteine proteins  
 
     Cloning and expression of N-terminal cysteine proteins will be reported elsewhere. 
Purified enhanced green fluorescent protein (EGFP) having an N-terminal cysteine was 
incubated for up to 24 hours with probes 6-2, 6-3, 6-4 & 6-5, respectively, in order to 
assess our labeling strategy. Probes were prepared as 200 µM stocks (25 x in DMSO) and 
stored at -20 
o
C. In a typical labeling reaction, 6 µl of each probe (final concentration: 8 
µM) was added to 50 µl of pure protein (1 mg/ml) dissolved in 1 x PBS (final 
concentration of protein: ~2 nM), with or without 1 mM DTT, and the reaction was 
topped up with 1 x PBS to a final volume of 150 µl. DTT was shown in our experiments, 
where live cells were used, to reduce background labelings. At specific time intervals, 15 
µl of the reaction was withdrawn and quenched by addition of 1.7 µl of 100 mM cysteine 
to the reaction mixture (final concentration of cysteine: 10 mM), followed by 
denaturation with SDS-PAGE loading dye at 95 oC for 3 min. The loading dye also 
serves to hydrolyze the diacetates groups on probes 6-2 and 6-4, thereby releasing the 
fluorescence. Upon separation with a 12% SDS-PAGE gel, the fluorescence labeling of 
EGFP by probes 6-2, 6-3 and 6-4 was conveniently visualized by scanning the resulting 
gel with a Typhoon™ 9200 fluorescence scanner (Amersham Biosciences, USA). 
Fluorescence intensity of each protein band was analysed using the software, Image 
Quant 5.2, preinstalled on the instrument. In all cases, more than 75% of labeling was 
obtained in 3 hours for all three probes. For the labeling of EGFP with probe 6-5, an anti-
biotin Western blot was performed to visualize the amount of biotinylated EGFP. Briefly, 
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following SDS-PAGE separation, the resulting gel was electroblotted onto a 
polyvinylidene difluoride (PVDF) membrane (BioRad, USA) and blocked for 1 h with 
5% non-fat dry milk in PBST (phosphate buffered saline, pH 7.4 with 0.1% Tween 20) 
(Fig. 7.18) The membrane was incubated with anti biotin-conjugated HRP (NEB, USA) 
in an 1:3000 dilution in milk-PBST for 1 h and then washed with PBST (3 x 15 min). 










Fig. 7.20 SDS-PAGE of purified N-terminal cysteine EGFP labeled with a) probe 6-2 
and b) probe 6-3 followed by visualization with fluorescence gel scanner; and c) probe 6-





7.6.3 Protein labeling inside live bacterial cells. 
  
A DNA construct containing N-terminal Cysteine GST was transformed into the 
E.coli expression strain ER2566 (NEB) and grown in 100mg/L ampicillin containing LB 
media at 37°C in a 250rpm air shaker. At OD600 ~ 0.6, protein expression was induced 
with 0.3mM IPTG (isopropyl-β-D-thiogalactoside). Cells were grown for 12h at room 
temperature to optimize protein expression as well as self-cleavage of the intein-fusion 
protein to generate N-terminal cysteine proteins in vivo. For labeling, 8µM of the TMR 
probe (probe 6-3) was added directly to the LB media and the cells incubated for 24h. 
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Cells were harvested by centrifugation at 4000rpm for 10min and resuspended in 1x PBS 
buffer (pH 7.4) containing 10% glycerol and left standing for 30min. This procedure was 
repeated 3 times for complete removal of any free probe. Subsequently, cells were used 
for either fluorescence microscope or SDS-PAGE experiments.  
For fluorescence microscope experiments, cells were mounted on clean glass slides 
coated with 1.5% agarose. Fluorescence images were recorded with a AxioSkop 40  
fluorescent microscope (Carl Zeiss, Germany) equipped with a cooled CCD camera 
(AxioCam, Zeiss) using a 100x oil objective. TMR fluorescence imaging was recorded 
using a BP546/12 excitation and LP590 emission filter (Zeiss).  
For SDS-PAGE experiments, the labeled cells, upon washes as mentioned above, 
were harvested by centrifugation. The cell pellet was treated directly with SDS-PAGE 
loading dye, and analyzed by 12% SDS-PAGE gel and fluorescence scanning (Typhoon 


























      High-throughput enzymology occupies a pivotal role in the modern drug discovery 
programs and relies on high-throughput amenable chemical reactions that allow rapid 
synthesis of diverse chemical libraries for the interrogation of different classes of 
enzymes. We have successfully applied ‘click’ chemistry, solid-phase ‘amide-bond’ 
formation reaction and Microwave-assisted synthesis as high-throughput platforms to 
synthesize large and diverse libraries of inhibitors targeting various PTPs as well as other 
vital enzymes. The highlight of all the above described approaches is their simplicity and 
the high-quality of the final products. The second part of my thesis demonstrates our 
successful synthesis of a novel class of activity-based probes targeting various proteases. 
Further, these probes were used to generate unique substrate fingerprint profiles of 
proteases which could answer to potential problems like substrate identification, catalytic 
mechanism of unknown proteases. The last part of my thesis narrates our successful 
synthesis of a set of small molecule probes for the site-specific labeling of N-terminal 
cysteine proteins in live cells. I believe that all the above approaches will be valuable 
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Azide Est % 
Purity* Obs MW 
1H NMR 13C NMR 
1 2-A1-2C >80% N.D. N.D N.D 
2 2-A2-2C >95% 195.060 Y Y 
3 2-A3-2C >60% N.D. N.D N.D 
4 2-A4-2C >60% N.D. N.D N.D 
5 2-A5-2C >60% N.D. N.D N.D 
6 2-A6-2C >95% N.D. N.D N.D 
7 2-A7-2C >95% N.D. N.D N.D 
8 2-A8-2C >95% N.D. N.D N.D 
9 2-A9-2C >95% N.D. N.D N.D 
10 2-A10-2C >95% N.D. N.D N.D 
11 2-A11-2C >95% N.D. N.D N.D 
12 2-A12-2C >95% N.D. N.D N.D 
13 2-B1-2C >60% 269.098 Y Y 
14 2-B2-2C >60% N.D. Y Y 
15 2-B3-2C >95% N.D. N.D N.D 
16 2-B4-2C >95% N.D. N.D N.D 
17 2-B5-2C >95% 267.100 Y Y 
18 2-B6-2C >90% N.D. N.D N.D 
19 2-B7-2C >95% N.D. N.D N.D 
20 2-B8-2C >95% N.D. N.D N.D 
21 2-B9-2C >95% N.D. N.D N.D 
22 2-B10-2C >95% N.D. N.D N.D 
23 2-B11-2C >95% N.D. N.D N.D 
24 2-B12-2C >95% 207.080 Y Y 
25 2-C1-2C >90% N.D. N.D N.D 
26 2-C2-2C >95% N.D. N.D N.D 
27 2-C3-2C >60% N.D. N.D N.D 
28 2-C4-2C >95% N.D. Y Y 
29 2-C5-2C >95% 205.102 N.D N.D 
30 2-C6-2C >95% N.D. N.D N.D 
31 2-C7-2C >95% 205.103 Y Y 
32 2-C8-2C >95% N.D. N.D N.D 
33 2-C9-2C >95% N.D. N.D N.D 
34 2-C10-2C >95% N.D. Y Y 
35 2-C11-2C >95% 275.179 Y Y 
36 2-C12-2C >95% 277.099 N.D N.D 
37 2-D1-2C >95% N.D. Y Y 
38 2-D2-2C >90% N.D. N.D N.D 
39 2-D3-2C >60% N.D. N.D N.D 
40 2-D4-2C >60% N.D. N.D N.D 
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41 2-A1-4C >95% N.D. Y Y 
42 2-A2-4C >95% N.D. N.D N.D 
43 2-A3-4C >95% N.D. N.D N.D 
44 2-A4-4C >95% N.D. N.D N.D 
45 2-A5-4C >95% N.D. N.D N.D 
46 2-A6-4C >95% N.D. Y Y 
47 2-A7-4C >90% N.D. N.D N.D 
48 2-A8-4C >95% N.D. Y Y 
49 2-A9-4C >95% N.D. N.D N.D 
50 2-A10-4C >50% N.D. N.D N.D 
51 2-A11-4C >95% N.D. Y Y 
52 2-A12-4C >95% N.D. N.D N.D 
53 2-B1-4C >95% N.D. N.D N.D 
54 2-B2-4C >95% N.D. N.D N.D 
55 2-B3-4C >95% N.D. N.D N.D 
56 2-B4-4C >95% N.D. Y Y 
57 2-B5-4C >95% N.D. N.D N.D 
58 2-B6-4C >95% N.D. N.D N.D 
59 2-B7-4C >95% N.D. Y Y 
60 2-B8-4C >95% N.D. Y Y 
61 2-B9-4C >95% N.D. N.D N.D 
62 2-B10-4C >95% N.D. N.D N.D 
63 2-B11-4C >95% N.D. Y Y 
64 2-B12-4C >95% N.D. Y Y 
65 2-C1-4C >95% N.D. N.D N.D 
66 2-C2-4C >95% N.D. N.D N.D 
67 2-C3-4C  - N.D. N.D N.D 
68 2-C4-4C >95% N.D. N.D N.D 
69 2-C5-4C >95% N.D. N.D N.D 
70 2-C6-4C >95% N.D. Y Y 
71 2-C7-4C >95% N.D. N.D N.D 
72 2-C8-4C >95% N.D. N.D N.D 
73 2-C9-4C >95% N.D. N.D N.D 
74 2-C10-4C >95% N.D. N.D N.D 
75 2-C11-4C >10 % N.D. N.D N.D 
76 2-C12-4C >50% N.D. N.D N.D 
77 2-D1-4C >95% N.D. N.D N.D 
78 2-D2-4C >60% N.D. N.D N.D 
79 2-D3-4C >30% N.D. N.D N.D 
80 2-D4-4C >95% N.D. N.D N.D 
81 2-D5-4C >90 % N.D. Y N.D 
82 2-D6-4C >90 % N.D. Y N.D 
83 2-D7-4C >90 % N.D. Y N.D 
84 2-A1-5C >95% 237.111 N.D N.D 
85 2-A2-5C >80% 237.106 N.D N.D 
86 2-A3-5C >95% 255.102 N.D N.D 
87 2-A4-5C >95% 251.124 N.D N.D 
88 2-A5-5C >95% 251.124 N.D N.D 
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89 2-A6-5C >95% 251.127 Y Y 
90 2-A7-5C >95% 287.038 N.D N.D 
91 2-A8-5C >95% 253.079 Y Y 
92 2-A9-5C >95% 267.097 N.D N.D 
93 2-A10-5C >95% N.D. N.D N.D 
94 2-A11-5C >95% 283.094 N.D N.D 
95 2-A12-5C >95% 263.148 Y Y 
96 2-B1-5C >90% 311.140 N.D N.D 
97 2-B2-5C >95% 279.143 N.D N.D 
98 2-B3-5C >95% 263.148 Y Y 
99 2-B4-5C >95% 249.133 Y Y 
100 2-B5-5C >95% 309.151 N.D N.D 
101 2-B6-5C >95% 277.163 Y Y 
102 2-B7-5C >95% 265.108 N.D N.D 
103 2-B8-5C >95% 303.103 N.D N.D 
104 2-B9-5C >95% 249.131 N.D N.D 
105 2-B10-5C >95% 279.143 Y Y 
106 2-B11-5C >95% 311.146 N.D N.D 
107 2-B12-5C >95% 249.132 N.D N.D 
108 2-C1-5C >95% 305.196 N.D N.D 
109 2-C2-5C >95% 345.110 Y Y 
110 2-C3-5C >95% 303.104 N.D N.D 
111 2-C4-5C >95% 247.152 N.D N.D 
112 2-C5-5C >95% 247.153 Y Y 
113 2-C6-5C >95% 275.182 N.D N.D 
114 2-C7-5C >90% 247.149 N.D N.D 
115 2-C8-5C >95% 289.200 N.D N.D 
116 2-C9-5C >95% 291.144 Y Y 
117 2-C10-5C  -  -   -  - 
118 2-C11-5C >95% 317.233 N.D N.D 
119 2-C12-5C >95% 269.163 N.D N.D 
120 2-D1-5C >95% 319.156 N.D N.D 
121 2-D2-5C >50% N.D. N.D N.D 
122 2-D3-5C >20% N.D. N.D N.D 
123 2-D4-5C >50% N.D. N.D N.D 
124 2-D5-5C >90% N.D. Y N.D 
125 2-D8-5C >90% N.D. Y N.D 
126 2-D9-5C >90% N.D. Y N.D 
127 2-D10-5C >95% N.D. Y N.D 
128 2-A1-6C >95% 251.124 Y Y 
129 2-A2-6C >60 % N.D. N.D N.D 
      
130 2-A3-6C >80% N.D. N.D N.D 
131 2-A4-6C >80% 269.112 N.D N.D 
132 2-A5-6C >85% 265.137 N.D N.D 
133 2-A6-6C >95% 265.136 N.D N.D 
134 2-A7-6C >80% 301.049 N.D N.D 
135 2-A8-6C >95% 267.091 Y Y 
136 2-A9-6C >80% 281.108 N.D N.D 
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137 2-A10-6C >95% 301.051 N.D N.D 
138 2-A11-6C >95% 297.104 Y Y 
139 2-A12-6C >95% 277.157 Y Y 
140 2-B1-6C >60% N.D. N.D N.D 
141 2-B2-6C >95% 293.151 N.D N.D 
142 2-B3-6C >95% 277.156 Y Y 
143 2-B4-6C >95% 263.142 Y Y 
144 2-B5-6C >95% 323.160 Y Y 
145 2-B6-6C >95% 291.174 N.D N.D 
146 2-B7-6C >95% 279.120 N.D N.D 
147 2-B8-6C  -  -  -  - 
148 2-B9-6C  -  -  -  - 
149 2-B10-6C >95% 279.120 Y Y 
150 2-B11-6C >95% 293.153 Y Y 
151 2-B12-6C >95% 263.142 N.D N.D 
152 2-C1-6C >95% 319.205 N.D N.D 
153 2-C2-6C  -  -  -  - 
154 2-C3-6C  -  -  -  - 
155 2-C4-6C >95% 261.163 N.D N.D 
156 2-C5-6C >95% 261.163 N.D N.D 
157 2-C6-6C >95% 289.195 N.D N.D 
158 2-C7-6C >60% N.D. N.D N.D 
159 2-C8-6C >90% 303.209 N.D N.D 
160 2-C9-6C >95% 305.153 N.D N.D 
161 2-C10-6C  -  -  -  - 
162 2-C11-6C >95% 331.240 N.D N.D 
163 2-C12-6C >50% 283.148 N.D N.D 
164 2-D1-6C >95% 333.163 N.D N.D 
165 2-D2-6C >15% 284.129 N.D N.D 
166 2-D3-6C >40% N.D. N.D N.D 
167 2-D4-6C >80% 297.165 N.D N.D 
168 2-E1-2C >80% 254.068 N.D N.D 
169 2-E2-2C >95% 260.063 N.D N.D 
170 2-E3-2C >95% 263.056 N.D N.D 
171 2-E4-2C >95% 275.077 N.D N.D 
172 2-E5-2C >95% 275.077 N.D N.D 
173 2-E6-2C >95% N.D. N.D N.D 
174 2-E7-2C >60% N.D. N.D N.D 
175 2-E8-2C >95% 249.098 N.D N.D 
176 2-E9-2C >95% 249.098 N.D N.D 
177 2-E10-2C >65% 219.124 N.D N.D 
178 2-E11-2C >95% 219.125 N.D N.D 
179 2-E12-2C >50% 216.084 N.D N.D 
180 2-F1-2C >90% N.D. N.D N.D 
181 2-F2-2C >95% N.D. N.D N.D 
182 2-F3-2C >95% 241.108 N.D N.D 
183 2-F4-2C >95% 241.108 N.D N.D 
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184 2-F5-2C >50% N.D. N.D N.D 
185 2-F6-2C >50% 221.102 N.D N.D 
186 2-F7-2C >65% 221.102 N.D N.D 
187 2-F8-2C >60% 241.049 N.D N.D 
188 2-F9-2C >40% 221.103 N.D N.D 
189 2-F10-2C >95% 217.106 N.D N.D 
190 2-F11-2C >95% 217.106 N.D N.D 
191 2-F12-2C >40% N.D. N.D N.D 
192 2-G1-2C >95% 191.092 Y Y 
193 2-G2-2C >95% 209.081 Y Y 
194 2-G3-2C >95% 227.073 Y Y 
195 2-G4-2C >95% 227.072 Y Y 
196 2-G5-2C >95% 277.068 Y Y 
197 2-G6-2C >90% N.D. Y Y 
198 2-G7-2C >95% 245.060 Y Y 
199 2-G8-2C >95% 209.081 Y Y 
200 2-G9-2C >80% 304.983 Y Y 
201 2-G10-2C >95% 219.123 Y Y 
202 2-H1-2C >95% N.D. N.D N.D 
203 2-H1-4C >80% N.D. N.D N.D 
204 2-H1-5C >60% N.D. N.D N.D 
205 2-H1-6C >60% N.D. N.D N.D 
206 2-I1-2C >95% N.D. Y Y 
207 2-I2-2C >95% N.D. Y Y 
208 2-I3-2C >90% N.D. N.D N.D 
209 2-I4-2C >95% N.D. N.D N.D 
210 2-I5-2C >85% N.D. N.D N.D 
211 2-I6-2C >95% N.D. N.D N.D 
212 2-I7-2C >85% N.D. N.D N.D 
213 2-I8-2C >90% N.D. N.D N.D 
214 2-I9-2C >85% N.D. N.D N.D 
215 2-I10-2C >95% N.D. N.D N.D 
216 2-I11-2C >80% N.D. N.D N.D 
217 2-I12-2C >80% N.D. N.D N.D 
218 2-J1-2C >85% N.D. N.D N.D 
219 2-J2-2C >80% N.D. N.D N.D 
220 2-J3-2C >95% N.D. N.D N.D 
221 2-J4-2C  - N.D. N.D N.D 
222 2-J5-2C >95% N.D. N.D N.D 
223 2-J6-2C >95% N.D. Y Y 
224 2-J7-2C >95% N.D. Y Y 
225 2-J8-2C >85% N.D. N.D N.D 
226 2-J9-2C >95% N.D. N.D N.D 
227 2-J10-2C >95% N.D. N.D N.D 
228 2-J11-2C >70% N.D. N.D N.D 
229 2-J12-2C >90% N.D. N.D N.D 
230 2-K1-2C >90% N.D. N.D N.D 
231 2-I1-3C >95% N.D. Y Y 
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232 2-I2-3C >95% N.D. N.D N.D 
233 2-I3-3C >95% N.D. N.D N.D 
234 2-I4-3C >95% N.D. Y Y 
235 2-I5-3C >90% N.D. N.D N.D 
236 2-I6-3C N.D N.D. N.D N.D 
237 2-I7-3C >95% N.D. Y Y 
238 2-I8-3C >85% N.D. N.D N.D 
239 2-I9-3C >95% N.D. N.D N.D 
240 2-I10-3C >95% N.D. N.D N.D 
241 2-I11-3C N.D N.D. N.D N.D 
242 2-I12-3C 95% N.D. N.D N.D 
243 2-J1-3C >80% N.D. N.D N.D 
244 2-J2-3C >95% N.D. N.D N.D 
245 2-J3-3C >95% N.D. N.D N.D 
246 2-J4-3C N.D N.D. N.D N.D 
247 2-J5-3C >95% N.D. N.D N.D 
248 2-J6-3C >95% N.D. Y Y 
249 2-J7-3C >95% N.D. N.D N.D 
250 2-J8-3C  - N.D. N.D N.D 
251 2-J9-3C >95% N.D. N.D N.D 
252 2-J10-3C >95% N.D. N.D N.D 
253 2-J11-3C >90% N.D. N.D N.D 
254 2-I1-4C >95% N.D. Y Y 
255 2-I2-4C >95% N.D. Y Y 
256 2-I3-4C >90% N.D. N.D N.D 
257 2-I4-4C >95% N.D. N.D N.D 
258 2-I5-4C >85% N.D. N.D N.D 
259 2-I6-4C >85% N.D. N.D N.D 
260 2-I7-4C >85% N.D. N.D N.D 
261 2-I8-4C >75% N.D. N.D N.D 
262 2-I9-4C >80% N.D. N.D N.D 
263 2-I10-4C >90% N.D. N.D N.D 
264 2-I11-4C >70% N.D. N.D N.D 
265 2-I12-4C >90% N.D. N.D N.D 
266 2-J1-4C >70% N.D. N.D N.D 
267 2-J2-4C >80% N.D. N.D N.D 
268 2-J3-4C >95% N.D. N.D N.D 
269 2-J4-4C >95% N.D. N.D N.D 
270 2-J5-4C >95% N.D. Y Y 
271 2-J6-4C >95% N.D. Y Y 
272 2-J7-4C >95% N.D. N.D N.D 
273 2-J8-4C >90% N.D. N.D N.D 
274 2-J9-4C >95% N.D. N.D N.D 
275 2-J10-4C >70% N.D. N.D N.D 
276 2-J11-4C >80% N.D. N.D N.D 
277 2-I1-5C >95% N.D. Y Y 
278 2-I2-5C >95% N.D. Y Y 
279 2-I3-5C >95% N.D. N.D N.D 
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280 2-I4-5C >95% N.D. N.D N.D 
281 2-I5-5C >80% N.D. N.D N.D 
282 2-l6-5C >85% N.D. N.D N.D 
283 2-I7-5C >85% N.D. N.D N.D 
284 2-I8-5C >60% N.D. N.D N.D 
285 2-I9-5C >90% N.D. N.D N.D 
286 2-I10-5C >90% N.D. N.D N.D 
287 2-I11-5C >75% N.D. N.D N.D 
288 2-I12-5C >90% N.D. N.D N.D 
289 2-J1-5C >75% N.D. N.D N.D 
290 2-J2-5C >90% N.D. N.D N.D 
291 2-J3-5C >95% N.D. N.D N.D 
292 2-J4-5C  - N.D. N.D N.D 
293 2-J5-5C >95% N.D. N.D N.D 
294 2-J6-5C >95% N.D. Y Y 
295 2-J7-5C >95% N.D. Y Y 
296 2-J8-5C >95% N.D. N.D N.D 
297 2-J9-5C >95% N.D. N.D N.D 
298 2-J10-5C >85% N.D. N.D N.D 
299 2-J11-5C >70% N.D. N.D N.D 
300 2-I1-6C >95% N.D. Y Y 
301 2-I2-6C >95% N.D. Y Y 
302 2-I3-6C >95% N.D. N.D N.D 
303 2-I4-6C >95% N.D. N.D N.D 
304 2-I5-6C >95% N.D. N.D N.D 
305 2-I6-6C >90% N.D. N.D N.D 
306 2-I7-6C >95% N.D. N.D N.D 
307 2-I8-6C >90% N.D. N.D N.D 
308 2-I9-6C >90% N.D. N.D N.D 
309 2-I10-6C >95% N.D. N.D N.D 
310 2-I11-6C >60% N.D. N.D N.D 
311 2-I12-6C >95% N.D. N.D N.D 
312 2-J1-6C >75% N.D. N.D N.D 
313 2-J2-6C >90% N.D. N.D N.D 
314 2-J3-6C >95% N.D. N.D N.D 
315 2-J4-6C  - N.D. N.D N.D 
316 2-J5-6C >95% N.D. N.D N.D 
317 2-J6-6C >95% N.D. Y Y 
318 2-J7-6C >95% N.D. Y Y 
319 2-J8-6C >95% N.D. N.D N.D 
320 2-J9-6C >95% N.D. N.D N.D 
321 2-J10-6C >95% N.D. N.D N.D 
322 2-J11-6C >60% N.D. N.D N.D 
323 2-L1-2C >80% N.D. N.D N.D 
324 2-L1-5C >85 % N.D. N.D N.D 
325 2-L1-6C >90% N.D. N.D N.D 
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Color 
Code  Building Blocks   
      
    Amine   
    Solution phase synthesis (amine/sulfonyl chloride) 
    Acid   
    Acid chloride   
    Sulfonyl chloride   
    Chlorformate   
   
 
"-" = No characterizations 
(LCMS/NMR) were done 
 
"N.D." = Although the product is 
correct, the molecular mass did not 
show up in the mass spectrometry 
(due to low ionization which is 
  
      
      
     A - D  IS AMINE BUILDING BLOCKS     
     E - G IS ACID BUILDING BLOCKS     
     
H IS ACID CHLORIDE BUILDING 
BLOCKS     
     
I - K SULFONYL CHLORIDE 
BUILDING BLOCKS     
     
L IS CHLOROFORMATE BUILDING 
BLOCKS     



















Table 10.2 Observed molecular weight [MS (TOF)] of the representative triazole 




Summary of Characterization of Triazole products 
 
# Triazole ID Obs MS # Triazole ID Obs MS 
      
1 2-A-2-A1-5C 480.148 74 2-G-2-A7-5C 544.111 
2 2-A-2-A3-5C 498.136 75 2-G-2-A9-5C 524.167 
3 2-A-2-A4-5C 498.136 76 2-G-2-A10-5C  544.115 
4 2-A-2-A5-5C 494.164 77 2-G-2-B2-5C 536.208 
5 2-A-2-A8-5C 496.114 78 2-G-2-B7-5C 522.172 
6 2-A-2-A9-5C 510.135 79 2-G-2-B8-5C 560.171 
7 2-A-2-A10-5C 530.08 80 2-G-2-B1-2S 516.131 
8  2-A-2-A11-5C 526.127 81 2-G-2-B1-5S 558.179 
9 2-A-2-A12-5C 506.177 82 2-G-2-E1-3C      511.129 
10 2-A-2-B1-2C 512.131 83 2-G-2-B6-2C 520.103 
11 2-A-2-B2-2C 480.129 84 2-G-2-A1-5S      568.172 
12 2-A-2-B3-2C 464.133 85 2-G-2-A2-2S 560.148 
13 2-A-2-B4-2C 450.12 86 2-G-2-A2-5S 602.195 
14 2-A-2-B5-2C  510.137 87 2-H-2-A2-2C 595.927 
15 2-A-2-B6-2C 478.153 88 2-H-2-A2-2C  595.921 
16 2-A-2-B7-2C 466.094 89 2-H-2-A4-2C 613.919 
17 2-A-2-B8-2C 504.089 90 2-H-2-A5-2C 609.948 
18 2-A-2-B9-2C 450.118 91 2-H-2-A9-2C 625.914 
19 2-A-2-B10-2C 480.134 92 2-H-2-A11-2C 641.908 
20 2-A-2-B11-2C 512.133 93 2-H-2-A12-2C 621.966 
21 2-A-2-B12-2C 450.12 94 2-H-2-E2-3C 661.887 
22 2-B-2-A1-5C 514.125 95 2-H-2-E3-3C   645.923 
23 2-B-2-A2-5C 514.125 96 2-H-2-E4-3C 663.923 
24 2-B-2-A3-5C 532.118 97 2-H-2-E6-3C 639.943 
25 2-B-2-A4-5C 532.117 98 2-H-2-E7-3C 649.958 
26 2-B-2-A5-5C 528.144 99    2-H-2-E12-3C    617.922 
27 2-B-2-A6-5C 528.145 100 2-H-2-A1-5C 637.984 
28 2-B-2-A8-5C 530.096 101 2-H-2-A2-5C 637.978 
29 2-B-2-B1-2S 536.048 102 2-H-2-A3-5C 655.967 
30 2-B-2-B2-5S 546.089 103 2-H-2-A4-5C  655.968 
31 2-C-2-A1-5C 498.156 104 2-H-2-A5-5C 629.989 
32 2-C-2-A2-5C 498.158 105 2-H-2-A4-5C 655.968 
33 2-C-2-A3-5C 516.144 106 2-I-2-A1-2C 456.101 
34 2-C-2-A4-5C 516.144 107 2-I-2-A2-2C 456.104 
35 2-C-2-A5-5C 512.17 108 2-I-2-A4-2C 474.101 
36 2-C-2-A9-5C 528.148 109 2-I-2-A5-2C 470.127 
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37 2-C-2-A10-5C 548.088 110 2-I-2-A6-2C 470.125 
38 2-C-2-E1-6C 512.172 111 2-I-2-A8-2C 472.082 
39 2-C-2-E2-6C 512.172 112 2-I-2-A9-2C 486.098 
40 2-C-2-E3-6C 530.164 113 2-I-2-A11-2C 502.098 
41 2-C-2-E4-6C 530.162 114 2-I-2-A12-2C  482.154 
42 2-C-2-E5-6C 526.191 115 2-I-2-B1-2C 530.15 
43 2-C-2-E6-6C 526.152 116 2-I-2-B2-2C 498.148 
44 2-C-2-A9-5C 528.148 117 2-I-2-B3-2C 482.145 
45 2-D-2-A1-5C 578.234 118 2-I-2-B4-2C 468.129 
46 2-D-2-A4-5C 596.2 119 2-I-2-B5-2C 528.159 
47 2-D-2-A6-5C 592.212 120 2-I-2-B6-2C 496.163 
48 2-E-2-A1-2C 471.086 121 2-I-2-B7-2C 484.104 
49 2-E-2-A2-2C 471.097 122 2-I-2-B8-2C 522.101 
50 2-E-2-A5-2C 485.114 123 2-J-2-A1-2C 438.122 
51 2-E-2-E1-4C 499.129 124 2-J-2-A2-2C 438.125 
52 2-E-2-A1-5C 513.143 125 2-J-2-A4-2C  456.119 
53 2-E-2-A2-5C 513.139 126    2-J-2-A5-2C     452.139 
54 2-E-2-A3-5C 531.135 127 2-J-2-A6-2C 452.145 
55 2-E-2-A4-5C 531.13 128 2-J-2-A8-2C 454.098 
56 2-E-2-A5-5C 527.155 129 2-J-2-A9-2C 468.112 
57 2-F-2-A6-2C 482.133 130 2-J-2-A11-2C 484.153 
58 2-F-2-A8-2C 484.088 131 2-J-2-A12-2C 464.163 
59 2-F-2-A9-2C 498.107 132 2-J-2-E4-4C   484.153 
60 2-F-2-A11-2C 514.109 133 2-J-2-E5-4C 480.176 
61 2-F-2-A12-2C  494.163 134 2-J-2-E6-4C 480.178 
62 2-F-2-B3-2C 494.158 135 2-J-2-A1-5C 480.153 
63 2-F-2-B4-2C 480.147 136 2-J-2-A2-5C 480.153 
64 2-F-2-B5-2C 540.164 137 2-J-2-A3-5C 480.163 
65 2-F-2-A1-5C 510.178 138   2-J-2-A4-5C     498.15 
66 2-F-2-A2-5C 510.173 139 2-J-2-A5-5C 498.153 
67 2-G-2-A1-2C  452.139 140 2-J-2-A6-5C 494.183 
68 2-G-2-A2-2C 452.141 141 2-J-2-A11-5C 526.146 
69 2-G-2-A1-5C  494.179 142 2-J-2-A12-5C  506.2 
70 2-G-2-A2-5C  494.177 143 2-J-2-E1-6C 494.176 
71 2-G-2-A3-5C 512.168 144 2-J-2-E2-6C 494.176 
72 2-G-2-A4-5C 512.169 145 2-J-2-E3-6C 512.163 




























        
1 3-A1 3-A 3-a1 - - Yes 115.3 
2 3-A2 3-A 3-a2 - - Yes 167.8 
3 3-A3 3-A 3-a3 - - Yes 0 
4 3-A4 3-A 3-a4 >95 % - - 106.8 
5 3-A5 3-A 3-a5 >95 % 463 - 216.4 
6 3-A6 3-A 3-a6 >95 % 412 - 111 
7 3-A7 3-A 3-a7 >95 % 520 - 77.3 
8 3-A8 3-A 3-a8 - - - 177.1 
9 3-A9 3-A 3-a9 >95 % - - 125.9 
10 3-A10 3-A 3-a10 >95 % 438 - 395.3 
11 3-A11 3-A 3-a11 >95 % 482 - 66.6 
12 3-A12 3-A 3-a12 - - Yes  
13 3-A13 3-A 3-a13 >95 % 425 - 120.9 
14 3-A14 3-A 3-a14 >95 % 484 - 139.4 
15 3-A15 3-A 3-a15 - - - 60.8 
16 3-A16 3-A 3-a16 >95 % 478 Yes 145.9 
17 3-A17 3-A 3-a17 >95 % 440 - 115.9 
18 3-A18 3-A 3-a18 >60 % - - >400 
19 3-A19 3-A 3-a19 >95 % 439 - 182.9 
20 3-A20 3-A 3-a20 >95 % 424 - 216.5 
21 3-A21 3-A 3-a21 - - - 27.6 
22 3-A22 3-A 3-a22 - - - 148.7 
23 3-A23 3-A 3-a23 - - Yes 0 
24 3-A24 3-A 3-a24 >95 % 472 - 99.4 
25 3-A25 3-A 3-a25 >50 % - - 192.6 
26 3-A26 3-A 3-a26 >80 % 494 - 8.8 
27 3-A27 3-A 3-a27 >95 % 467 Yes 68 
28 3-A28 3-A 3-a28 >95 % 466 - 157.9 
29 3-A29 3-A 3-a29 >95 % 424 - 75.5 
30 3-A30 3-A 3-a30 >95 % 464 Yes 75 
31 3-A31 3-A 3-a31 >95 % 423 Yes 147.2 
32 3-A32 3-A 3-a32 >90 % 466 - 150.7 
33 3-A33 3-A 3-a33 >95 % 512 - 0 
34 3-A34 3-A 3-a34 - - - 20.6 
35 3-A35 3-A 3-a35 - - - 34.2 
 224
36 3-B1 3-B 3-a36 - - - >400 
37 3-B2 3-B 3-a37 >70 % 454 -  
38 3-B3 3-B 3-a38 - - - >400 
39 3-B4 3-B 3-a39 - - Yes >400 
40 3-B5 3-B 3-a40 - - - 236.3 
41 3-B6 3-B 3-a41 >60 % 440 - >400 
42 3-B7 3-B 3-a42 >90 % - - 36.5 
43 3-B8 3-B 3-a43 - - - 58.7 
44 3-B9 3-B 3-a44 - - Yes >400 
45 3-B10 3-B 3-a45 >95 % 467 Yes >400 
46 3-B11 3-B 3-a46 >95 % 509 - 0 
47 3-B12 3-B 3-a47 - - - 183.2 
48 3-B13 3-B 3-a48 >95 % 452 - 204.2 
49 3-B14 3-B 3-a49 >95 % 512 - 256.8 
50 3-B15 3-B 3-a50 >95 % 481 - >400 
51 3-B16 3-B 3-a51 >95 % 529 - 174.1 
52 3-B17 3-B 3-a52 >95 % 469 Yes >400 
53 3-B18 3-B 3-a53 - - - >400 
54 3-B19 3-B 3-a54 >95 % 467 - 304.7 
55 3-B20 3-B 3-a55 - - - 149.7 
56 3-B21 3-B 3-a56 >95 % 524 Yes 105.8 
57 3-B22 3-B 3-a57 - - - 275.2 
58 3-B23 3-B 3-a58 >95 % 487 Yes 117.2 
59 3-B24 3-B 3-a59 >95 % 500 - 365.9 
60 3-B25 3-B 3-a60 - - - 20.5 
61 3-B26 3-B 3-a61 - - - 197.7 
62 3-B27 3-B 3-a62 - - - 378.8 
63 3-B28 3-B 3-a63 - - - 244.5 
64 3-B29 3-B 3-a64 >95 % 451 - >400 
65 3-B30 3-B 3-a65 - - - >400 
66 3-B31 3-B 3-a66 >95 % 451 - >400 
67 3-B32 3-B 3-a67 - - - 379.3 
68 3-B33 3-B 3-a68 - - - >400 
69 3-B34 3-B 3-a69 - - - >400 
































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 03:58:43
DATE_d : Aug 07 2007
NS :             32
O1 :        1853.43 Hz
O2 :        1853.43 Hz
O3 :        1853.43 Hz
SFO1 :   300.1318534 MHz
SFO2 :   300.1318534 MHz
SFO3 :   300.1318534 MHz
*** 1D NMR Plot Parameters ***
SR :           4.70 Hz


















































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 19:48:25
DATE_d : Aug 08 2007
NS :             20
O1 :        1002.80 Hz
O2 :        1853.43 Hz
O3 :        1853.43 Hz
SFO1 :   300.1310028 MHz
SFO2 :   300.1318534 MHz
SFO3 :   300.1318534 MHz
*** 1D NMR Plot Parameters ***
SR :           0.80 Hz
























































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 19:27:52
DATE_d : Aug 08 2007
NS :             20
O1 :        1002.10 Hz
O2 :        1853.43 Hz
O3 :        1853.43 Hz
SFO1 :    300.1310021 MHz
SFO2 :    300.1318534 MHz
SFO3 :    300.1318534 MHz
*** 1D NMR Plot Parameters ***





































































































































































































































































































































*** Acquisition  Parameters ***
INSTRUM : av500
NS :              8
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :    500.1330885 MHz
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
SI :          16384
*** 1D NMR Plot Parameters ***
Start :          12.00 ppm
Stop :          -0.48 ppm
SR :           7.76 Hz









































































































































































































































































































































































































































































*** Acquisition  Parameters ***
AQ_mod : dqd
AUNM : au_zg
BF1 :    300.1300000 MHz
DATE_t : 03:40:08
DATE_d : Mar 14 2007
NS :             16
O2 :        1853.43 Hz
PARMODE : 1D
RG :    287.3999939
SFO1 :    300.1318534 MHz
SOLVENT : DMSO
SW :        17.9519 ppm
SW_h :       5387.931 Hz
TE :          300.0 K
YMAX_a : 1216539136.0000000
YMIN_a : -928285824.0000000
*** 1D NMR Plot Parameters ***
SR :          12.52 Hz






































































































































































































































































































































10.3 LC-MS spectra for selected compounds 
 
 Compound 2-A-2-A3-2C  
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2487Channel 2 (254.00 nm)
 
